

# EUCAIM's HyperOntology

language [en](#)

This version:

<https://cancerimage.eu/ontology/EUCAIM#/0.1beta>

Latest version:

<https://cancerimage.eu/ontology/EUCAIM#>

Revision:

0.1 beta

Authors:

LIMICS

Contributors:

FORTH

Publisher:

LIMICS

Download serialization:

Format [JSON LD](#)

Format [RDF/XML](#)

Format [N Triples](#)

Format [TTL](#)

License:

License [EUCAIM](#)

Cite as:

LIMICS. EUCAIM's HyperOntology. Revision: 0.1 beta. Retrieved from:  
<https://cancerimage.eu/ontology/EUCAIM#/0.1beta>

---

## Ontology Specification Draft

This document presents the content of the Hyperontology version 0.1 beta (release March 14, 2024) achieved by applying a bottom-up approach. The development process is based mainly on the clinical and imaging knowledge provided by the AI4HI projects as use cases classified per cancer types. All the provided knowledge is organized in the ORSD document. Two main types of mappings are considered in this phase: 1) is-a to build the hierarchical structure of the Hyperontology and 2) exactMatch to enrich the content with synonyms (alternative labels), codes, and definitions. Besides, syntactic mappings are performed to integrate the Hyperontology with OMOP and FHIR standards. The curation and enrichment processes are in progress. Three main modules are defined in the hyperontology: 1) clinical module that includes tumor grade/stage, procedures (surgical/therapeutic), medication, findings, lab tests, results, metastasis, etc. 2) imaging module that includes categories related to imaging procedures, modalities, body parts, etc. 3) common module that includes staging/grading values and other qualifier values such as time patterns, absence and presence findings, and age at diagnosis. An additional module, Correspondence module, is envisaged to define the main OMOP and FHIR classes/entities required for syntactic integration with these standards. We note that "NotClassified" category is temporarily defined for the concepts that are not yet classified and will be managed in version 0.2 beta.

## Cross-reference for EUCAIM's HyperOntology classes, object properties and data properties back to [ToC](#)

This section provides details for each class and property defined by EUCAIM's HyperOntology.

### Classes

- [1+](#)
- [2+](#)
- [3+](#)
- [3D CRT three dimensional conformal radiation therapy](#)

- [Abdomen](#)
- [Abdomen and Pelvis](#)
- [Abdomen excision](#)
- [Abdomen proper](#)
- [Abdominal abscess](#)
- [Abdominal cavity injury](#)
- [Abdominal mass](#)
- [Abdominal organ finding](#)
- [Abdominal visceral abscess](#)
- [Abdominopelvic cross-sectional segment](#)
- [Abdominopelvic segment of trunk](#)
- [Abemaciclib](#)
- [Abnormal finding on evaluation procedure](#)
- [Abnormal sexual function](#)
- [Abscess](#)
- [Abscess of digestive system](#)
- [Abscess of liver](#)
- [Absence findings](#)
- [Absent](#)
- [Acinar cell carcinoma of prostate gland](#)
- [Acoustic feature of mass](#)
- [Action](#)
- [Active surveillance of prostate cancer](#)
- [ADAC](#)
- [Adenocarcinoma NOS](#)
- [Adenocarcinoma of liver](#)
- [Adenocarcinoma of pelvis](#)
- [Adenocarcinoma with mixed subtypes](#)
- [Adenocarcinoma with neuroendocrine differentiation of prostate gland](#)
- [Adenocarcinoma, NOS, of prostate gland](#)
- [Adenoma of liver](#)
- [Adenomas and adenocarcinomas](#)
- [Adenosquamous carcinoma of prostate gland](#)
- [Adenosquamous cell carcinoma](#)
- [Adjectival modifier](#)
- [Administration of hormone \(procedure\)](#)
- [Administration of medication](#)
- [Administrative statuses](#)
- [Adrenal gland](#)
- [Age AND/OR growth period](#)
- [Age at diagnosis](#)
- [Age at onset of clinical finding](#)
- [Agfa](#)
- [AJCC/UICC 7th clinical M0 Category](#)
- [AJCC/UICC 7th clinical M1 Category](#)
- [AJCC/UICC 7th clinical M1a Category](#)
- [AJCC/UICC 7th clinical M1b Category](#)
- [AJCC/UICC 7th clinical M1c Category](#)
- [AJCC/UICC 7th clinical MX Category](#)
- [AJCC/UICC 7th clinical N0 Category](#)
- [AJCC/UICC 7th clinical N1 Category](#)
- [AJCC/UICC 7th clinical NX Category](#)
- [AJCC/UICC 7th clinical T2 Category](#)
- [AJCC/UICC 7th clinical T2a Category](#)

- [AJCC/UICC 7th clinical T2b Category](#)
- [AJCC/UICC 7th clinical T2c Category](#)
- [AJCC/UICC 7th clinical T3 Category](#)
- [AJCC/UICC 7th clinical T3a Category](#)
- [AJCC/UICC 7th clinical T3b Category](#)
- [AJCC/UICC 7th clinical T4 Category](#)
- [AJCC/UICC 7th clinical TX Category](#)
- [AJCC/UICC 7th edition](#)
- [AJCC/UICC 7th M0 Category](#)
- [AJCC/UICC 7th M1 Category](#)
- [AJCC/UICC 7th M1a Category](#)
- [AJCC/UICC 7th M1b Category](#)
- [AJCC/UICC 7th M1c Category](#)
- [AJCC/UICC 7th MX Category](#)
- [AJCC/UICC 7th N0 Category](#)
- [AJCC/UICC 7th N1 Category](#)
- [AJCC/UICC 7th NX Category](#)
- [AJCC/UICC 7th pathological M1a Category](#)
- [AJCC/UICC 7th pathological N0 Category](#)
- [AJCC/UICC 7th pathological N1 Category](#)
- [AJCC/UICC 7th pathological NX Category](#)
- [AJCC/UICC 7th pathological T1 Category](#)
- [AJCC/UICC 7th pathological T1a Category](#)
- [AJCC/UICC 7th pathological T1b Category](#)
- [AJCC/UICC 7th pathological T1c Category](#)
- [AJCC/UICC 7th pathological T2 Category](#)
- [AJCC/UICC 7th pathological T2a Category](#)
- [AJCC/UICC 7th pathological T2b Category](#)
- [AJCC/UICC 7th pathological T2c Category](#)
- [AJCC/UICC 7th pathological T3 Category](#)
- [AJCC/UICC 7th pathological T3a Category](#)
- [AJCC/UICC 7th pathological T3b Category](#)
- [AJCC/UICC 7th pathological T4 Category](#)
- [AJCC/UICC 7th pathological TX Category](#)
- [AJCC/UICC 7th T1 Category](#)
- [AJCC/UICC 7th T1a Category](#)
- [AJCC/UICC 7th T1b Category](#)
- [AJCC/UICC 7th T1c Category](#)
- [AJCC/UICC 7th T2 Category](#)
- [AJCC/UICC 7th T2a Category](#)
- [AJCC/UICC 7th T2b Category](#)
- [AJCC/UICC 7th T2c Category](#)
- [AJCC/UICC 7th T3 Category](#)
- [AJCC/UICC 7th T3a Category](#)
- [AJCC/UICC 7th T3b Category](#)
- [AJCC/UICC 7th T4 Category](#)
- [AJCC/UICC 7th TX Category](#)
- [AJCC/UICC clinical M0 Category](#)
- [AJCC/UICC clinical M1 Category](#)
- [AJCC/UICC clinical M1a Category](#)
- [AJCC/UICC clinical M1b Category](#)
- [AJCC/UICC clinical M1c Category](#)
- [AJCC/UICC clinical MX Category](#)
- [AJCC/UICC clinical N0 Category](#)

- [AJCC/UICC clinical N1 Category](#)
- [AJCC/UICC clinical NX Category](#)
- [AJCC/UICC clinical T2 Category](#)
- [AJCC/UICC clinical T2a Category](#)
- [AJCC/UICC clinical T2b Category](#)
- [AJCC/UICC clinical T2c Category](#)
- [AJCC/UICC clinical T3 Category](#)
- [AJCC/UICC clinical T3a Category](#)
- [AJCC/UICC clinical T3b Category](#)
- [AJCC/UICC clinical T4 Category](#)
- [AJCC/UICC clinical TX Category](#)
- [AJCC/UICC finding](#)
- [AJCC/UICC M0 Category](#)
- [AJCC/UICC M1 Category](#)
- [AJCC/UICC M1a Category](#)
- [AJCC/UICC M1b Category](#)
- [AJCC/UICC M1c Category](#)
- [AJCC/UICC MX Category](#)
- [AJCC/UICC N0 Category](#)
- [AJCC/UICC N1 Category](#)
- [AJCC/UICC NX Category](#)
- [AJCC/UICC pathological N0 Category](#)
- [AJCC/UICC pathological N1 Category](#)
- [AJCC/UICC pathological NX Category](#)
- [AJCC/UICC pathological T1 Category](#)
- [AJCC/UICC pathological T1a Category](#)
- [AJCC/UICC pathological T1b Category](#)
- [AJCC/UICC pathological T1c Category](#)
- [AJCC/UICC pathological T2 Category](#)
- [AJCC/UICC pathological T2a Category](#)
- [AJCC/UICC pathological T2b Category](#)
- [AJCC/UICC pathological T2c Category](#)
- [AJCC/UICC pathological T3 Category](#)
- [AJCC/UICC pathological T3a Category](#)
- [AJCC/UICC pathological T3b Category](#)
- [AJCC/UICC pathological T4 Category](#)
- [AJCC/UICC pathological TX Category](#)
- [AJCC/UICC T1 Category](#)
- [AJCC/UICC T1a Category](#)
- [AJCC/UICC T1b Category](#)
- [AJCC/UICC T1c Category](#)
- [AJCC/UICC T2 Category](#)
- [AJCC/UICC T2a Category](#)
- [AJCC/UICC T2b Category](#)
- [AJCC/UICC T2c Category](#)
- [AJCC/UICC T3 Category](#)
- [AJCC/UICC T3a Category](#)
- [AJCC/UICC T3b Category](#)
- [AJCC/UICC T4 Category](#)
- [AJCC/UICC TX Category](#)
- [Alanine aminotransferase \[Enzymatic activity/volume\] in Blood](#)
- [Albumin/Protein.total in 24 hour Urine by Electrophoresis](#)
- [Alcoholic liver damage](#)
- [Alive](#)



- [Alkaline phosphatase \[Enzymatic activity/volume\] in Blood](#)
- [Alkylating agent](#)
- [American Joint Committee on Cancer allowable value](#)
- [American Joint Committee on Cancer clinical grade allowable value](#)
- [American Joint Committee on Cancer clinical M category allowable value](#)
- [American Joint Committee on Cancer clinical N category allowable value](#)
- [American Joint Committee on Cancer clinical stage group allowable value](#)
- [American Joint Committee on Cancer clinical T category allowable value](#)
- [American Joint Committee on Cancer grade GX](#)
- [American Joint Committee on Cancer pathological grade allowable value](#)
- [American Joint Committee on Cancer pathological M category allowable value](#)
- [American Joint Committee on Cancer pathological N category allowable value](#)
- [American Joint Committee on Cancer pathological stage group allowable value](#)
- [American Joint Committee on Cancer pathological T category allowable value](#)
- [American Joint Committee on Cancer pM1](#)
- [American Joint Committee on Cancer pM1a \(qualifier value\)](#)
- [American Joint Committee on Cancer pM1b \(qualifier value\)](#)
- [American Joint Committee on Cancer pM1c \(qualifier value\)](#)
- [American Joint Committee on Cancer yp grade allowable value](#)
- [American Joint Committee on Cancer ypN category allowable value](#)
- [American Joint Committee on Cancer ypT category allowable value](#)
- [Anastrozole](#)
- [Anatomic pathology procedure](#)
- [Anatomical Plane](#)
- [Androgen deprivation therapy](#)
- [Androgen level](#)
- [Angiosarcoma](#)
- [Angiosarcoma of liver](#)
- [Anorectal structure](#)
- [Anterior fibromuscular stroma of prostate](#)
- [Antineoplastic agent](#)
- [Antineoplastic Agents](#)
- [ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS](#)
- [Antineoplastic chemoimmunotherapy](#)
- [Aorta](#)
- [Apical anterior fibromuscular stroma of prostate](#)
- [Apical peripheral zone of prostate](#)
- [Apical transition zone of prostate](#)
- [Architectural distortion of breast](#)
- [Arm](#)
- [Aspartate aminotransferase \[Enzymatic activity/volume\] in Serum or Plasma](#)
- [Aspartate aminotransferase measurement](#)
- [Assessment scales](#)
- [Atezolizumab](#)
- [Auricular region structure](#)
- [Autoimmune disease](#)
- [Autoimmune hepatitis](#)
- [Autoimmune liver disease](#)
- [Automatic](#)
- [Axial skeleton structure](#)
- [Axillary lymph node](#)
- [Basal anterior fibromuscular stroma of prostate](#)
- [Basal cell adenocarcinoma of prostate gland](#)
- [Basal peripheral zone of prostate](#)

- [Basal transition zone of prostate](#)
- [Base of prostate](#)
- [Baseline](#)
- [Benign](#)
- [Benign adenomatous neoplasm](#)
- [Benign neoplasm of liver](#)
- [Benign neoplastic disease](#)
- [Benign prostatic hyperplasia](#)
- [Benign tumor of digestive organ](#)
- [Bilateral](#)
- [Biliary tract structure](#)
- [Binary](#)
- [Biomedical device](#)
- [Biopsy](#)
- [Biopsy finding](#)
- [Biopsy of abdomen using ultrasound guidance](#)
- [Biopsy of male genital system](#)
- [Biopsy of prostate](#)
- [Biopsy of trunk](#)
- [Biopsy result abnormal](#)
- [Biopsy result normal](#)
- [Bladder control - finding](#)
- [Bladder finding](#)
- [Block dissection of pelvic lymph nodes](#)
- [Body organ structure](#)
- [Body part](#)
- [Body part structure](#)
- [Body structure](#)
- [Body substance sample](#)
- [Bone and/or joint structure of cranium](#)
- [Bone structure of femur](#)
- [Bone structure of head](#)
- [Bounding box](#)
- [Bowel finding](#)
- [Bowels: fully continent](#)
- [Brain](#)
- [Brain and spinal cord structure](#)
- [Brain stem](#)
- [BRCA1 gene mutation detected](#)
- [BRCA1 gene mutation not detected](#)
- [BRCA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal](#)
- [BRCA1 mutation carrier detection test](#)
- [BRCA1+BRCA2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal](#)
- [BRCA2 gene mutation detected](#)
- [BRCA2 gene mutation not detected](#)
- [BRCA2 mutation carrier detection test](#)
- [Breast](#)
- [Breast cancer](#)
- [Breast cancer genetic marker of susceptibility detected](#)
- [Breast cancer genetic marker of susceptibility not detected](#)
- [Breast fed](#)
- [Breast finding](#)
- [Breast signs and symptoms](#)
- [Bronchus and lung](#)

- [C reactive protein \[Mass/volume\] in Blood by High sensitivity method](#)
- [Calcifications](#)
- [Calcium \[Mass/volume\] in Blood](#)
- [Cancer Ag 15-3](#)
- [Cancer Ag 15-3 \[Units/volume\] in Serum or Plasma](#)
- [Cancer Ag 15-3 | Serum or Plasma | Chemistry - non-challenge](#)
- [Cancer Ag 15-3|Arbitrary Concentration|Moment in time|Blood, Serum or Plasma](#)
- [Cancer antigen 15-3 measurement](#)
- [Cancer Grade](#)
- [Cancer of prostate](#)
- [Cancer Patient](#)
- [Cancer staging](#)
- [Canon](#)
- [Capecitabine](#)
- [Carbamazepine Injection](#)
- [Carboplatin](#)
- [Carcinoembryonic Ag.\[Mass/volume\] in Serum or Plasma](#)
- [Carcinoembryonic Ag|Mass Concentration|Moment in time|Blood, Serum or Plasma](#)
- [Carcinoembryonic Ag|Moment in time|Serum or Plasma](#)
- [Carcinoembryonic antigen measurement](#)
- [Carcinoma in situ](#)
- [Carcinoma in situ of male genital organ](#)
- [Carcinoma in situ of prostate](#)
- [Carcinoma of breast](#)
- [Carcinoma of colon](#)
- [Carcinoma of genital organ](#)
- [Carcinoma of prostate](#)
- [Care regime](#)
- [Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain](#)
- [Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain](#)
- [Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain](#)
- [Central zone of left half prostate](#)
- [Central zone of prostate](#)
- [Central zone of right half prostate](#)
- [Cervical spine](#)
- [Chemoradiotherapy](#)
- [Chemotherapy](#)
- [Chemotherapy cycle](#)
- [Chemotherapy Regimen](#)
- [Chest](#)
- [Chest and abdomen](#)
- [Chest imaging](#)
- [Chest injury](#)
- [Chest, abdomen, and pelvis](#)
- [Child-Pugh score](#)
- [Child-Pugh score class A](#)
- [Child-Pugh score class B](#)
- [Child-Pugh score class C](#)
- [Cholangiocarcinoma](#)
- [Cholangitis](#)
- [Cholesterol \[Mass/volume\] in Serum or Plasma](#)
- [Cholesterol in HDL \[Mass/volume\] in Serum or Plasma](#)
- [Cholesterol in LDL \[Mass/volume\] in Serum or Plasma](#)
- [Cholesterol measurement](#)

- [Chronic digestive system disorder](#)
- [Chronic disease](#)
- [Chronic disease monitoring](#)
- [Chronic hepatitis](#)
- [Chronic inflammatory disorder](#)
- [Chronic liver disease](#)
- [Cirrhosis of liver](#)
- [Clinical equipment and/or device](#)
- [Clinical finding](#)
- [Clinical history/examination observable](#)
- [Clinical Module](#)
- [Clinical specialty](#)
- [Clinical Test Result](#)
- [Clip](#)
- [cM category](#)
- [cM0](#)
- [cM1](#)
- [cM1a](#)
- [cM1b](#)
- [cM1c](#)
- [cN category](#)
- [cN0](#)
- [cN1](#)
- [cN1mi](#)
- [cN2](#)
- [cN2a](#)
- [cN2b](#)
- [cN3](#)
- [cN3a](#)
- [cN3b](#)
- [cN3c](#)
- [cNX](#)
- [Co-morbid conditions](#)
- [Colon](#)
- [Colon and rectum](#)
- [Colon cancer](#)
- [Combined site](#)
- [Common Module](#)
- [Complete excision](#)
- [Computed tomography](#)
- [Conformal radiotherapy](#)
- [Context values](#)
- [Continent of urine](#)
- [Contouring](#)
- [Correspondence Module](#)
- [Cortisol \[Mass/volume\] in Serum or Plasma](#)
- [Creatinine \[Mass/volume\] in Blood](#)
- [Creatinine \[Mass/volume\] in Urine](#)
- [Cross-sectional abdomen](#)
- [Cross-sectional pelvis](#)
- [cross-sectional procedure attribute](#)
- [cT category](#)
- [cT0](#)
- [cT1](#)

- [cT1a](#)
- [cT1b](#)
- [cT1c](#)
- [cT1mi](#)
- [cT2](#)
- [cT2a](#)
- [cT2b](#)
- [cT2c](#)
- [cT3](#)
- [cT3a](#)
- [cT3b](#)
- [cT4](#)
- [cT4a](#)
- [cT4b](#)
- [cT4c](#)
- [cT4d](#)
- [cTisDCIs](#)
- [cTisPaget](#)
- [cubic millimeter](#)
- [Cyclophosphamide](#)
- [Cyst of abdomen](#)
- [Cyst of liver](#)
- [Cystadenoma of liver](#)
- [Cystic, mucinous and serous neoplasms](#)
- [Damage](#)
- [Dead](#)
- [Degenerative disorder](#)
- [Degrees of severity](#)
- [Deposit](#)
- [Derived](#)
- [Destructive procedure](#)
- [device](#)
- [Diagnosis](#)
- [Diagnostic ultrasonography procedure](#)
- [Diagnostic/Screening Processes or Results](#)
- [Diffuse intrinsic pontine glioma](#)
- [Digestive organ structure](#)
- [Digital examination](#)
- [Digital examination of rectum](#)
- [Digital mammography](#)
- [Digital Radiography](#)
- [Disease](#)
- [Disease caused by parasite](#)
- [Disease due to Taeniidae](#)
- [Disease Grade Qualifier](#)
- [Disease morphology qualifier](#)
- [Disease of liver](#)
- [Disease qualifier](#)
- [Disorder caused by alcohol](#)
- [Disorder due to infection](#)
- [Disorder of abdomen](#)
- [Disorder of abdominopelvic segment of trunk](#)
- [Disorder of body cavity](#)
- [Disorder of breast](#)

- [Disorder of digestive organ](#)
- [Disorder of digestive system](#)
- [Disorder of male genital organ](#)
- [Disorder of male reproductive system](#)
- [Disorder of pelvic region of trunk](#)
- [Disorder of pelvis](#)
- [Disorder of prostate](#)
- [Disorder of thoracic segment of trunk](#)
- [Disorder of thorax](#)
- [Disorder of trunk](#)
- [Distant Metastasis \(NOS\)](#)
- [Docetaxel](#)
- [Docetaxel Injection](#)
- [Domain-OMOP](#)
- [Domain: Drug](#)
- [Domain: Meas Value](#)
- [Domain: Measurement](#)
- [Domain: Observation](#)
- [Domain: Observation](#)
- [Domain: Procedure](#)
- [Domain: Spec Anatomic Site](#)
- [Doxorubicin](#)
- [Doxorubicin liposomal](#)
- [Drug measurement](#)
- [Drug or medicament](#)
- [Drug therapy](#)
- [Drug-induced disorder of liver](#)
- [Drug-induced lesion](#)
- [Drug-related disorder](#)
- [DUCT CARCINOMA/ Invasive carcinoma of no special type](#)
- [Ductal and lobular neoplasms](#)
- [Durvalumab](#)
- [Dysplasia](#)
- [Dysplastic nodule](#)
- [Ear](#)
- [Ear, nose and throat structure](#)
- [Echinococcosis](#)
- [Echinococcosis of liver](#)
- [ECOG performance status - grade 0](#)
- [ECOG performance status - grade 1](#)
- [ECOG performance status - grade 2](#)
- [ECOG performance status - grade 3](#)
- [ECOG performance status - grade 4](#)
- [ECOG performance status - grade 5](#)
- [ECOG performance status finding](#)
- [Edition of American Joint Commission on Cancer, Cancer Staging Manual used for TNM staging](#)
- [Elscint](#)
- [Embryonal neuroepithelial tumor](#)
- [Endocrine gland structure](#)
- [ENDOCRINE THERAPY](#)
- [Endoscopic operation](#)
- [Endoscopic procedure](#)
- [Entire body region](#)
- [Entire limb](#)

- [Enzyme level - finding](#)
- [Enzyme measurement](#)
- [Epirubicin](#)
- [ER negative](#)
- [ER positive](#)
- [ERBB2 gene duplication \[Presence\] in Breast cancer specimen by FISH](#)
- [Eribulin](#)
- [Esaote](#)
- [Estrogen receptor Ag.\[Presence\] in Breast cancer specimen by Immune stain](#)
- [Evaluation finding](#)
- [Evaluation of gastrointestinal tract](#)
- [Evaluation procedure](#)
- [Examination by method](#)
- [Examination of abdomen](#)
- [Excision](#)
- [Excision of abdominal lymph node](#)
- [Excision of pelvic lymph node](#)
- [Excision of pelvis](#)
- [Exemestane](#)
- [External beam radiation therapy procedure](#)
- [Extramural vein invasion](#)
- [Extramural vein invasion \[Presence\] in Colorectal cancer specimen by Light microscopy](#)
- [Extramural vein invasion | Colorectal cancer specimen | Pathology.](#)
- [Extraprostatic Extension \(EPE\)](#)
- [Extremity](#)
- [Extremity part](#)
- [Eye region structure](#)
- [Face and/or neck structure](#)
- [Family history of cancer](#)
- [Family history of clinical finding](#)
- [Family history of disorder](#)
- [Family history of neoplasm](#)
- [Family history unknown](#)
- [Family history with explicit context](#)
- [Feet first orientation](#)
- [FEMALE](#)
- [Female \(finding\)](#)
- [Female genital tract functions](#)
- [Female genital tract structure](#)
- [Female genitalia finding](#)
- [Fibrolamellar hepatocellular carcinoma](#)
- [Finding context value](#)
- [Finding of abdomen](#)
- [Finding of abdominopelvic segment of trunk](#)
- [Finding of bowel continence](#)
- [Finding of change compared to previous radiologic examination](#)
- [Finding of change compared to previous radiologic examination finding](#)
- [Finding of defecation](#)
- [Finding of Hepatitis B status](#)
- [Finding of Hepatitis C status](#)
- [Finding of immune status](#)
- [Finding of large intestine](#)
- [Finding of lesion](#)
- [Finding of pelvic region of trunk](#)

- [Finding of pelvis](#)
- [Finding of region of thorax](#)
- [Finding of sexual function](#)
- [Finding of substance level](#)
- [Finding of trunk structure](#)
- [Finding of upper trunk](#)
- [Finding of urinary tract proper](#)
- [Finding related to biological sex](#)
- [Finding suspected or known present](#)
- [Finding value](#)
- [Finding with explicit context](#)
- [First degree](#)
- [Flowsheet - laboratory](#)
- [Fluorouracil](#)
- [focal damage](#)
- [Focal nodular hyperplasia of liver](#)
- [FOLFIRI](#)
- [FOLFIRINOX](#)
- [FOLFOX](#)
- [Follow-up](#)
- [Follow-up status](#)
- [Foot](#)
- [Free prostate specific antigen level](#)
- [Free:total PSA ratio](#)
- [Frequencies](#)
- [Frequency interval](#)
- [Fujifilm](#)
- [Function](#)
- [Functional finding](#)
- [Functional finding of gastrointestinal tract](#)
- [G1 - American Joint Committee on Cancer grade G1](#)
- [G2 - American Joint Committee on Cancer grade G2](#)
- [G3 - American Joint Committee on Cancer grade G3](#)
- [Gallbladder](#)
- [Gamma glutamyl transferase \[Enzymatic activity/volume\] in Serum or Plasma](#)
- [Gastrointestinal and digestive injury](#)
- [Gastrointestinal tract finding](#)
- [Gemcitabine](#)
- [Gender](#)
- [Gene mutation](#)
- [General adjectival modifier](#)
- [General body state finding](#)
- [General clinical state finding](#)
- [General Electric](#)
- [General finding of observation of patient](#)
- [General problem AND/OR complaint](#)
- [Generic tumor staging descriptor](#)
- [Genetic finding](#)
- [Genetic finding detected](#)
- [Genetic finding not detected](#)
- [Genetic test](#)
- [Genital finding](#)
- [Genitourinary sample](#)
- [Glandular zone of prostate](#)



- [Gleason finding](#)
- [Gleason grade finding for prostatic cancer](#)
- [Gleason grade group 1](#)
- [Gleason grade group 2](#)
- [Gleason grade group 3](#)
- [Gleason grade group 4](#)
- [Gleason grade group 5](#)
- [Gleason grade score 10 out of 10](#)
- [Gleason grade score 2 out of 10](#)
- [Gleason grade score 3 out of 10](#)
- [Gleason grade score 4 out of 10](#)
- [Gleason grade score 5 out of 10](#)
- [Gleason grade score 6 out of 10](#)
- [Gleason grade score 7 out of 10](#)
- [Gleason grade score 8 out of 10](#)
- [Gleason grade score 9 out of 10](#)
- [Gleason Primary Pattern Grade 1](#)
- [Gleason Primary Pattern Grade 2](#)
- [Gleason Primary Pattern Grade 3](#)
- [Gleason Primary Pattern Grade 4](#)
- [Gleason Primary Pattern Grade 5](#)
- [Gleason Secondary Pattern Grade 1](#)
- [Gleason Secondary Pattern Grade 2](#)
- [Gleason Secondary Pattern Grade 3](#)
- [Gleason Secondary Pattern Grade 4](#)
- [Gleason Secondary Pattern Grade 5](#)
- [Glucose \[Mass/volume\] in Venous blood](#)
- [Glycoproteins measurement](#)
- [Gonadotropin releasing hormone analogues](#)
- [Grade 1 tumor](#)
- [Grade 2 tumor](#)
- [Grade 3 tumor](#)
- [Grade 4 tumor](#)
- [Grades](#)
- [Gravida \(observable entity\)](#)
- [Growth alteration](#)
- [GX: Histologic grade cannot be assessed](#)
- [Head](#)
- [Head and neck](#)
- [Head first orientation](#)
- [Heart](#)
- [Heart and/or pericardium structure](#)
- [Heart, mediastinum, and pleura](#)
- [Hemangioma](#)
- [Hematocrit \[Volume Fraction\] of Blood](#)
- [Hemoglobin \[Mass/volume\] in Blood](#)
- [Hemoglobin A1c/Hemoglobin.total in Blood by HPLC](#)
- [Hepatic cystadenoma](#)
- [Hepatic fibrosis](#)
- [HER2](#)
- [HER2 \[Presence\] in Breast cancer specimen by Immune stain](#)
- [HER2 negative](#)
- [HER2 positive](#)
- [HER2 | Breast cancer specimen | Pathology](#)

- [High density lipoprotein cholesterol measurement](#)
- [High risk of recurrence, prostate cancer](#)
- [Hip joint](#)
- [Hip region structure](#)
- [Histologic feature of neoplasm](#)
- [Histologic test](#)
- [Histologic type of malignant neoplasm](#)
- [Histologic type of primary malignant neoplasm](#)
- [Histological](#)
- [Histological grades](#)
- [Histopathology](#)
- [Histopathology finding](#)
- [Histopathology Result](#)
- [Histopathology test](#)
- [History of clinical finding in subject](#)
- [Hitachi](#)
- [HORMONE ANTAGONISTS AND RELATED AGENTS](#)
- [Hormone measurement](#)
- [Hormone receptor negative neoplasm](#)
- [Hormone receptor positive tumor](#)
- [Hormone refractory prostate cancer](#)
- [Hormone replacement therapy](#)
- [Hormone sensitive prostate cancer](#)
- [Hormone therapy](#)
- [HORMONES AND RELATED AGENTS](#)
- [Human epidermal growth factor 2 negative carcinoma of breast](#)
- [Hyperplasia of prostate](#)
- [Hypofractionated stereotactic radiotherapy using megavoltage radiation](#)
- [I](#)
- [I.M.S](#)
- [IGRT \(image-guided radiation therapy\)](#)
- [II](#)
- [IIA](#)
- [IIB](#)
- [IIC](#)
- [III](#)
- [IIIA](#)
- [IIIB](#)
- [IIIC](#)
- [Imaging \(Procedure\)](#)
- [Imaging by body site](#)
- [Imaging finding](#)
- [Imaging guidance](#)
- [Imaging guided biopsy](#)
- [Imaging modality](#)
- [Imaging Module](#)
- [Imaging observable](#)
- [Imaging of abdomen](#)
- [Imaging of genitourinary system](#)
- [Imaging of pelvis](#)
- [imaging procedure descriptor](#)
- [imaging procedure property](#)
- [Imaging result abnormal](#)
- [Imaging result normal](#)

- [Immunologic agent](#)
- [Immunological therapy](#)
- [Immunotherapeutic agent](#)
- [Immunotherapy](#)
- [Immunotherapy for cancer](#)
- [Impaired urinary system function](#)
- [Incontinence](#)
- [Incontinence of feces](#)
- [Indeterminate](#)
- [Infant feeding method - finding](#)
- [Infection of liver caused by parasite](#)
- [Infiltrating duct carcinoma of prostate](#)
- [Infiltrating duct carcinoma, NOS, of prostate gland](#)
- [Inflammation of specific body organs](#)
- [Inflammatory disease of liver](#)
- [Injury of abdomen](#)
- [Injury of breast](#)
- [Insulin \[Units/volume\] in Serum or Plasma](#)
- [Insulin measurement](#)
- [Intensity modulated radiation therapy](#)
- [Intermediate risk of recurrence, prostate cancer](#)
- [Interpretation of findings](#)
- [Intervals of weeks and months](#)
- [Interventional procedure](#)
- [Intestinal structure](#)
- [Intra-abdominal collection](#)
- [Intra-abdominal digestive structure](#)
- [Intra-abdominal proper structure](#)
- [Intra-abdominal urinary structure](#)
- [Intra-abdominopelvic structure](#)
- [Intra-pelvic structure of true pelvis](#)
- [Intraabdominal bile collection](#)
- [Intracranial structure](#)
- [Intraductal carcinoma, noninfiltrating, NOS, of prostate gland](#)
- [Invasion into the Seminal vesicle](#)
- [Invasive](#)
- [IV](#)
- [IVA](#)
- [IVB](#)
- [Joint structure of lower extremity](#)
- [Joint structure of pelvic girdle](#)
- [Kidney](#)
- [Knee](#)
- [Known](#)
- [Known absent](#)
- [Known present](#)
- [Laboratory procedure](#)
- [Laboratory procedure categorized by method](#)
- [Laboratory procedure performed](#)
- [Laboratory Procedures](#)
- [Laboratory test](#)
- [Laboratory Test Result](#)
- [Lactate dehydrogenase \[Enzymatic activity/volume\] in Red Blood Cells](#)
- [Laparoscopic procedure](#)

- [Laparoscopic Procedures on the Prostate](#)
- [Laparoscopic prostatectomy](#)
- [Laparoscopic radical prostatectomy](#)
- [Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed](#)
- [Lapatinib](#)
- [Large cell neuroendocrine carcinoma of prostate gland](#)
- [Large intestine part](#)
- [Laterality](#)
- [Left anterior apical part of transition zone of prostate](#)
- [Left anterior apical peripheral zone of prostate](#)
- [Left anterior basal peripheral zone of prostate](#)
- [Left anterior basal transition zone of prostate](#)
- [Left anterior middle peripheral zone of prostate](#)
- [Left anterior middle transition zone of prostate](#)
- [Left apical anterior fibromuscular stroma of prostate](#)
- [Left apical peripheral zone of prostate](#)
- [Left apical transition zone of prostate](#)
- [Left basal anterior fibromuscular stroma of prostate](#)
- [Left basal peripheral zone of prostate](#)
- [Left basal transition zone of prostate](#)
- [Left breast structure](#)
- [Left lateral middle peripheral zone of prostate](#)
- [Left middle anterior fibromuscular stroma of prostate](#)
- [Left middle transition zone of prostate](#)
- [Left position](#)
- [Left posterior apical part of transition zone of prostate](#)
- [Left posterior basal transition zone of prostate](#)
- [Left posterior middle transition zone of prostate](#)
- [Left posterolateral apical peripheral zone of prostate](#)
- [Left posterolateral basal peripheral zone of prostate](#)
- [Left posterolateral middle peripheral zone of prostate](#)
- [Left posteromedial apical peripheral zone of prostate](#)
- [Left posteromedial middle peripheral zone of prostate](#)
- [Left thorax structure](#)
- [Length dimension of neoplasm](#)
- [Lesion](#)
- [Lesion observable](#)
- [Lesion of liver](#)
- [Lesion of prostate](#)
- [Lesion size](#)
- [Lesion size, additional dimension](#)
- [Lesion size, greatest dimension](#)
- [Letrozole](#)
- [Leukocytes \[# /volume\] in Stem cell product](#)
- [Liver](#)
- [Liver and intrahepatic bile ducts](#)
- [Liver and/or biliary structure](#)
- [Liver cancer](#)
- [Liver cell carcinoma](#)
- [Liver damage](#)
- [Liver disorder due to infection](#)
- [Liver finding](#)
- [Liver mass](#)

- [Liver regeneration](#)
- [Low density lipoprotein cholesterol measurement](#)
- [Low risk of recurrence, prostate cancer](#)
- [Lower body part structure](#)
- [Lower bowel structures](#)
- [Lower gastrointestinal procedure](#)
- [Lower respiratory tract structure](#)
- [Lumbar spine](#)
- [Lumbosacral region of spine structure](#)
- [Lumbosacral spine](#)
- [Lung](#)
- [Lung cancer](#)
- [Lymph node observable](#)
- [Lymph node structure of limb](#)
- [Lymph Nodes with Metastasis](#)
- [Lymphatic \(small vessel\) tumor invasion finding](#)
- [Lymphatic small vessel invasion by tumor absent](#)
- [Lymphatic small vessel invasion by tumor present](#)
- [Lymphovascular invasion](#)
- [Lymphovascular invasion extent](#)
- [Lymphovascular invasion extent in Cancer specimen Qualitative](#)
- [Lymphovascular invasion extent | Cancer specimen | Pathology](#)
- [M category](#)
- [Macrocalcifications](#)
- [Magnetic resonance imaging](#)
- [Magnetic resonance imaging guidance](#)
- [Magnetic resonance imaging of breast for screening for malignant neoplasm procedure](#)
- [MALE](#)
- [Male \(finding\)](#)
- [Male genital organ structure](#)
- [Male genital sample](#)
- [Malignant](#)
- [Malignant adenomatous neoplasm](#)
- [Malignant adenomatous neoplasm - category](#)
- [Malignant epithelial neoplasm](#)
- [Malignant glioma](#)
- [Malignant lymphoma](#)
- [Malignant lymphoma of liver](#)
- [Malignant neoplasm of abdomen](#)
- [Malignant neoplasm of anorectum](#)
- [Malignant neoplasm of colon and/or rectum](#)
- [Malignant neoplasm of female breast](#)
- [Malignant neoplasm of genital structure](#)
- [Malignant neoplasm of genitourinary organ](#)
- [Malignant neoplasm of intraabdominal organ](#)
- [Malignant neoplasm of lower respiratory tract](#)
- [Malignant neoplasm of rectum](#)
- [Malignant neoplasm of thorax](#)
- [Malignant neoplasms of digestive organs](#)
- [Malignant neoplastic disease](#)
- [Malignant neuroendocrine neoplasm, neural](#)
- [Malignant neuroendocrine tumor](#)
- [Malignant tumor of axilla](#)
- [Malignant tumor of digestive organ](#)

- [Malignant tumor of intestine](#)
- [Malignant tumor of large intestine](#)
- [Malignant tumor of lymphoid hemopoietic and related tissue](#)
- [Malignant tumor of male genital organ](#)
- [Malignant tumor of pelvis](#)
- [Malignant tumor of upper limb](#)
- [Malignant tumor staging](#)
- [Mammographic architectural distortion of breast finding](#)
- [Mammographic breast composition finding \(finding\)](#)
- [Mammographic breast tissue appearance](#)
- [Mammography](#)
- [Mammography assessment finding](#)
- [Mammography finding](#)
- [Mammography normal](#)
- [Mammography reference location](#)
- [Management of drug regimen](#)
- [Manual](#)
- [Manufacturer](#)
- [Marconi](#)
- [Mass](#)
- [Mass of digestive structure](#)
- [Mass-Molar conversion](#)
- [Measure of pregnancy](#)
- [Measurement](#)
- [Measurement finding](#)
- [Measurement finding within reference range](#)
- [Measurement of level of drug in blood](#)
- [Measurement of level of substance in blood](#)
- [Measurement of liver enzyme](#)
- [Measurement of substance](#)
- [Measurement of substance in specimen](#)
- [Mediastinum](#)
- [Medical therapy](#)
- [Medication](#)
- [Medication Review](#)
- [Mediso](#)
- [Melan-A and Ki67 Ag.\[Identifier\] in Tissue by Immune stain](#)
- [Menopause finding](#)
- [Menopause, function](#)
- [Metastasis](#)
- [Metastasis to adrenal gland](#)
- [Metastasis to bone](#)
- [Metastasis to brain](#)
- [Metastasis to central nervous system](#)
- [Metastasis to digestive organ](#)
- [Metastasis to digestive organs](#)
- [Metastasis to endocrine gland](#)
- [Metastasis to intrathoracic organs](#)
- [Metastasis to kidney](#)
- [Metastasis to lung](#)
- [Metastasis to nervous system](#)
- [Metastasis to retroperitoneum](#)
- [Metastasis to the Viscera](#)
- [Methotrexate](#)

- [mg/kg](#)
- [mg/m<sup>2</sup>](#)
- [Microscopic specimen observation](#)
- [Middle anterior fibromuscular stroma of prostate](#)
- [Middle peripheral zone of prostate](#)
- [Middle region of prostate](#)
- [Middle transition zone of prostate](#)
- [MiE](#)
- [millimeter](#)
- [Missing Value Reason](#)
- [Mixed neuroendocrine non-neuroendocrine neoplasm](#)
- [Modified Ryan Scheme for Tumor Regression](#)
- [Modifier mainly for procedure](#)
- [Molecular genetic test](#)
- [Molecular pathology](#)
- [Monitoring of patient](#)
- [Monitoring of patient with cancer](#)
- [Morphologic Finding](#)
- [Morphologically abnormal structure](#)
- [Morphologically altered structure](#)
- [MR Echo Type](#)
- [MR procedure attribute](#)
- [MRI guided biopsy](#)
- [MRI guided biopsy of prostate](#)
- [MRI of breast](#)
- [MRI of breast for screening](#)
- [MRI of breast for screening for malignant neoplasm](#)
- [MRI of chest](#)
- [MRI of pelvis](#)
- [MRI of prostate](#)
- [MRI scan abnormal](#)
- [MRI scan normal](#)
- [MRI-US fusion guided prostate biopsy](#)
- [Mucinous adenocarcinoma](#)
- [Multiparametric magnetic resonance imaging](#)
- [Multiparametric MRI of prostate](#)
- [Musculoskeletal structure of sacral spine](#)
- [Musculoskeletal structure of spine](#)
- [N category](#)
- [Nab paclitaxel](#)
- [nanogram per deciliter](#)
- [nanogram per milliliter](#)
- [nanomole per liter](#)
- [Natriuretic peptide B \[Mass/volume\] in Blood](#)
- [Neck](#)
- [Neck and chest](#)
- [Neck, chest and abdomen](#)
- [Negative](#)
- [Neoadjuvant antineoplastic therapy](#)
- [Neoplasm](#)
- [Neoplasm and/or hamartoma](#)
- [Neoplasm observable](#)
- [Neoplasm of axilla](#)
- [Neoplasm of axillary lymph nodes](#)

- [Neoplasm of breast](#)
- [Neoplasm of colon](#)
- [Neoplasm of digestive organ](#)
- [Neoplasm of extremity](#)
- [Neoplasm of female breast](#)
- [Neoplasm of intra-abdominal organs](#)
- [Neoplasm of large intestine](#)
- [Neoplasm of liver](#)
- [Neoplasm of lung](#)
- [Neoplasm of male genital organ](#)
- [Neoplasm of pelvis](#)
- [Neoplasm of prostate](#)
- [Neoplasm of rectum](#)
- [Neoplasm of shoulder](#)
- [Neoplasm of trunk](#)
- [Neoplasm of upper limb](#)
- [Neoplasm, benign](#)
- [Neoplasm, malignant of prostate gland](#)
- [Neoplastic disease](#)
- [Neuroblastoma](#)
- [Neuroendocrine carcinoma](#)
- [Neuroendocrine Carcinoma, NOS](#)
- [Neuroendocrine tumor](#)
- [Neuroendocrine tumor, NOS, of prostate gland](#)
- [No anti-cancer treatment - watchful waiting](#)
- [No family history of clinical finding](#)
- [No vascular invasion by tumor](#)
- [Nodule](#)
- [Non-alcoholic fatty liver disease](#)
- [Non-coronary systemic artery structure](#)
- [None](#)
- [Normal sexual function](#)
- [Not detected](#)
- [Not identified](#)
- [NotClassified](#)
- [Nuclear medicine](#)
- [Nuclear medicine imaging procedure](#)
- [Number of births at term](#)
- [Number of lymph nodes containing metastatic neoplasm in excised specimen](#)
- [Number of lymph nodes examined by microscopy in excised specimen](#)
- [Observable entity](#)
- [Obstetric history](#)
- [Open prostatectomy](#)
- [Operation on abdominal region](#)
- [Operation on male genital system](#)
- [Operation on prostate](#)
- [Operations by approach](#)
- [Operative procedure on pelvis](#)
- [Optic canal](#)
- [Orbit structure](#)
- [Organ within abdominopelvic cavity](#)
- [Other hormone antagonists and related agents](#)
- [Paclitaxel](#)
- [PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method](#)



- [Palbociclib](#)
- [Palpation](#)
- [Palpation of abdomen](#)
- [PAM50](#)
- [Pancreas](#)
- [Pathology](#)
- [Pathology Result](#)
- [Patient](#)
- [Patient Orientation](#)
- [Patient Position](#)
- [Pectoral region structure](#)
- [Pelvic alimentary structure](#)
- [Pelvic echography](#)
- [Pelvic lymphadenectomy](#)
- [Pelvic organ finding](#)
- [Pelvis](#)
- [Pelvis and lower extremities](#)
- [Pembrolizumab](#)
- [percent](#)
- [Performance measure status](#)
- [Perineal prostatectomy](#)
- [Perineural Invasion](#)
- [Perineural invasion \[Presence\] in Cancer specimen](#)
- [Perineural invasion | Cancer specimen | Pathology](#)
- [Peripheral zone of prostate](#)
- [Person](#)
- [Person in the healthcare environment](#)
- [Pertuzumab](#)
- [Pharmaceutical / biologic product \(product\)](#)
- [Pharmacological assessment](#)
- [Pharmacotherapy](#)
- [Philips](#)
- [Physical object](#)
- [Picker International](#)
- [Platelets \[# / volume\] in Blood](#)
- [pM category](#)
- [pM0](#)
- [pM1](#)
- [pM1a](#)
- [pM1b](#)
- [pM1c](#)
- [pM1d](#)
- [pN category](#)
- [pN0](#)
- [pN1](#)
- [pN2](#)
- [pN3](#)
- [pN3a](#)
- [pN3b](#)
- [pN3c](#)
- [pNX](#)
- [Positive](#)
- [Positron emission tomography](#)
- [Postmenopausal - Menopause present](#)

- [Potassium \[Mass/volume\] in Blood](#)
- [PR negative](#)
- [PR positive](#)
- [Pregnancy observable](#)
- [Pregnancy, childbirth / puerperium observable](#)
- [Premenopause - Menopause absent](#)
- [Presence findings](#)
- [Presence of direct invasion by malignant neoplasm](#)
- [Presence of direct invasion by neoplasm](#)
- [Presence of direct invasion by primary malignant neoplasm](#)
- [Presence of direct invasion by primary malignant neoplasm to lymphatic vessel and/or small blood vessel](#)
- [Presence of metastatic discontinuous spread of malignant neoplasm of colon to pericolic tissue](#)
- [Presence of metastatic discontinuous spread of primary malignant neoplasm](#)
- [Present](#)
- [Primary](#)
- [Primary adenocarcinoma of pelvis](#)
- [Primary Gleason Pattern 1](#)
- [Primary Gleason Pattern 2](#)
- [Primary Gleason Pattern 3](#)
- [Primary Gleason Pattern 4](#)
- [Primary Gleason Pattern 5](#)
- [Primary malignant adenomatous neoplasm](#)
- [Primary malignant neoplasm](#)
- [Primary malignant neoplasm of abdomen](#)
- [Primary malignant neoplasm of breast](#)
- [Primary malignant neoplasm of breast with axillary lymph node invasion](#)
- [Primary malignant neoplasm of colon](#)
- [Primary malignant neoplasm of female breast](#)
- [Primary malignant neoplasm of intestinal tract](#)
- [Primary malignant neoplasm of intra-abdominal organs](#)
- [Primary malignant neoplasm of large intestine](#)
- [Primary malignant neoplasm of liver](#)
- [Primary malignant neoplasm of male genital organ](#)
- [Primary malignant neoplasm of pelvis](#)
- [Primary malignant neoplasm of prostate](#)
- [Primary malignant neoplasm of rectum](#)
- [Primary malignant neoplasm of trunk](#)
- [Primary pattern unknown, secondary pattern unknown](#)
- [Primary sclerosing cholangitis](#)
- [Primary tumor size](#)
- [problematic](#)
- [Procedure](#)
- [Procedure carried out on subject](#)
- [Procedure on abdomen](#)
- [Procedure on genitourinary system](#)
- [Procedure on large intestine](#)
- [Procedure on lymph node](#)
- [Procedure on lymphoid organ](#)
- [Procedure on male genital organ](#)
- [Procedure on male genital system](#)
- [Procedure on organ](#)
- [Procedure on pelvic region of trunk](#)
- [Procedure on pelvis](#)
- [Procedure on prostate](#)

- [Procedure on rectum](#)
- [Procedure on thorax](#)
- [Procedure on trunk](#)
- [Procedure with explicit context](#)
- [Procedures on breast](#)
- [Progesterone receptor Ag \[Presence\] in Breast cancer specimen by Immune stain](#)
- [Progesterone receptor Ag \[Presence\] in Breast cancer specimen by Immune stain \(LOINC, 85339-0\),](#)
- [Projection radiography](#)
- [Prostate](#)
- [Prostate and vas deferens structures](#)
- [Prostate cancer risk of recurrence not determined or neither low, intermediate nor high](#)
- [Prostate finding](#)
- [Prostate mass](#)
- [Prostate part](#)
- [Prostate specific Ag \[Mass/volume\] in Serum or Plasma](#)
- [Prostate specific antigen measurement](#)
- [Prostate specific antigen normal](#)
- [Prostatectomy](#)
- [Prostatic and/or seminal vesicle structures](#)
- [Prostatic gland structure](#)
- [Protein level - finding](#)
- [Protein measurement](#)
- [pT category](#)
- [pT0](#)
- [pT1](#)
- [pT2](#)
- [pT2a](#)
- [pT2b](#)
- [pT2c](#)
- [pT3](#)
- [pT3a](#)
- [pT3b](#)
- [pT4](#)
- [pT4a](#)
- [pT4b](#)
- [pTis](#)
- [pTX](#)
- [Pulmonary structure including vessels and lymphoid tissue](#)
- [Qualifier](#)
- [Qualifier for certainty of diagnosis](#)
- [Qualitative distribution of primary malignant neoplasm](#)
- [Radiation oncology AND/OR radiotherapy](#)
- [Radiation Therapy \(Procedure\)](#)
- [Radiation Therapy @ Male Reproductive System \(Procedure\)](#)
- [Radiation Therapy @ Male Reproductive System @ Beam Radiation @ Prostate Display label: Beam Radiation of Prostate](#)
- [Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate](#)
- [Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate @ High Dose Rate \(HDR\) \(Display label: Brachytherapy of Prostate - High Dose Rate\)](#)
- [Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate @ Low Dose Rate \(LDR\) \(Display label: Brachytherapy of Prostate - Low Dose Rate\)](#)
- [Radiation therapy care](#)
- [Radiation Therapy, Male Reproductive System, Beam Radiation](#)
- [Radiation Therapy, Male Reproductive System, Brachytherapy](#)

- [Radical Perineal prostatectomy](#)
- [Radical prostatectomy](#)
- [Radical Retropubic prostatectomy](#)
- [Radiographic imaging procedure](#)
- [Radiographic lesion margin characteristics](#)
- [Radiographic lesion shape finding](#)
- [Radiographic procedure of chest](#)
- [Radiologic finding](#)
- [Radiology result normal](#)
- [Ranked categories](#)
- [Reason for no specific anti-cancer treatment](#)
- [Reasons for treatment](#)
- [Rectal cancer](#)
- [Rectal examination](#)
- [Rectum](#)
- [Recurrent tumor](#)
- [Regimes and therapies](#)
- [Region of prostate](#)
- [Regional lymph node structure](#)
- [Regional lymph nodes examined \[#\]. Specimen](#)
- [Regular frequency](#)
- [Removal](#)
- [Removal - action](#)
- [Removal of entire genital organ](#)
- [removal technique](#)
- [Residual cancer burden class](#)
- [ResourceType-FHIR](#)
- [ResourceType: Condition](#)
- [ResourceType: Diagnostic Report](#)
- [ResourceType: Medication Administration](#)
- [ResourceType: Observation](#)
- [Retroperitoneal compartment structure](#)
- [Retropubic prostatectomy](#)
- [Ribociclib](#)
- [Right anterior apical part of transition zone of prostate](#)
- [Right anterior apical peripheral zone of prostate](#)
- [Right anterior basal peripheral zone of prostate](#)
- [Right anterior basal transition zone of prostate](#)
- [Right anterior middle peripheral zone of prostate](#)
- [Right anterior middle transition zone of prostate](#)
- [Right apical anterior fibromuscular stroma of prostate](#)
- [Right apical peripheral zone of prostate](#)
- [Right apical transition zone of prostate](#)
- [Right basal anterior fibromuscular stroma of prostate](#)
- [Right basal peripheral zone of prostate](#)
- [Right basal transition zone of prostate](#)
- [Right breast structure](#)
- [Right lateral middle peripheral zone of prostate](#)
- [Right middle anterior fibromuscular stroma of prostate](#)
- [Right middle transition zone of prostate](#)
- [Right position](#)
- [Right posterior apical part of transition zone of prostate](#)
- [Right posterior basal transition zone of prostate](#)
- [Right posterior middle transition zone of prostate](#)

- [Right posterolateral apical peripheral zone of prostate](#)
- [Right posterolateral basal peripheral zone of prostate](#)
- [Right posterolateral middle peripheral zone of prostate](#)
- [Right posteromedial apical peripheral zone of prostate](#)
- [Right posteromedial middle peripheral zone of prostate](#)
- [Right thorax structure](#)
- [Robot assisted laparoscopic radical prostatectomy](#)
- [Robotic assisted surgery](#)
- [Sacituzumab govitecan](#)
- [Sacrum](#)
- [Sampling - action \(qualifier value\)](#)
- [Sarcoma](#)
- [Sarcoma of liver](#)
- [Scalp and/or neck structure](#)
- [Sclerosing cholangitis](#)
- [Screening for cancer](#)
- [Screening for disorder](#)
- [Screening for malignant neoplasm of breast](#)
- [Screening for neoplasm](#)
- [Screening procedure](#)
- [Second degree](#)
- [Secondary Gleason Pattern 1](#)
- [Secondary Gleason Pattern 2](#)
- [Secondary Gleason Pattern 3](#)
- [Secondary Gleason Pattern 4](#)
- [Secondary Gleason Pattern 5](#)
- [Secondary malignant neoplasm of axilla](#)
- [Secondary malignant neoplasm of axillary lymph nodes](#)
- [Secondary malignant neoplasm of intra-abdominal organs](#)
- [Secondary malignant neoplasm of liver](#)
- [Secondary malignant neoplasm of trunk](#)
- [Secondary malignant neoplasm of viscera](#)
- [Secondary malignant neoplastic disease](#)
- [Semiautomatic](#)
- [Seminal Vesicles](#)
- [Serum testosterone measurement](#)
- [Sex assigned at birth](#)
- [Sexual function](#)
- [Shimadzu](#)
- [Shoulder](#)
- [Siemens](#)
- [Situation with explicit context](#)
- [Skull](#)
- [Skull foramen](#)
- [Small cell carcinoma](#)
- [Small cell carcinoma of prostate](#)
- [Small cell carcinoma, NOS, of prostate gland](#)
- [Small intestine](#)
- [Sodium \[Moles/volume\] in Blood](#)
- [Specimen](#)
- [Specimen from genital system](#)
- [Specimen from prostate](#)
- [Spine](#)
- [Squamous cell carcinoma](#)

- [Squamous cell carcinoma of male genital](#)
- [Squamous cell carcinoma of prostate](#)
- [Squamous cell carcinoma, NOS, of prostate gland](#)
- [Staging and scales](#)
- [Staining method](#)
- [Start time](#)
- [Status of regression of tumor](#)
- [steatosis of liver](#)
- [Stereotactic radiation therapy using megavoltage radiation](#)
- [Stereotactic radiotherapy](#)
- [Steroid measurement](#)
- [Stop time](#)
- [Structure of abdomen proper](#)
- [Structure of abdominopelvic organ](#)
- [Structure of abdominopelvic viscus](#)
- [Structure of ankle and/or foot](#)
- [Structure of anterior section of prostate](#)
- [Structure of apex of prostate](#)
- [Structure of body conduit](#)
- [Structure of breast and/or endocrine system](#)
- [Structure of compartment of abdomen](#)
- [Structure of endocrine system](#)
- [Structure of female genital system in pelvic cavity](#)
- [Structure of female internal genital organ](#)
- [Structure of femur](#)
- [Structure of free lower limb](#)
- [Structure of free upper limb](#)
- [Structure of genitourinary system](#)
- [Structure of great blood vessel \(organ\)](#)
- [Structure of half of body lateral to midsagittal plane](#)
- [Structure of half of thorax lateral to midsagittal plane](#)
- [Structure of half of trunk lateral to midsagittal plane](#)
- [Structure of joint region](#)
- [Structure of joint region of lower limb](#)
- [Structure of large artery](#)
- [Structure of large intestine](#)
- [Structure of lateral half of abdomen lateral to midsagittal plane](#)
- [Structure of left half of body](#)
- [Structure of left half of prostate](#)
- [Structure of lesser wing of sphenoid bone](#)
- [Structure of long bone of lower limb](#)
- [Structure of lung and/or mediastinum](#)
- [Structure of lymph node](#)
- [Structure of lymphatic system](#)
- [Structure of lymphatic system of axilla](#)
- [Structure of lymphatic system of upper limb](#)
- [Structure of mammary region](#)
- [Structure of musculoskeletal system of cervical spine](#)
- [Structure of musculoskeletal system of lumbar spine](#)
- [Structure of musculoskeletal system of thoracic spine](#)
- [Structure of orbital region](#)
- [Structure of organ in respiratory system](#)
- [Structure of organ within abdomen proper cavity](#)
- [Structure of organ within cavity of true pelvis](#)

- [Structure of pelvic segment of trunk](#)
- [Structure of pelvic viscus](#)
- [Structure of peripheral auditory system](#)
- [Structure of posterior arch of pelvic ring](#)
- [Structure of posterior section of prostate](#)
- [Structure of pulmopleural compartment](#)
- [Structure of right half of prostate](#)
- [Structure of shoulder and/or upper arm](#)
- [Structure of shoulder girdle region](#)
- [Structure of spheroidal joint](#)
- [Structure of subdivision of abdominopelvic compartment](#)
- [Structure of subregion of trunk](#)
- [Structure of thoracic cavity and/or content](#)
- [Structure of thoracic viscus](#)
- [Structure of upper urinary system](#)
- [Structure of urinary organ](#)
- [Structure of vertebral column and/or spinal cord](#)
- [Structure of vertebral region of cervical part of back](#)
- [Structure of vertebral region of lumbar part of back](#)
- [Structure of vertebral region of thoracic part of back](#)
- [Structure of viscus](#)
- [Subdivision of intra-abdominopelvic structure](#)
- [Surgical clip](#)
- [Surgical procedure](#)
- [Surgical Procedures on the Male Genital System](#)
- [Surgical Procedures on the Prostate](#)
- [Surgical removal](#)
- [Survival time](#)
- [Surviving free of recurrence of neoplastic disease](#)
- [Suspicious](#)
- [Systemic artery of trunk](#)
- [T category](#)
- [Tamoxifen](#)
- [Targeted medication therapy review](#)
- [TDM1](#)
- [Temporal Qualifier](#)
- [Testosterone measurement](#)
- [Therapeutic procedure](#)
- [Thoracic segment of trunk](#)
- [Thoracic spine](#)
- [Thyrotropin \[Units/volume\] in Blood](#)
- [Time patterns](#)
- [Timepoint](#)
- [Tissue Contrast](#)
- [Tissue specimen](#)
- [Tissue specimen from genital system](#)
- [Tissue specimen from prostate](#)
- [TNM category](#)
- [TNM classification of malignant tumor after operation](#)
- [TNM Clin M](#)
- [TNM Clin N](#)
- [TNM Clin Stage Group](#)
- [TNM Clin T](#)
- [TNM Path M](#)

- [TNM Path N](#)
- [TNM Path Stage Group](#)
- [TNM Path T](#)
- [TNM stage grouping](#)
- [TNM tumor staging classifications](#)
- [Tomography](#)
- [Toshiba](#)
- [Total prostate specific antigen level](#)
- [Transition zone of prostate](#)
- [Transitional cell carcinoma, NOS, of prostate gland](#)
- [Trastuzumab](#)
- [Trastuzumab deruxtecan](#)
- [Treatment changed](#)
- [Triglyceride \[Mass/volume\] in Blood](#)
- [Triple negative malignant neoplasm of breast](#)
- [Trunk excision](#)
- [Trunk structure](#)
- [Tucatinib](#)
- [Tumor antigen measurement](#)
- [Tumor calcification](#)
- [Tumor configuration \(finding\)](#)
- [Tumor configuration observable entity](#)
- [Tumor finding](#)
- [Tumor focality](#)
- [Tumor histopathological grade status values](#)
- [Tumor invasion finding](#)
- [Tumor invasion of perineural tissue absent \(prostate\)](#)
- [Tumor invasion of perineural tissue present \(prostate\)](#)
- [Tumor marker measurement](#)
- [Tumor Progression](#)
- [Tumor Regression Grade](#)
- [Tumor Regression Score 0](#)
- [Tumor Regression Score 1](#)
- [Tumor Regression Score 2](#)
- [Tumor Regression Score 3](#)
- [Tumor staging](#)
- [Tumor volume](#)
- [Ultrasonic guidance procedure](#)
- [Ultrasonographic observable](#)
- [Ultrasonography of abdomen](#)
- [Ultrasound](#)
- [Ultrasound guided biopsy](#)
- [Ultrasound scan finding](#)
- [Unilateral](#)
- [Unit of measure](#)
- [Unknown](#)
- [Upper body part structure](#)
- [Upper extremity part](#)
- [Upper limb lymph node structure](#)
- [Urate \[Mass/volume\] in Blood](#)
- [Urea \[Mass/volume\] in Blood](#)
- [Urinary incontinence](#)
- [Urinary system finding](#)
- [Urinary tract](#)



- [Urogenital finding](#)
- [US male genital system](#)
- [US scan and biopsy of pelvis](#)
- [US scan and biopsy of prostate](#)
- [US scan of genitourinary system](#)
- [US scan of prostate](#)
- [US-guided systematic biopsy](#)
- [Uses contraception \(finding\)](#)
- [Uses hormonal contraception](#)
- [Uterus](#)
- [Uterus and fallopian tubes](#)
- [Vascular invasion by tumor present](#)
- [Vinorelbine](#)
- [X-Ray Computed Tomography](#)
- [X-Ray mammography](#)
- [Yes](#)
- [ypN0](#)
- [ypN1](#)
- [ypN1a](#)
- [ypN1b](#)
- [ypN1c](#)
- [ypN1mi](#)
- [ypN2](#)
- [ypN2a](#)
- [ypN2b](#)
- [ypN3](#)
- [ypN3a](#)
- [ypN3b](#)
- [ypN3c](#)
- [ypT0](#)
- [ypT1](#)
- [ypT1a](#)
- [ypT1b](#)
- [ypT1c](#)
- [ypT1mi](#)
- [ypT2](#)
- [ypT3](#)
- [ypT4](#)
- [ypT4a](#)
- [ypT4b](#)
- [ypT4c](#)
- [ypT4d](#)
- [ypTis](#)
- [ypTx](#)

**1+<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001877>

has super-classes

[NotClassified](#)<sup>c</sup>

**2+<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001879>

has super-classes

[NotClassified](#)<sup>c</sup>

**3+<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001882>

has super-classes

[NotClassified](#)<sup>c</sup>

**3D CRT three dimensional conformal radiation therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028468>

has super-classes

[Conformal radiotherapy](#)<sup>c</sup>

**Abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000093>

Subdivision of trunk proper which is demarcated from the thorax internally by the inferior surface of the sternocostal part of the diaphragm and externally by the costal margin, from the back of abdomen by the external surface of the posterior abdominal wall, from the perineum by the superior surface of the urogenital diaphragm and from the lower limbs by the inguinal folds; together with the thorax, and perineum, it constitutes the trunk proper. Examples: There is only one abdomen. [FMA]

has super-classes

[Abdomen and Pelvis](#)<sup>c</sup>, [Abdominopelvic cross-sectional segment](#)<sup>c</sup>, [Abdominopelvic segment of trunk](#)<sup>c</sup>, [Chest, abdomen, and pelvis](#)<sup>c</sup>

has sub-classes

[Abdomen proper](#)<sup>c</sup>, [Intra-abdominopelvic structure](#)<sup>c</sup>, [Pelvis](#)<sup>c</sup>, [Structure of abdomen proper](#)<sup>c</sup>, [Structure of compartment of abdomen](#)<sup>c</sup>

**Abdomen and Pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000476>

has super-classes

[Chest, abdomen, and pelvis](#)<sup>c</sup>

has sub-classes

[Abdomen](#)<sup>c</sup>, [Colon](#)<sup>c</sup>

**Abdomen excision<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000242>

has super-classes

[Operation on abdominal region](#)<sup>c</sup>, [Trunk excision](#)<sup>c</sup>

has sub-classes

[Excision of abdominal lymph node](#)<sup>c</sup>, [Prostatectomy](#)<sup>c</sup>

## **Abdomen proper<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016479>

has super-classes

[Abdomen](#)<sup>c</sup>

has sub-classes

[Intra-abdominal proper structure](#)<sup>c</sup>

## **Abdominal abscess<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042193>

has super-classes

[Disorder of abdomen](#)<sup>c</sup>

has sub-classes

[Abdominal visceral abscess](#)<sup>c</sup>

## **Abdominal cavity injury<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041257>

has super-classes

[Injury of abdomen](#)<sup>c</sup>

has sub-classes

[Liver damage](#)<sup>c</sup>

## **Abdominal mass<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000282>

has super-classes

[Finding of abdomen](#)<sup>c</sup>

has sub-classes

[Cyst of abdomen](#)<sup>c</sup>, [Liver mass](#)<sup>c</sup>, [Prostate mass](#)<sup>c</sup>

## **Abdominal organ finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000305>

has super-classes

[Finding of abdomen](#)<sup>c</sup>

has sub-classes

[Abdominal visceral abscess](#)<sup>c</sup>, [Bowel finding](#)<sup>c</sup>, [Liver finding](#)<sup>c</sup>, [Neoplasm of intra-abdominal organs](#)<sup>c</sup>,  
[Pelvic organ finding](#)<sup>c</sup>

## **Abdominal visceral abscess<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042085>

has super-classes

[Abdominal abscess<sup>c</sup>](#), [Abdominal organ finding<sup>c</sup>](#)

has sub-classes

[Abscess of liver<sup>c</sup>](#)

## **Abdominopelvic cross-sectional segment<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000269>

This cross-sectional segment is bounded superiorly by a virtual horizontal plane at the level of the junction between T8 and T9 (and thus also includes part of the thoracic volume below this level); and inferiorly it extends to the perineum, including the volume of the true and false pelvic cavities and part but not necessarily the entire external genitalia. The volume includes the entire transverse thickness of the body over the longitudinal extent between the superior (upper) and inferior (lower) boundaries including the skin and subcutaneous tissue. The segment relates to the cross-sectional or projectional volume as perceived by transmissive or emissive imaging. [SNOMEDCT]

has super-classes

[Body part<sup>c</sup>](#), [Structure of subregion of trunk<sup>c</sup>](#)

has sub-classes

[Abdomen<sup>c</sup>](#), [Cross-sectional abdomen<sup>c</sup>](#)

## **Abdominopelvic segment of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000267>

This segment relates to the volume of the trunk that is bounded by and includes: superiorly thoracic diaphragm and inferiorly the perineum and external genitalia. The volume includes the entire transverse thickness of the body over the longitudinal extent between these upper (superior) and lower (inferior) boundaries including the overlying muscles, skin and subcutaneous tissue. The segment includes the abdominopelvic cavity, contents and wall including the posterior lumbar region, the volume of the true and false pelvic cavities including the bony pelvis and pelvic wall, the entire perineum and external genitalia including skin and subcutaneous tissue. [SNOMEDCT]

has super-classes

[Body part<sup>c</sup>](#), [Chest, abdomen, and pelvis<sup>c</sup>](#), [Lower body part structure<sup>c</sup>](#), [Structure of subregion of trunk<sup>c</sup>](#)

has sub-classes

[Abdomen<sup>c</sup>](#), [Structure of pelvic segment of trunk<sup>c</sup>](#)

## **Abemaciclib<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036270>

An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase,

suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Abnormal finding on evaluation procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003797>

has super-classes

[Evaluation finding](#)<sup>c</sup>

has sub-classes

[Biopsy result abnormal](#)<sup>c</sup>, [Imaging result abnormal](#)<sup>c</sup>

### **Abnormal sexual function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024222>

has super-classes

[Finding of sexual function](#)<sup>c</sup>

### **Abscess<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036517>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Abscess of digestive system](#)<sup>c</sup>

### **Abscess of digestive system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036538>

has super-classes

[Abscess](#)<sup>c</sup>

has sub-classes

[Abscess of liver](#)<sup>c</sup>

### **Abscess of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046390>

has super-classes

[Abdominal visceral abscess](#)<sup>c</sup>, [Abscess of digestive system](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>, [Liver mass](#)<sup>c</sup>

### **Absence findings<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001079>

has super-classes

[Finding value](#)<sup>c</sup>

has sub-classes

[Absent](#)<sup>c</sup>, [Negative](#)<sup>c</sup>, [None](#)<sup>c</sup>, [Not detected](#)<sup>c</sup>

**Absent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001886>

has super-classes

[Absence findings](#)<sup>c</sup>

**Acinar cell carcinoma of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021457>

has super-classes

[Primary malignant neoplasm of prostate](#)<sup>c</sup>

**Acoustic feature of mass<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035461>

has super-classes

[Ultrasonographic observable](#)<sup>c</sup>

**Action<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001054>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Removal - action](#)<sup>c</sup>

**Active surveillance of prostate cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028587>

has super-classes

[Monitoring of patient with cancer](#)<sup>c</sup>

**ADAC<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000052>

has super-classes

[Manufacturer](#)<sup>c</sup>

**Adenocarcinoma NOS<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047138>

has super-classes

[Adenomas and adenocarcinomas](#)<sup>c</sup>

**Adenocarcinoma of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038137>

has super-classes

[Liver cancer](#)<sup>c</sup>, [Malignant adenomatous neoplasm](#)<sup>c</sup>

has sub-classes

[Liver cell carcinoma](#)<sup>c</sup>

**Adenocarcinoma of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007487>

has super-classes

[Malignant adenomatous neoplasm](#)<sup>c</sup>, [Malignant tumor of pelvis](#)<sup>c</sup>

has sub-classes

[Primary adenocarcinoma of pelvis](#)<sup>c</sup>

**Adenocarcinoma with mixed subtypes<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045788>

has super-classes

[Adenomas and adenocarcinomas](#)<sup>c</sup>

**Adenocarcinoma with neuroendocrine differentiation of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021492>

has super-classes

[Neuroendocrine tumor](#)<sup>c</sup>, [Primary adenocarcinoma of pelvis](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>

**Adenocarcinoma, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033194>

has super-classes

[Diagnosis](#)<sup>c</sup>

## **Adenoma of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036427>

has super-classes

[Benign adenomatous neoplasm<sup>c</sup>](#), [Benign neoplasm of liver<sup>c</sup>](#)

has sub-classes

[Cystadenoma of liver<sup>c</sup>](#), [Hepatic cystadenoma<sup>c</sup>](#)

## **Adenomas and adenocarcinomas<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045781>

has super-classes

[Diagnosis<sup>c</sup>](#)

has sub-classes

[Adenocarcinoma NOS<sup>c</sup>](#), [Adenocarcinoma with mixed subtypes<sup>c</sup>](#), [Mixed neuroendocrine non-neuroendocrine neoplasm<sup>c</sup>](#), [Neuroendocrine Carcinoma, NOS<sup>c</sup>](#)

## **Adenosquamous carcinoma of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021525>

has super-classes

[Adenosquamous cell carcinoma<sup>c</sup>](#), [Primary adenocarcinoma of pelvis<sup>c</sup>](#), [Primary malignant neoplasm of prostate<sup>c</sup>](#), [Squamous cell carcinoma of prostate<sup>c</sup>](#)

## **Adenosquamous cell carcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016677>

has super-classes

[Malignant adenomatous neoplasm<sup>c</sup>](#), [Primary malignant neoplasm<sup>c</sup>](#), [Squamous cell carcinoma<sup>c</sup>](#)

has sub-classes

[Adenosquamous carcinoma of prostate gland<sup>c</sup>](#)

## **Adjectival modifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000024>

has super-classes

[Qualifier<sup>c</sup>](#)

has sub-classes

[General adjectival modifier<sup>c</sup>](#)

## **Administration of hormone (procedure)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034319>



has super-classes

[Administration of medication](#)<sup>c</sup>

has sub-classes

[Hormone therapy](#)<sup>c</sup>

### **Administration of medication<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034187>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Administration of hormone \(procedure\)](#)<sup>c</sup>, [Chemotherapy](#)<sup>c</sup>, [Pharmacotherapy](#)<sup>c</sup>

### **Administrative statuses<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000363>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Follow-up status](#)<sup>c</sup>, [Performance measure status](#)<sup>c</sup>, [Reasons for treatment](#)<sup>c</sup>

### **Adrenal gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000125>

A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex). [NCIT]

has super-classes

[Endocrine gland structure](#)<sup>c</sup>, [Retroperitoneal compartment structure](#)<sup>c</sup>, [Structure of lateral half of abdomen lateral to midsagittal plane](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>

### **Age AND/OR growth period<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000126>

has super-classes

[Common Module](#)<sup>c</sup>

has sub-classes

[Age at diagnosis](#)<sup>c</sup>, [Age at onset of clinical finding](#)<sup>c</sup>

### **Age at diagnosis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000131>

has super-classes

[Age AND/OR growth period](#)<sup>c</sup>

**Age at onset of clinical finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000128>

has super-classes

[Age AND/OR growth period](#)<sup>c</sup>

**Agfa<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000051>

has super-classes

[Manufacturer](#)<sup>c</sup>

**AJCC/UICC 7th clinical M0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021462>

has super-classes

[AJCC/UICC 7th M0 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical M0 Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical M1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015453>

has super-classes

[AJCC/UICC 7th M1 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1a Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical M1b Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical M1c Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical M1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021468>

is equivalent to

[TNM Path M](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cM1a](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th M1a Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical M1 Category](#)<sup>c</sup>, [AJCC/UICC clinical M1a Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical M1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021475>

is equivalent to

[TNM Clin M](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cM1b](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th M1b Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical M1 Category](#)<sup>c</sup>, [AJCC/UICC clinical M1b Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical M1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021483>

has super-classes

[AJCC/UICC 7th M1c Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical M1 Category](#)<sup>c</sup>, [AJCC/UICC clinical M1c Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical MX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021502>

has super-classes

[AJCC/UICC 7th MX Category](#)<sup>c</sup>, [AJCC/UICC clinical MX Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical N0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021513>

is equivalent to

[TNM Clin N](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cN0](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th N0 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical N0 Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical N1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021538>

is equivalent to

[TNM Clin N](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cN1](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th N1 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical N1 Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical NX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021552>

has super-classes

[AJCC/UICC 7th NX Category](#)<sup>c</sup>, [AJCC/UICC clinical NX Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical T2 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015455>

has super-classes

[AJCC/UICC 7th T2 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical T2 Category](#)<sup>c</sup>  
has sub-classes

[AJCC/UICC 7th clinical T2a Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T2b Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T2c Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical T2a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021567>

is equivalent to

[TNM Clin T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cT2a](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2a Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T2 Category](#)<sup>c</sup>, [AJCC/UICC clinical T2a Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical T2b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021583>

is equivalent to

[TNM Clin T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cT2b](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2b Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T2 Category](#)<sup>c</sup>, [AJCC/UICC clinical T2b Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical T2c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021618>

is equivalent to

[TNM Clin T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cT2c](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2c Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T2 Category](#)<sup>c</sup>, [AJCC/UICC clinical T2c Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical T3 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015458>

has super-classes

[AJCC/UICC 7th T3 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T3a Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T3b Category](#)<sup>c</sup>

**AJCC/UICC 7th clinical T3a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021637>

is equivalent to

[TNM Clin T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cT3a](#)<sup>c</sup>)  
has super-classes

[AJCC/UICC 7th T3a Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T3 Category](#)<sup>c</sup>, [AJCC/UICC clinical T3a Category](#)<sup>c</sup>

### **AJCC/UICC 7th clinical T3b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021678>

is equivalent to

[TNM Clin T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cT3b](#)<sup>c</sup>)  
has super-classes

[AJCC/UICC 7th T3b Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T3 Category](#)<sup>c</sup>, [AJCC/UICC clinical T3b Category](#)<sup>c</sup>

### **AJCC/UICC 7th clinical T4 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021700>

is equivalent to

[TNM Clin T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [cT4](#)<sup>c</sup>)  
has super-classes

[AJCC/UICC 7th T4 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC clinical T4 Category](#)<sup>c</sup>

### **AJCC/UICC 7th clinical TX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021723>

has super-classes

[AJCC/UICC 7th TX Category](#)<sup>c</sup>, [AJCC/UICC clinical TX Category](#)<sup>c</sup>

### **AJCC/UICC 7th edition<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000417>

has super-classes

[AJCC/UICC finding](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M0 Category](#)<sup>c</sup>, [AJCC/UICC 7th M1 Category](#)<sup>c</sup>, [AJCC/UICC 7th MX Category](#)<sup>c</sup>,  
[AJCC/UICC 7th N0 Category](#)<sup>c</sup>, [AJCC/UICC 7th N1 Category](#)<sup>c</sup>, [AJCC/UICC 7th NX Category](#)<sup>c</sup>,  
[AJCC/UICC 7th T1 Category](#)<sup>c</sup>, [AJCC/UICC 7th T2 Category](#)<sup>c</sup>, [AJCC/UICC 7th T3 Category](#)<sup>c</sup>,  
[AJCC/UICC 7th T4 Category](#)<sup>c</sup>, [AJCC/UICC 7th TX Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical M0 Category](#)<sup>c</sup>,  
[AJCC/UICC 7th clinical M1 Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical N0 Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical N1 Category](#)<sup>c</sup>,  
[AJCC/UICC 7th clinical T2 Category](#)<sup>c</sup>, [AJCC/UICC 7th clinical T3 Category](#)<sup>c</sup>,  
[AJCC/UICC 7th clinical T4 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological N0 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological N1 Category](#)<sup>c</sup>,  
[AJCC/UICC 7th pathological T1 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T2 Category](#)<sup>c</sup>,  
[AJCC/UICC 7th pathological T3 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T4 Category](#)<sup>c</sup>

## **AJCC/UICC 7th M0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015462>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC M0 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M0 Category](#)<sup>c</sup>

## **AJCC/UICC 7th M1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000437>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M1a Category](#)<sup>c</sup>, [AJCC/UICC 7th M1b Category](#)<sup>c</sup>, [AJCC/UICC 7th M1c Category](#)<sup>c</sup>,  
[AJCC/UICC 7th clinical M1 Category](#)<sup>c</sup>

## **AJCC/UICC 7th M1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016727>

has super-classes

[AJCC/UICC 7th M1 Category](#)<sup>c</sup>, [AJCC/UICC M1a Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1a Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological M1a Category](#)<sup>c</sup>

## **AJCC/UICC 7th M1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016778>

has super-classes

[AJCC/UICC 7th M1 Category](#)<sup>c</sup>, [AJCC/UICC M1b Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1b Category](#)<sup>c</sup>

## **AJCC/UICC 7th M1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016830>

has super-classes

[AJCC/UICC 7th M1 Category](#)<sup>c</sup>, [AJCC/UICC M1c Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1c Category](#)<sup>c</sup>

## **AJCC/UICC 7th MX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015467>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC MX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical MX Category](#)<sup>c</sup>

### **AJCC/UICC 7th N0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015473>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC N0 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical N0 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological N0 Category](#)<sup>c</sup>

### **AJCC/UICC 7th N1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015480>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC N1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical N1 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological N1 Category](#)<sup>c</sup>

### **AJCC/UICC 7th NX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015488>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC NX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical NX Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological NX Category](#)<sup>c</sup>

### **AJCC/UICC 7th pathological M1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034108>

is equivalent to

[TNM Path M](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pM1a](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th M1a Category](#)<sup>c</sup>

### **AJCC/UICC 7th pathological N0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021747>

is equivalent to

[TNM Path N](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pN0](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th N0 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC pathological N0 Category](#)<sup>c</sup>

## **AJCC/UICC 7th pathological N1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021772>

is equivalent to

[TNM Path N](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pN1](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th N1 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC pathological N1 Category](#)<sup>c</sup>

## **AJCC/UICC 7th pathological NX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021798>

has super-classes

[AJCC/UICC 7th NX Category](#)<sup>c</sup>, [AJCC/UICC pathological NX Category](#)<sup>c</sup>

## **AJCC/UICC 7th pathological T1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015497>

is equivalent to

[TNM Path T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pT1](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T1 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC pathological T1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T1a Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T1b Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T1c Category](#)<sup>c</sup>

## **AJCC/UICC 7th pathological T1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021600>

has super-classes

[AJCC/UICC 7th T1a Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T1 Category](#)<sup>c</sup>, [AJCC/UICC pathological T1a Category](#)<sup>c</sup>

## **AJCC/UICC 7th pathological T1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021657>

has super-classes

[AJCC/UICC 7th T1b Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T1 Category](#)<sup>c</sup>, [AJCC/UICC pathological T1b Category](#)<sup>c</sup>

## **AJCC/UICC 7th pathological T1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021825>

has super-classes



[AJCC/UICC 7th T1c Category](#) <sup>c</sup>, [AJCC/UICC 7th pathological T1 Category](#) <sup>c</sup>, [AJCC/UICC pathological T1c Category](#) <sup>c</sup>

## **AJCC/UICC 7th pathological T2 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015507>

is equivalent to

[TNM Path T](#) <sup>c</sup> and ([Has Answer](#) <sup>op</sup> exactly 1 [pT2](#) <sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2 Category](#) <sup>c</sup>, [AJCC/UICC 7th edition](#) <sup>c</sup>, [AJCC/UICC pathological T2 Category](#) <sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T2a Category](#) <sup>c</sup>, [AJCC/UICC 7th pathological T2b Category](#) <sup>c</sup>, [AJCC/UICC 7th pathological T2c Category](#) <sup>c</sup>

## **AJCC/UICC 7th pathological T2a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021853>

is equivalent to

[TNM Path T](#) <sup>c</sup> and ([Has Answer](#) <sup>op</sup> exactly 1 [pT2a](#) <sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2a Category](#) <sup>c</sup>, [AJCC/UICC 7th pathological T2 Category](#) <sup>c</sup>, [AJCC/UICC pathological T2a Category](#) <sup>c</sup>

## **AJCC/UICC 7th pathological T2b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021882>

is equivalent to

[TNM Path T](#) <sup>c</sup> and ([Has Answer](#) <sup>op</sup> exactly 1 [pT2b](#) <sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2b Category](#) <sup>c</sup>, [AJCC/UICC 7th pathological T2 Category](#) <sup>c</sup>, [AJCC/UICC pathological T2b Category](#) <sup>c</sup>

## **AJCC/UICC 7th pathological T2c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021912>

is equivalent to

[TNM Path T](#) <sup>c</sup> and ([Has Answer](#) <sup>op</sup> exactly 1 [pT2c](#) <sup>c</sup>)

has super-classes

[AJCC/UICC 7th T2c Category](#) <sup>c</sup>, [AJCC/UICC 7th pathological T2 Category](#) <sup>c</sup>, [AJCC/UICC pathological T2c Category](#) <sup>c</sup>

## **AJCC/UICC 7th pathological T3 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015518>

is equivalent to

[TNM Path T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pT3](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T3 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC pathological T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T3a Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T3b Category](#)<sup>c</sup>

### **AJCC/UICC 7th pathological T3a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021943>

is equivalent to

[TNM Path T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pT3a](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T3a Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T3 Category](#)<sup>c</sup>, [AJCC/UICC pathological T3a Category](#)<sup>c</sup>

### **AJCC/UICC 7th pathological T3b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021975>

is equivalent to

[TNM Path T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pT3b](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T3b Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T3 Category](#)<sup>c</sup>, [AJCC/UICC pathological T3b Category](#)<sup>c</sup>

### **AJCC/UICC 7th pathological T4 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022008>

is equivalent to

[TNM Path T](#)<sup>c</sup> and ([Has Answer](#)<sup>op</sup> exactly 1 [pT4](#)<sup>c</sup>)

has super-classes

[AJCC/UICC 7th T4 Category](#)<sup>c</sup>, [AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC pathological T4 Category](#)<sup>c</sup>

### **AJCC/UICC 7th pathological TX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022042>

has super-classes

[AJCC/UICC 7th TX Category](#)<sup>c</sup>, [AJCC/UICC pathological TX Category](#)<sup>c</sup>

### **AJCC/UICC 7th T1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000458>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC T1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th T1a Category](#)<sup>c</sup>, [AJCC/UICC 7th T1b Category](#)<sup>c</sup>, [AJCC/UICC 7th T1c Category](#)<sup>c</sup>,  
[AJCC/UICC 7th pathological T1 Category](#)<sup>c</sup>

**AJCC/UICC 7th T1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015530>

has super-classes

[AJCC/UICC 7th T1 Category](#)<sup>c</sup>, [AJCC/UICC T1a Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T1a Category](#)<sup>c</sup>

**AJCC/UICC 7th T1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015543>

has super-classes

[AJCC/UICC 7th T1 Category](#)<sup>c</sup>, [AJCC/UICC T1b Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T1b Category](#)<sup>c</sup>

**AJCC/UICC 7th T1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015557>

has super-classes

[AJCC/UICC 7th T1 Category](#)<sup>c</sup>, [AJCC/UICC T1c Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T1c Category](#)<sup>c</sup>

**AJCC/UICC 7th T2 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000480>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th T2a Category](#)<sup>c</sup>, [AJCC/UICC 7th T2b Category](#)<sup>c</sup>, [AJCC/UICC 7th T2c Category](#)<sup>c</sup>,  
[AJCC/UICC 7th clinical T2 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T2 Category](#)<sup>c</sup>

**AJCC/UICC 7th T2a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015572>

has super-classes

[AJCC/UICC 7th T2 Category](#)<sup>c</sup>, [AJCC/UICC T2a Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T2a Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T2a Category](#)<sup>c</sup>

## **AJCC/UICC 7th T2b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015588>

has super-classes

[AJCC/UICC 7th T2 Category<sup>c</sup>](#), [AJCC/UICC T2b Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th clinical T2b Category<sup>c</sup>](#), [AJCC/UICC 7th pathological T2b Category<sup>c</sup>](#)

## **AJCC/UICC 7th T2c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015605>

has super-classes

[AJCC/UICC 7th T2 Category<sup>c</sup>](#), [AJCC/UICC T2c Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th clinical T2c Category<sup>c</sup>](#), [AJCC/UICC 7th pathological T2c Category<sup>c</sup>](#)

## **AJCC/UICC 7th T3 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000503>

has super-classes

[AJCC/UICC 7th edition<sup>c</sup>](#), [AJCC/UICC T3 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T3a Category<sup>c</sup>](#), [AJCC/UICC 7th T3b Category<sup>c</sup>](#), [AJCC/UICC 7th clinical T3 Category<sup>c</sup>](#), [AJCC/UICC 7th pathological T3 Category<sup>c</sup>](#)

## **AJCC/UICC 7th T3a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015623>

has super-classes

[AJCC/UICC 7th T3 Category<sup>c</sup>](#), [AJCC/UICC T3a Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th clinical T3a Category<sup>c</sup>](#), [AJCC/UICC 7th pathological T3a Category<sup>c</sup>](#)

## **AJCC/UICC 7th T3b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015642>

has super-classes

[AJCC/UICC 7th T3 Category<sup>c</sup>](#), [AJCC/UICC T3b Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th clinical T3b Category<sup>c</sup>](#), [AJCC/UICC 7th pathological T3b Category<sup>c</sup>](#)

## **AJCC/UICC 7th T4 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015662>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC T4 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T4 Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological T4 Category](#)<sup>c</sup>

**AJCC/UICC 7th TX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015683>

has super-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC TX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical TX Category](#)<sup>c</sup>, [AJCC/UICC 7th pathological TX Category](#)<sup>c</sup>

**AJCC/UICC clinical M0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016883>

has super-classes

[AJCC/UICC M0 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M0 Category](#)<sup>c</sup>

**AJCC/UICC clinical M1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000857>

has super-classes

[AJCC/UICC M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1 Category](#)<sup>c</sup>, [AJCC/UICC clinical M1a Category](#)<sup>c</sup>, [AJCC/UICC clinical M1b Category](#)<sup>c</sup>, [AJCC/UICC clinical M1c Category](#)<sup>c</sup>

**AJCC/UICC clinical M1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016937>

has super-classes

[AJCC/UICC M1a Category](#)<sup>c</sup>, [AJCC/UICC clinical M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1a Category](#)<sup>c</sup>

**AJCC/UICC clinical M1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016992>

has super-classes

[AJCC/UICC M1b Category](#)<sup>c</sup>, [AJCC/UICC clinical M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1b Category](#)<sup>c</sup>

**AJCC/UICC clinical M1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017048>

has super-classes

[AJCC/UICC M1c Category](#)<sup>c</sup>, [AJCC/UICC clinical M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical M1c Category](#)<sup>c</sup>

**AJCC/UICC clinical MX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017105>

has super-classes

[AJCC/UICC MX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical MX Category](#)<sup>c</sup>

**AJCC/UICC clinical N0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017163>

has super-classes

[AJCC/UICC N0 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical N0 Category](#)<sup>c</sup>

**AJCC/UICC clinical N1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017222>

has super-classes

[AJCC/UICC N1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical N1 Category](#)<sup>c</sup>

**AJCC/UICC clinical NX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017282>

has super-classes

[AJCC/UICC NX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical NX Category](#)<sup>c</sup>

**AJCC/UICC clinical T2 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001130>

has super-classes

[AJCC/UICC T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T2 Category](#)<sup>c</sup>, [AJCC/UICC clinical T2a Category](#)<sup>c</sup>, [AJCC/UICC clinical T2b Category](#)<sup>c</sup>, [AJCC/UICC clinical T2c Category](#)<sup>c</sup>

**AJCC/UICC clinical T2a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017343>

has super-classes

[AJCC/UICC T2a Category](#)<sup>c</sup>, [AJCC/UICC clinical T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T2a Category](#)<sup>c</sup>

**AJCC/UICC clinical T2b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017405>

has super-classes

[AJCC/UICC T2b Category](#)<sup>c</sup>, [AJCC/UICC clinical T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T2b Category](#)<sup>c</sup>

**AJCC/UICC clinical T2c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017468>

has super-classes

[AJCC/UICC T2c Category](#)<sup>c</sup>, [AJCC/UICC clinical T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T2c Category](#)<sup>c</sup>

**AJCC/UICC clinical T3 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001355>

has super-classes

[AJCC/UICC T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T3 Category](#)<sup>c</sup>, [AJCC/UICC clinical T3a Category](#)<sup>c</sup>, [AJCC/UICC clinical T3b Category](#)<sup>c</sup>

**AJCC/UICC clinical T3a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017532>

has super-classes

[AJCC/UICC T3a Category](#)<sup>c</sup>, [AJCC/UICC clinical T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T3a Category](#)<sup>c</sup>

**AJCC/UICC clinical T3b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017597>

has super-classes

[AJCC/UICC T3b Category](#)<sup>c</sup>, [AJCC/UICC clinical T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T3b Category](#)<sup>c</sup>

**AJCC/UICC clinical T4 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017663>

has super-classes

[AJCC/UICC T4 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical T4 Category](#)<sup>c</sup>

**AJCC/UICC clinical TX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017730>

has super-classes

[AJCC/UICC TX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th clinical TX Category](#)<sup>c</sup>

**AJCC/UICC finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000398>

has super-classes

[Cancer staging](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th edition](#)<sup>c</sup>, [AJCC/UICC M0 Category](#)<sup>c</sup>, [AJCC/UICC M1 Category](#)<sup>c</sup>, [AJCC/UICC MX Category](#)<sup>c</sup>, [AJCC/UICC N0 Category](#)<sup>c</sup>, [AJCC/UICC N1 Category](#)<sup>c</sup>, [AJCC/UICC NX Category](#)<sup>c</sup>, [AJCC/UICC T1 Category](#)<sup>c</sup>, [AJCC/UICC T2 Category](#)<sup>c</sup>, [AJCC/UICC T3 Category](#)<sup>c</sup>, [AJCC/UICC T4 Category](#)<sup>c</sup>, [AJCC/UICC TX Category](#)<sup>c</sup>

**AJCC/UICC M0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000527>

has super-classes



[AJCC/UICC finding](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M0 Category](#)<sup>c</sup>, [AJCC/UICC clinical M0 Category](#)<sup>c</sup>

**AJCC/UICC M1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000822>

has super-classes

[AJCC/UICC finding](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M1 Category](#)<sup>c</sup>, [AJCC/UICC M1a Category](#)<sup>c</sup>, [AJCC/UICC M1b Category](#)<sup>c</sup>, [AJCC/UICC M1c Category](#)<sup>c</sup>, [AJCC/UICC clinical M1 Category](#)<sup>c</sup>

**AJCC/UICC M1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000893>

has super-classes

[AJCC/UICC M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M1a Category](#)<sup>c</sup>, [AJCC/UICC clinical M1a Category](#)<sup>c</sup>

**AJCC/UICC M1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002642>

has super-classes

[AJCC/UICC M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M1b Category](#)<sup>c</sup>, [AJCC/UICC clinical M1b Category](#)<sup>c</sup>

**AJCC/UICC M1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000930>

has super-classes

[AJCC/UICC M1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th M1c Category](#)<sup>c</sup>, [AJCC/UICC clinical M1c Category](#)<sup>c</sup>

**AJCC/UICC MX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000552>

has super-classes

[AJCC/UICC finding](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th MX Category](#)<sup>c</sup>, [AJCC/UICC clinical MX Category](#)<sup>c</sup>

## **AJCC/UICC N0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000578>

has super-classes

[AJCC/UICC finding<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th N0 Category<sup>c</sup>](#), [AJCC/UICC clinical N0 Category<sup>c</sup>](#), [AJCC/UICC pathological N0 Category<sup>c</sup>](#)

## **AJCC/UICC N1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000605>

has super-classes

[AJCC/UICC finding<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th N1 Category<sup>c</sup>](#), [AJCC/UICC clinical N1 Category<sup>c</sup>](#), [AJCC/UICC pathological N1 Category<sup>c</sup>](#)

## **AJCC/UICC NX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000633>

has super-classes

[AJCC/UICC finding<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th NX Category<sup>c</sup>](#), [AJCC/UICC clinical NX Category<sup>c</sup>](#), [AJCC/UICC pathological NX Category<sup>c</sup>](#)

## **AJCC/UICC pathological N0 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017798>

has super-classes

[AJCC/UICC N0 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological N0 Category<sup>c</sup>](#)

## **AJCC/UICC pathological N1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017867>

has super-classes

[AJCC/UICC N1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological N1 Category<sup>c</sup>](#)

## **AJCC/UICC pathological NX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1017937>

has super-classes

[AJCC/UICC NX Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological NX Category<sup>c</sup>](#)

## **AJCC/UICC pathological T1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000968>

has super-classes

[AJCC/UICC T1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological T1 Category<sup>c</sup>](#), [AJCC/UICC pathological T1a Category<sup>c</sup>](#), [AJCC/UICC pathological T1b Category<sup>c</sup>](#), [AJCC/UICC pathological T1c Category<sup>c</sup>](#)

## **AJCC/UICC pathological T1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015705>

has super-classes

[AJCC/UICC T1a Category<sup>c</sup>](#), [AJCC/UICC pathological T1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological T1a Category<sup>c</sup>](#)

## **AJCC/UICC pathological T1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015728>

has super-classes

[AJCC/UICC T1b Category<sup>c</sup>](#), [AJCC/UICC pathological T1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological T1b Category<sup>c</sup>](#)

## **AJCC/UICC pathological T1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015752>

has super-classes

[AJCC/UICC T1c Category<sup>c</sup>](#), [AJCC/UICC pathological T1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th pathological T1c Category<sup>c</sup>](#)

## **AJCC/UICC pathological T2 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001173>

has super-classes

[AJCC/UICC T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T2 Category](#)<sup>c</sup>, [AJCC/UICC pathological T2a Category](#)<sup>c</sup>, [AJCC/UICC pathological T2b Category](#)<sup>c</sup>, [AJCC/UICC pathological T2c Category](#)<sup>c</sup>

**AJCC/UICC pathological T2a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015777>

has super-classes

[AJCC/UICC T2a Category](#)<sup>c</sup>, [AJCC/UICC pathological T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T2a Category](#)<sup>c</sup>

**AJCC/UICC pathological T2b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015803>

has super-classes

[AJCC/UICC T2b Category](#)<sup>c</sup>, [AJCC/UICC pathological T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T2b Category](#)<sup>c</sup>

**AJCC/UICC pathological T2c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015830>

has super-classes

[AJCC/UICC T2c Category](#)<sup>c</sup>, [AJCC/UICC pathological T2 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T2c Category](#)<sup>c</sup>

**AJCC/UICC pathological T3 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001403>

has super-classes

[AJCC/UICC T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T3 Category](#)<sup>c</sup>, [AJCC/UICC pathological T3a Category](#)<sup>c</sup>, [AJCC/UICC pathological T3b Category](#)<sup>c</sup>

**AJCC/UICC pathological T3a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015858>

has super-classes

[AJCC/UICC T3a Category](#)<sup>c</sup>, [AJCC/UICC pathological T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T3a Category](#)<sup>c</sup>

**AJCC/UICC pathological T3b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015887>

has super-classes

[AJCC/UICC T3b Category](#)<sup>c</sup>, [AJCC/UICC pathological T3 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T3b Category](#)<sup>c</sup>

**AJCC/UICC pathological T4 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018008>

has super-classes

[AJCC/UICC T4 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological T4 Category](#)<sup>c</sup>

**AJCC/UICC pathological TX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018080>

has super-classes

[AJCC/UICC TX Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th pathological TX Category](#)<sup>c</sup>

**AJCC/UICC T1 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000662>

has super-classes

[AJCC/UICC finding](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th T1 Category](#)<sup>c</sup>, [AJCC/UICC T1a Category](#)<sup>c</sup>, [AJCC/UICC T1b Category](#)<sup>c</sup>, [AJCC/UICC T1c Category](#)<sup>c</sup>, [AJCC/UICC pathological T1 Category](#)<sup>c</sup>

**AJCC/UICC T1a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001007>

has super-classes

[AJCC/UICC T1 Category](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th T1a Category](#)<sup>c</sup>, [AJCC/UICC pathological T1a Category](#)<sup>c</sup>

## **AJCC/UICC T1b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001047>

has super-classes

[AJCC/UICC T1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T1b Category<sup>c</sup>](#), [AJCC/UICC pathological T1b Category<sup>c</sup>](#)

## **AJCC/UICC T1c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001088>

has super-classes

[AJCC/UICC T1 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T1c Category<sup>c</sup>](#), [AJCC/UICC pathological T1c Category<sup>c</sup>](#)

## **AJCC/UICC T2 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000692>

has super-classes

[AJCC/UICC finding<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T2 Category<sup>c</sup>](#), [AJCC/UICC T2a Category<sup>c</sup>](#), [AJCC/UICC T2b Category<sup>c</sup>](#), [AJCC/UICC T2c Category<sup>c</sup>](#), [AJCC/UICC clinical T2 Category<sup>c</sup>](#), [AJCC/UICC pathological T2 Category<sup>c</sup>](#)

## **AJCC/UICC T2a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001217>

has super-classes

[AJCC/UICC T2 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T2a Category<sup>c</sup>](#), [AJCC/UICC clinical T2a Category<sup>c</sup>](#), [AJCC/UICC pathological T2a Category<sup>c</sup>](#)

## **AJCC/UICC T2b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001262>

has super-classes

[AJCC/UICC T2 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T2b Category<sup>c</sup>](#), [AJCC/UICC clinical T2b Category<sup>c</sup>](#), [AJCC/UICC pathological T2b Category<sup>c</sup>](#)

## **AJCC/UICC T2c Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001308>

has super-classes

[AJCC/UICC T2 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T2c Category<sup>c</sup>](#), [AJCC/UICC clinical T2c Category<sup>c</sup>](#), [AJCC/UICC pathological T2c Category<sup>c</sup>](#)

## **AJCC/UICC T3 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000723>

has super-classes

[AJCC/UICC finding<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T3 Category<sup>c</sup>](#), [AJCC/UICC T3a Category<sup>c</sup>](#), [AJCC/UICC T3b Category<sup>c</sup>](#), [AJCC/UICC clinical T3 Category<sup>c</sup>](#), [AJCC/UICC pathological T3 Category<sup>c</sup>](#)

## **AJCC/UICC T3a Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001452>

has super-classes

[AJCC/UICC T3 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T3a Category<sup>c</sup>](#), [AJCC/UICC clinical T3a Category<sup>c</sup>](#), [AJCC/UICC pathological T3a Category<sup>c</sup>](#)

## **AJCC/UICC T3b Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001502>

has super-classes

[AJCC/UICC T3 Category<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T3b Category<sup>c</sup>](#), [AJCC/UICC clinical T3b Category<sup>c</sup>](#), [AJCC/UICC pathological T3b Category<sup>c</sup>](#)

## **AJCC/UICC T4 Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000755>

has super-classes

[AJCC/UICC finding<sup>c</sup>](#)

has sub-classes

[AJCC/UICC 7th T4 Category](#)<sup>c</sup>, [AJCC/UICC clinical T4 Category](#)<sup>c</sup>, [AJCC/UICC pathological T4 Category](#)<sup>c</sup>

**AJCC/UICC TX Category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000788>

has super-classes

[AJCC/UICC finding](#)<sup>c</sup>

has sub-classes

[AJCC/UICC 7th TX Category](#)<sup>c</sup>, [AJCC/UICC clinical TX Category](#)<sup>c</sup>, [AJCC/UICC pathological TX Category](#)<sup>c</sup>

**Alanine aminotransferase [Enzymatic activity/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033782>

has super-classes

[Laboratory test](#)<sup>c</sup>

**Albumin/Protein.total in 24 hour Urine by Electrophoresis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034070>

has super-classes

[Laboratory test](#)<sup>c</sup>

**Alcoholic liver damage<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047530>

has super-classes

[Disorder caused by alcohol](#)<sup>c</sup>, [Drug-induced disorder of liver](#)<sup>c</sup>, [Drug-induced lesion](#)<sup>c</sup>, [Liver damage](#)<sup>c</sup>

**Alive<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024297>

has super-classes

[General clinical state finding](#)<sup>c</sup>

**Alkaline phosphatase [Enzymatic activity/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033839>

has super-classes

[Laboratory test](#)<sup>c</sup>

**Alkylating agent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036307>

has super-classes

[Drug or medicament](#) <sup>c</sup>

has sub-classes

[Cyclophosphamide](#) <sup>c</sup>

## **American Joint Committee on Cancer allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000183>

has super-classes

[Finding value](#) <sup>c</sup>

has sub-classes

[American Joint Committee on Cancer clinical M category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer clinical N category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer clinical T category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer clinical grade allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer clinical stage group allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological N category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological T category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological grade allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer yp grade allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer ypN category allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer ypT category allowable value](#) <sup>c</sup>

## **American Joint Committee on Cancer clinical grade allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001746>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[American Joint Committee on Cancer grade GX](#) <sup>c</sup>, [G1 - American Joint Committee on Cancer grade G1](#) <sup>c</sup>, [G2 - American Joint Committee on Cancer grade G2](#) <sup>c</sup>, [G3 - American Joint Committee on Cancer grade G3](#) <sup>c</sup>

## **American Joint Committee on Cancer clinical M category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000186>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[cM0](#) <sup>c</sup>, [cM1](#) <sup>c</sup>, [cM1a](#) <sup>c</sup>, [cM1b](#) <sup>c</sup>, [cM1c](#) <sup>c</sup>

**American Joint Committee on Cancer clinical N category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000190>

has super-classes

[American Joint Committee on Cancer allowable value<sup>c</sup>](#)

has sub-classes

[cN0<sup>c</sup>](#), [cN1<sup>c</sup>](#), [cN1mi<sup>c</sup>](#), [cN2<sup>c</sup>](#), [cN2a<sup>c</sup>](#), [cN2b<sup>c</sup>](#), [cN3<sup>c</sup>](#), [cN3a<sup>c</sup>](#), [cN3b<sup>c</sup>](#), [cN3c<sup>c</sup>](#), [cNX<sup>c</sup>](#)

**American Joint Committee on Cancer clinical stage group allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000195>

has super-classes

[American Joint Committee on Cancer allowable value<sup>c</sup>](#)

has sub-classes

[I<sup>c</sup>](#), [II<sup>c</sup>](#), [IIA<sup>c</sup>](#), [IIB<sup>c</sup>](#), [IIC<sup>c</sup>](#), [III<sup>c</sup>](#), [IIIA<sup>c</sup>](#), [IIIB<sup>c</sup>](#), [IIIC<sup>c</sup>](#), [IV<sup>c</sup>](#), [IVA<sup>c</sup>](#), [IVB<sup>c</sup>](#)

**American Joint Committee on Cancer clinical T category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000201>

has super-classes

[American Joint Committee on Cancer allowable value<sup>c</sup>](#)

has sub-classes

[cT0<sup>c</sup>](#), [cT1<sup>c</sup>](#), [cT1a<sup>c</sup>](#), [cT1b<sup>c</sup>](#), [cT1c<sup>c</sup>](#), [cT1mi<sup>c</sup>](#), [cT2<sup>c</sup>](#), [cT2a<sup>c</sup>](#), [cT2b<sup>c</sup>](#), [cT2c<sup>c</sup>](#), [cT3<sup>c</sup>](#), [cT3a<sup>c</sup>](#), [cT3b<sup>c</sup>](#), [cT4<sup>c</sup>](#), [cT4a<sup>c</sup>](#), [cT4b<sup>c</sup>](#), [cT4c<sup>c</sup>](#), [cT4d<sup>c</sup>](#), [cTisDCIs<sup>c</sup>](#), [cTisPaget<sup>c</sup>](#)

**American Joint Committee on Cancer grade GX<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001891>

has super-classes

[American Joint Committee on Cancer clinical grade allowable value<sup>c</sup>](#), [American Joint Committee on Cancer pathological grade allowable value<sup>c</sup>](#), [American Joint Committee on Cancer yp grade allowable value<sup>c</sup>](#)

**American Joint Committee on Cancer pathological grade allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001741>

has super-classes

[American Joint Committee on Cancer allowable value<sup>c</sup>](#)

has sub-classes

[American Joint Committee on Cancer grade GX](#) <sup>c</sup>, [G1 - American Joint Committee on Cancer grade G1](#) <sup>c</sup>, [G2 - American Joint Committee on Cancer grade G2](#) <sup>c</sup>, [G3 - American Joint Committee on Cancer grade G3](#) <sup>c</sup>

### **American Joint Committee on Cancer pathological M category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000208>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[American Joint Committee on Cancer pM1](#) <sup>c</sup>, [American Joint Committee on Cancer pM1a \(qualifier value\)](#) <sup>c</sup>, [American Joint Committee on Cancer pM1b \(qualifier value\)](#) <sup>c</sup>, [American Joint Committee on Cancer pM1c \(qualifier value\)](#) <sup>c</sup>, [pM0](#) <sup>c</sup>, [pM1](#) <sup>c</sup>, [pM1a](#) <sup>c</sup>, [pM1b](#) <sup>c</sup>, [pM1c](#) <sup>c</sup>, [pM1d](#) <sup>c</sup>

### **American Joint Committee on Cancer pathological N category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000216>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[pN0](#) <sup>c</sup>, [pN1](#) <sup>c</sup>, [pN2](#) <sup>c</sup>, [pN3](#) <sup>c</sup>, [pN3a](#) <sup>c</sup>, [pN3b](#) <sup>c</sup>, [pN3c](#) <sup>c</sup>, [pNX](#) <sup>c</sup>

### **American Joint Committee on Cancer pathological stage group allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000225>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[I](#) <sup>c</sup>, [II](#) <sup>c</sup>, [IIA](#) <sup>c</sup>, [IIB](#) <sup>c</sup>, [IIC](#) <sup>c</sup>, [III](#) <sup>c</sup>, [IIIA](#) <sup>c</sup>, [IIIB](#) <sup>c</sup>, [IIIC](#) <sup>c</sup>, [IV](#) <sup>c</sup>, [IVA](#) <sup>c</sup>, [IVB](#) <sup>c</sup>

### **American Joint Committee on Cancer pathological T category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000235>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[pT0](#) <sup>c</sup>, [pT1](#) <sup>c</sup>, [pT2](#) <sup>c</sup>, [pT2a](#) <sup>c</sup>, [pT2b](#) <sup>c</sup>, [pT2c](#) <sup>c</sup>, [pT3](#) <sup>c</sup>, [pT3a](#) <sup>c</sup>, [pT3b](#) <sup>c</sup>, [pT4](#) <sup>c</sup>, [pT4a](#) <sup>c</sup>, [pT4b](#) <sup>c</sup>, [pTX](#) <sup>c</sup>, [pTis](#) <sup>c</sup>

### **American Joint Committee on Cancer pM1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001184>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

**American Joint Committee on Cancer pM1a (qualifier value)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001199>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

**American Joint Committee on Cancer pM1b (qualifier value)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001215>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

**American Joint Committee on Cancer pM1c (qualifier value)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001232>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

**American Joint Committee on Cancer yp grade allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001743>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[American Joint Committee on Cancer grade GX](#) <sup>c</sup>, [G1 - American Joint Committee on Cancer grade G1](#) <sup>c</sup>,  
[G2 - American Joint Committee on Cancer grade G2](#) <sup>c</sup>, [G3 - American Joint Committee on Cancer grade G3](#) <sup>c</sup>

**American Joint Committee on Cancer ypN category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001052>

has super-classes

[American Joint Committee on Cancer allowable value](#) <sup>c</sup>

has sub-classes

[ypN0](#) <sup>c</sup>, [ypN1](#) <sup>c</sup>, [ypN1a](#) <sup>c</sup>, [ypN1b](#) <sup>c</sup>, [ypN1c](#) <sup>c</sup>, [ypN1mi](#) <sup>c</sup>, [ypN2](#) <sup>c</sup>, [ypN2a](#) <sup>c</sup>, [ypN2b](#) <sup>c</sup>, [ypN3](#) <sup>c</sup>, [ypN3a](#) <sup>c</sup>,  
[ypN3b](#) <sup>c</sup>, [ypN3c](#) <sup>c</sup>

## **American Joint Committee on Cancer ypT category allowable value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001605>

has super-classes

[American Joint Committee on Cancer allowable value<sup>c</sup>](#)

has sub-classes

[ypT0<sup>c</sup>](#), [ypT1<sup>c</sup>](#), [ypT1a<sup>c</sup>](#), [ypT1b<sup>c</sup>](#), [ypT1c<sup>c</sup>](#), [ypT1mi<sup>c</sup>](#), [ypT2<sup>c</sup>](#), [ypT3<sup>c</sup>](#), [ypT4<sup>c</sup>](#), [ypT4a<sup>c</sup>](#), [ypT4b<sup>c</sup>](#), [ypT4c<sup>c</sup>](#), [ypT4d<sup>c</sup>](#), [ypTis<sup>c</sup>](#), [ypTx<sup>c</sup>](#)

## **Anastrozole<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036111>

A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, anastrozole may inhibit tumor growth. (NCI04)

has super-classes

[Antineoplastic agent<sup>c</sup>](#)

## **Anatomic pathology procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034164>

has super-classes

[Laboratory procedure<sup>c</sup>](#)

has sub-classes

[Histopathology test<sup>c</sup>](#)

## **Anatomical Plane<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016614>

has super-classes

[Imaging Module<sup>c</sup>](#)

## **Androgen deprivation therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022437>

has super-classes

[Hormone therapy<sup>c</sup>](#)

## **Androgen level<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006897>

has super-classes

[Hormone measurement](#)<sup>c</sup>

has sub-classes

[Testosterone measurement](#)<sup>c</sup>

### **Angiosarcoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042302>

has super-classes

[Sarcoma](#)<sup>c</sup>

has sub-classes

[Angiosarcoma of liver](#)<sup>c</sup>

### **Angiosarcoma of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046706>

A malignant vascular neoplasm arising from the liver. [NCIT]

has super-classes

[Angiosarcoma](#)<sup>c</sup>, [Sarcoma of liver](#)<sup>c</sup>

### **Anorectal structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002484>

has super-classes

[Body part](#)<sup>c</sup>, [Pelvic alimentary structure](#)<sup>c</sup>, [Structure of pelvic segment of trunk](#)<sup>c</sup>

has sub-classes

[Rectum](#)<sup>c</sup>

### **Anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1013922>

has super-classes

[Structure of anterior section of prostate](#)<sup>c</sup>

has sub-classes

[Basal anterior fibromuscular stroma of prostate](#)<sup>c</sup>

### **Antineoplastic agent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035058>

has super-classes

[Drug or medicament](#)<sup>c</sup>

has sub-classes

[Anastrozole](#)<sup>c</sup>, [Atezolizumab](#)<sup>c</sup>, [Capecitabine](#)<sup>c</sup>, [Carboplatin](#)<sup>c</sup>, [Cyclophosphamide](#)<sup>c</sup>, [Docetaxel](#)<sup>c</sup>,  
[Doxorubicin](#)<sup>c</sup>, [Durvalumab](#)<sup>c</sup>, [Epirubicin](#)<sup>c</sup>, [Eribulin](#)<sup>c</sup>, [Exemestane](#)<sup>c</sup>, [Fluorouracil](#)<sup>c</sup>, [Gemcitabine](#)<sup>c</sup>,  
[Lapatinib](#)<sup>c</sup>, [Letrozole](#)<sup>c</sup>, [Methotrexate](#)<sup>c</sup>, [Nab paclitaxel](#)<sup>c</sup>, [Paclitaxel](#)<sup>c</sup>, [Pembrolizumab](#)<sup>c</sup>, [Pertuzumab](#)<sup>c</sup>,  
[Ribociclib](#)<sup>c</sup>, [Trastuzumab](#)<sup>c</sup>, [Tucatinib](#)<sup>c</sup>, [Vinorelbine](#)<sup>c</sup>

## **Antineoplastic Agents<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034115>

has super-classes

[Drug or medicament](#)<sup>c</sup>

## **ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001553>

has super-classes

[Drug or medicament](#)<sup>c</sup>

has sub-classes

[ENDOCRINE THERAPY](#)<sup>c</sup>

## **Antineoplastic chemoimmunotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035100>

has super-classes

[Immunotherapy for cancer](#)<sup>c</sup>

## **Aorta<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000103>

The main trunk of the systemic arteries. [MeSH]

has super-classes

[Non-coronary systemic artery structure](#)<sup>c</sup>, [Structure of great blood vessel \(organ\)](#)<sup>c</sup>, [Structure of large artery](#)<sup>c</sup>, [Systemic artery of trunk](#)<sup>c</sup>

## **Apical anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005325>

has super-classes

[Structure of apex of prostate](#)<sup>c</sup>

has sub-classes

[Left apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Right apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>

## **Apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005289>

has super-classes

[Structure of apex of prostate<sup>c</sup>](#)

has sub-classes

[Left apical peripheral zone of prostate<sup>c</sup>](#), [Right apical peripheral zone of prostate<sup>c</sup>](#)

## **Apical transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005311>

has super-classes

[Structure of apex of prostate<sup>c</sup>](#)

has sub-classes

[Left apical transition zone of prostate<sup>c</sup>](#), [Right apical transition zone of prostate<sup>c</sup>](#)

## **Architectural distortion of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016360>

has super-classes

[Mammographic breast tissue appearance<sup>c</sup>](#)

## **Arm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000108>

The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb. [NCIT]

has super-classes

[Entire limb<sup>c</sup>](#), [Extremity<sup>c</sup>](#), [Structure of free upper limb<sup>c</sup>](#), [Structure of shoulder and/or upper arm<sup>c</sup>](#)

has sub-classes

[Upper extremity part<sup>c</sup>](#)

## **Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033755>

has super-classes

[Aspartate aminotransferase measurement<sup>c</sup>](#)

## **Aspartate aminotransferase measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033729>



has super-classes

[Measurement of liver enzyme](#)<sup>c</sup>

has sub-classes

[Aspartate aminotransferase \[Enzymatic activity/volume\] in Serum or Plasma](#)<sup>c</sup>

### **Assessment scales<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037297>

has super-classes

[Staging and scales](#)<sup>c</sup>

has sub-classes

[Child-Pugh score](#)<sup>c</sup>

### **Atezolizumab<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036213>

A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

### **Auricular region structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000519>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Ear](#)<sup>c</sup>

### **Autoimmune disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039962>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Autoimmune liver disease](#)<sup>c</sup>

## **Autoimmune hepatitis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047776>

Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma. [NCIT]

has super-classes

[Autoimmune liver disease<sup>c</sup>](#), [Inflammatory disease of liver<sup>c</sup>](#)

## **Autoimmune liver disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037388>

has super-classes

[Autoimmune disease<sup>c</sup>](#), [Disease of liver<sup>c</sup>](#)

has sub-classes

[Autoimmune hepatitis<sup>c</sup>](#)

## **Automatic<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000008>

Values for segmentation method (ProCancer-I, Prostate gland segmentation UC)  
Operating with minimal human intervention; independent of external control. [NCIT]

has super-classes

[Modifier mainly for procedure<sup>c</sup>](#)

## **Axial skeleton structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003446>

has super-classes

[Body part<sup>c</sup>](#)

has sub-classes

[Spine<sup>c</sup>](#)

## **Axillary lymph node<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004494>

Axillary lymph nodes are often visible on mammograms. Normal nodes are smaller than 2 cm and contain hyperechoic fatty hilar areas. Larger nodes may be normal when a very thin cortical rim is seen around the hilar fat. Enlarged round lymph nodes or those with small or no fatty hilar areas are abnormal, although there is no specific feature or finding to distinguish a nodal metastasis from a benign reactive node. Presence of fat in the nodal hilus does not exclude metastatic involvement; replacement of the node by tumor may be a gradual process best detected by interval change. In a patient with breast cancer, a cortical bulge or cortical area of increased echogenicity may suggest tumor involvement. A normal lymph node can be up to 2 cm in longest dimension. Larger lymph nodes, 3 cm or longer, with very thin cortical rims and most of the node consisting of fat, are also normal. Large rounded nodes lymph nodes, 3 cm or longer, with very thin cortical rims and most of

the node consisting of fat, are also normal. Large rounded nodes with a paucity of hilar fat or none at all, should be evaluated further and correlated clinically. [RADLEX]

has super-classes

[Structure of lymphatic system of axilla](#)<sup>c</sup>, [Upper limb lymph node structure](#)<sup>c</sup>

### **Basal anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005320>

has super-classes

[Anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Base of prostate](#)<sup>c</sup>

has sub-classes

[Left basal anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Right basal anterior fibromuscular stroma of prostate](#)<sup>c</sup>

### **Basal cell adenocarcinoma of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022482>

has super-classes

[Primary adenocarcinoma of pelvis](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>

### **Basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005302>

has super-classes

[Base of prostate](#)<sup>c</sup>

has sub-classes

[Left basal peripheral zone of prostate](#)<sup>c</sup>, [Right basal peripheral zone of prostate](#)<sup>c</sup>

### **Basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005280>

has super-classes

[Base of prostate](#)<sup>c</sup>

has sub-classes

[Left basal transition zone of prostate](#)<sup>c</sup>, [Right basal transition zone of prostate](#)<sup>c</sup>

### **Base of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005277>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Basal anterior fibromuscular stroma of prostate](#) <sup>c</sup>, [Basal peripheral zone of prostate](#) <sup>c</sup>, [Basal transition zone of prostate](#) <sup>c</sup>

### **Baseline<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001948>

has super-classes

[Timepoint](#) <sup>c</sup>

### **Benign<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000059>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health. [NCIT]

has super-classes

[Disease morphology qualifier](#) <sup>c</sup>, [General adjectival modifier](#) <sup>c</sup>

### **Benign adenomatous neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040867>

has super-classes

[Benign neoplastic disease](#) <sup>c</sup>

has sub-classes

[Adenoma of liver](#) <sup>c</sup>

### **Benign neoplasm of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036398>

has super-classes

[Benign tumor of digestive organ](#) <sup>c</sup>, [Neoplasm of liver](#) <sup>c</sup>

has sub-classes

[Adenoma of liver](#) <sup>c</sup>

### **Benign neoplastic disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040678>

has super-classes

[Neoplastic disease](#) <sup>c</sup>

has sub-classes

[Benign adenomatous neoplasm](#) <sup>c</sup>, [Benign tumor of digestive organ](#) <sup>c</sup>

## **Benign prostatic hyperplasia<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024373>

has super-classes

[Hyperplasia of prostate](#)<sup>c</sup>

## **Benign tumor of digestive organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040772>

has super-classes

[Benign neoplastic disease](#)<sup>c</sup>

has sub-classes

[Benign neoplasm of liver](#)<sup>c</sup>

## **Bilateral<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016659>

has super-classes

[Laterality](#)<sup>c</sup>

## **Biliary tract structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000617>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Gallbladder](#)<sup>c</sup>

## **Binary<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000023>

Consisting of two (e.g., units, components, elements, terms, possibilities) or based on two. [NCIT]

has super-classes

[General adjectival modifier](#)<sup>c</sup>

## **Biomedical device<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000109>

has super-classes

[Clinical equipment and/or device](#)<sup>c</sup>

has sub-classes

[Clip](#)<sup>c</sup>

## **Biopsy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001712>

has super-classes

[Removal<sup>c</sup>](#)

has sub-classes

[Biopsy of trunk<sup>c</sup>](#), [Imaging guided biopsy<sup>c</sup>](#)

## **Biopsy finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018153>

has super-classes

[Evaluation finding<sup>c</sup>](#)

has sub-classes

[Biopsy result abnormal<sup>c</sup>](#), [Biopsy result normal<sup>c</sup>](#)

## **Biopsy of abdomen using ultrasound guidance<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016119>

has super-classes

[Ultrasonography of abdomen<sup>c</sup>](#), [Ultrasound guided biopsy<sup>c</sup>](#)

has sub-classes

[MRI-US fusion guided prostate biopsy<sup>c</sup>](#)

## **Biopsy of male genital system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001880>

has super-classes

[Biopsy of trunk<sup>c</sup>](#), [Procedure on male genital system<sup>c</sup>](#)

has sub-classes

[Biopsy of prostate<sup>c</sup>](#)

## **Biopsy of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001938>

has super-classes

[Biopsy of male genital system<sup>c</sup>](#), [Procedure on prostate<sup>c</sup>](#)

has sub-classes

[US scan and biopsy of prostate<sup>c</sup>](#)

## **Biopsy of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001767>

has super-classes

[Biopsy](#)<sup>c</sup>, [Procedure on trunk](#)<sup>c</sup>

has sub-classes

[Biopsy of male genital system](#)<sup>c</sup>, [US scan and biopsy of pelvis](#)<sup>c</sup>

### **Biopsy result abnormal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028707>

has super-classes

[Abnormal finding on evaluation procedure](#)<sup>c</sup>, [Biopsy finding](#)<sup>c</sup>

### **Biopsy result normal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028828>

has super-classes

[Biopsy finding](#)<sup>c</sup>

### **Bladder control - finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018227>

has super-classes

[Functional finding](#)<sup>c</sup>

has sub-classes

[Continent of urine](#)<sup>c</sup>, [Urinary incontinence](#)<sup>c</sup>

### **Bladder finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018302>

has super-classes

[Pelvic organ finding](#)<sup>c</sup>

has sub-classes

[Continent of urine](#)<sup>c</sup>, [Urinary incontinence](#)<sup>c</sup>

### **Block dissection of pelvic lymph nodes<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018378>

has super-classes

[Excision of pelvic lymph node](#)<sup>c</sup>

has sub-classes

[Pelvic lymphadenectomy](#)<sup>c</sup>

### **Body organ structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000402>

An anatomical structure that consists of the maximal set of organ parts so connected to one another that together they constitute a self-contained unit of macroscopic anatomy, distinct both morphologically and functionally from other such units. Together with other organs, an organ constitutes an organ system or a body part. An organ is divisible into organ parts but not organs (examples: femur, biceps, liver, heart, aorta, sciatic nerve, ovary). [SNOMEDCT]

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Breast](#)<sup>c</sup>, [Digestive organ structure](#)<sup>c</sup>, [Structure of abdominopelvic organ](#)<sup>c</sup>, [Structure of viscus](#)<sup>c</sup>

## **Body part<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000011>

has super-classes

[Imaging Module](#)<sup>c</sup>

has sub-classes

[Abdominopelvic cross-sectional segment](#)<sup>c</sup>, [Abdominopelvic segment of trunk](#)<sup>c</sup>, [Anorectal structure](#)<sup>c</sup>, [Auricular region structure](#)<sup>c</sup>, [Axial skeleton structure](#)<sup>c</sup>, [Biliary tract structure](#)<sup>c</sup>, [Body organ structure](#)<sup>c</sup>, [Body part structure](#)<sup>c</sup>, [Bone and/or joint structure of cranium](#)<sup>c</sup>, [Bone structure of head](#)<sup>c</sup>, [Brain and spinal cord structure](#)<sup>c</sup>, [Chest, abdomen, and pelvis](#)<sup>c</sup>, [Combined site](#)<sup>c</sup>, [Cross-sectional pelvis](#)<sup>c</sup>, [Digestive organ structure](#)<sup>c</sup>, [Ear, nose and throat structure](#)<sup>c</sup>, [Endocrine gland structure](#)<sup>c</sup>, [Entire body region](#)<sup>c</sup>, [Entire limb](#)<sup>c</sup>, [Eye region structure](#)<sup>c</sup>, [Face and/or neck structure](#)<sup>c</sup>, [Female genital tract structure](#)<sup>c</sup>, [Heart and/or pericardium structure](#)<sup>c</sup>, [Heart, mediastinum, and pleura](#)<sup>c</sup>, [Hip region structure](#)<sup>c</sup>, [Intestinal structure](#)<sup>c</sup>, [Intra-abdominal digestive structure](#)<sup>c</sup>, [Intra-abdominal urinary structure](#)<sup>c</sup>, [Intracranial structure](#)<sup>c</sup>, [Joint structure of lower extremity](#)<sup>c</sup>, [Joint structure of pelvic girdle](#)<sup>c</sup>, [Large intestine part](#)<sup>c</sup>, [Liver and intrahepatic bile ducts](#)<sup>c</sup>, [Liver and/or biliary structure](#)<sup>c</sup>, [Lower body part structure](#)<sup>c</sup>, [Lower bowel structures](#)<sup>c</sup>, [Lower respiratory tract structure](#)<sup>c</sup>, [Lumbosacral region of spine structure](#)<sup>c</sup>, [Male genital organ structure](#)<sup>c</sup>, [Musculoskeletal structure of sacral spine](#)<sup>c</sup>, [Musculoskeletal structure of spine](#)<sup>c</sup>, [Neck, chest and abdomen](#)<sup>c</sup>, [Non-coronary systemic artery structure](#)<sup>c</sup>, [Pectoral region structure](#)<sup>c</sup>, [Prostate and vas deferens structures](#)<sup>c</sup>, [Prostatic and/or seminal vesicle structures](#)<sup>c</sup>, [Pulmonary structure including vessels and lymphoid tissue](#)<sup>c</sup>, [Retroperitoneal compartment structure](#)<sup>c</sup>, [Scalp and/or neck structure](#)<sup>c</sup>, [Skull foramen](#)<sup>c</sup>, [Structure of ankle and/or foot](#)<sup>c</sup>, [Structure of body conduit](#)<sup>c</sup>, [Structure of breast and/or endocrine system](#)<sup>c</sup>, [Structure of endocrine system](#)<sup>c</sup>, [Structure of female genital system in pelvic cavity](#)<sup>c</sup>, [Structure of female internal genital organ](#)<sup>c</sup>, [Structure of free lower limb](#)<sup>c</sup>, [Structure of free upper limb](#)<sup>c</sup>, [Structure of genitourinary system](#)<sup>c</sup>, [Structure of great blood vessel \(organ\)](#)<sup>c</sup>, [Structure of half of body lateral to midsagittal plane](#)<sup>c</sup>, [Structure of half of thorax lateral to midsagittal plane](#)<sup>c</sup>, [Structure of joint region](#)<sup>c</sup>, [Structure of joint region of lower limb](#)<sup>c</sup>, [Structure of large artery](#)<sup>c</sup>, [Structure of lateral half of abdomen lateral to midsagittal plane](#)<sup>c</sup>, [Structure of lesser wing of sphenoid bone](#)<sup>c</sup>, [Structure of lung and/or mediastinum](#)<sup>c</sup>, [Structure of lymphatic system](#)<sup>c</sup>, [Structure of mammary region](#)<sup>c</sup>, [Structure of musculoskeletal system of cervical spine](#)<sup>c</sup>, [Structure of musculoskeletal system of lumbar spine](#)<sup>c</sup>, [Structure of musculoskeletal system of thoracic spine](#)<sup>c</sup>, [Structure of organ in respiratory system](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>, [Structure of organ within cavity of true pelvis](#)<sup>c</sup>, [Structure of pelvic segment of trunk](#)<sup>c</sup>, [Structure of pelvic viscus](#)<sup>c</sup>, [Structure of peripheral auditory system](#)<sup>c</sup>, [Structure of posterior arch of pelvic ring](#)<sup>c</sup>, [Structure of pulmopleural compartment](#)<sup>c</sup>, [Structure of](#)



[shoulder and/or upper arm](#)<sup>c</sup>, [Structure of shoulder girdle region](#)<sup>c</sup>, [Structure of spheroidal joint](#)<sup>c</sup>, [Structure of thoracic cavity and/or content](#)<sup>c</sup>, [Structure of thoracic viscus](#)<sup>c</sup>, [Structure of upper urinary system](#)<sup>c</sup>, [Structure of urinary organ](#)<sup>c</sup>, [Structure of vertebral column and/or spinal cord](#)<sup>c</sup>, [Structure of vertebral region of cervical part of back](#)<sup>c</sup>, [Structure of vertebral region of lumbar part of back](#)<sup>c</sup>, [Structure of vertebral region of thoracic part of back](#)<sup>c</sup>, [Systemic artery of trunk](#)<sup>c</sup>, [Thoracic segment of trunk](#)<sup>c</sup>, [Upper body part structure](#)<sup>c</sup>

### **Body part structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001046>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Body structure](#)<sup>c</sup>, [Extremity](#)<sup>c</sup>, [Intra-abdominopelvic structure](#)<sup>c</sup>, [Trunk structure](#)<sup>c</sup>

### **Body structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016384>

has super-classes

[Body part structure](#)<sup>c</sup>

has sub-classes

[Morphologically altered structure](#)<sup>c</sup>

### **Body substance sample<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002118>

has super-classes

[Specimen](#)<sup>c</sup>

has sub-classes

[Tissue specimen](#)<sup>c</sup>

### **Bone and/or joint structure of cranium<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000344>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Skull](#)<sup>c</sup>

### **Bone structure of femur<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004428>

has super-classes

[Structure of femur](#)<sup>c</sup>

### **Bone structure of head<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000332>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Skull](#)<sup>c</sup>

### **Bounding box<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000118>

Annotation type (INCISIVE, Annotation Definitions and guidelines)

has super-classes

[Qualifier](#)<sup>c</sup>

### **Bowel finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000318>

has super-classes

[Abdominal organ finding](#)<sup>c</sup>, [Gastrointestinal tract finding](#)<sup>c</sup>

has sub-classes

[Finding of large intestine](#)<sup>c</sup>

### **Bowels: fully continent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024450>

has super-classes

[Finding of bowel continence](#)<sup>c</sup>, [Finding of large intestine](#)<sup>c</sup>

### **Brain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000118>

An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium. [NCIT]

has super-classes

[Brain and spinal cord structure](#)<sup>c</sup>, [Intracranial structure](#)<sup>c</sup>

has sub-classes

[Brain stem](#)<sup>c</sup>

### **Brain and spinal cord structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000357>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Brain](#)<sup>c</sup>

### **Brain stem<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004393>

Three sections, the midbrain, pons and medulla oblongata, that are located at the base of the brain. The brain stem regulates the central nervous system, and is vital as a conduit for motor and sensory innervations. [NCIT]

has super-classes

[Brain](#)<sup>c</sup>

### **BRCA1 gene mutation detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035265>

has super-classes

[Breast cancer genetic marker of susceptibility detected](#)<sup>c</sup>

### **BRCA1 gene mutation not detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035286>

has super-classes

[Breast cancer genetic marker of susceptibility not detected](#)<sup>c</sup>

### **BRCA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046138>

A molecular genetics procedure that detects gene variants of BRCA1 in a blood or tissue specimen. [NCIT]

has super-classes

[Gene mutation](#)<sup>c</sup>, [Measurement](#)<sup>c</sup>

### **BRCA1 mutation carrier detection test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035226>

has super-classes

[Molecular genetic test](#)<sup>c</sup>

### **BRCA1+BRCA2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045865>

has super-classes

[Gene mutation](#)<sup>c</sup>, [Measurement](#)<sup>c</sup>

**BRCA2 gene mutation detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035308>

has super-classes

[Breast cancer genetic marker of susceptibility detected](#)<sup>c</sup>

**BRCA2 gene mutation not detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035331>

has super-classes

[Breast cancer genetic marker of susceptibility not detected](#)<sup>c</sup>

**BRCA2 mutation carrier detection test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035245>

has super-classes

[Molecular genetic test](#)<sup>c</sup>

**Breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000111>

One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest. [NCIT]

has super-classes

[Body organ structure](#)<sup>c</sup>, [Pectoral region structure](#)<sup>c</sup>, [Structure of breast and/or endocrine system](#)<sup>c</sup>, [Structure of half of thorax lateral to midsagittal plane](#)<sup>c</sup>, [Structure of mammary region](#)<sup>c</sup>

has sub-classes

[Left breast structure](#)<sup>c</sup>, [Right breast structure](#)<sup>c</sup>

**Breast cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000060>

A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla. [NCIT]

has super-classes

[Malignant neoplasm of thorax](#)<sup>c</sup>, [Neoplasm of breast](#)<sup>c</sup>

has sub-classes

[Carcinoma of breast](#)<sup>c</sup>, [Malignant neoplasm of female breast](#)<sup>c</sup>, [Primary malignant neoplasm of breast](#)<sup>c</sup>

### **Breast cancer genetic marker of susceptibility detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034574>

has super-classes

[Genetic finding detected](#)<sup>c</sup>

has sub-classes

[BRCA1 gene mutation detected](#)<sup>c</sup>, [BRCA2 gene mutation detected](#)<sup>c</sup>

### **Breast cancer genetic marker of susceptibility not detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034637>

has super-classes

[Genetic finding not detected](#)<sup>c</sup>

has sub-classes

[BRCA1 gene mutation not detected](#)<sup>c</sup>, [BRCA2 gene mutation not detected](#)<sup>c</sup>

### **Breast fed<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048461>

has super-classes

[Infant feeding method - finding](#)<sup>c</sup>

### **Breast finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037127>

has super-classes

[Finding of region of thorax](#)<sup>c</sup>

has sub-classes

[Breast signs and symptoms](#)<sup>c</sup>, [Disorder of breast](#)<sup>c</sup>

### **Breast signs and symptoms<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047840>

has super-classes

[Breast finding](#)<sup>c</sup>

### **Bronchus and lung<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004402>

A sample that contains lung and bronchial tissues. [NCIT]

has super-classes

[Combined site](#)<sup>c</sup>

### **C reactive protein [Mass/volume] in Blood by High sensitivity method<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033965>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Calcifications<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000102>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

Deposition of calcium in the tissues. It may be the result of a metabolic disorder or long-standing infection, or it may be associated with the presence of cancer. [NCIT]

has super-classes

[Deposit](#)<sup>c</sup>

### **Calcium [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033540>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Cancer Ag 15-3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040963>

has super-classes

[Tumor marker measurement](#)<sup>c</sup>

has sub-classes

[Cancer Ag 15-3 | Serum or Plasma | Chemistry - non-challenge](#)<sup>c</sup>

### **Cancer Ag 15-3 [Units/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045838>

A quantitative procedure that measures the concentration (units/volume) of cancer antigen 15-3 in a serum or plasma specimen. [NCIT]

has super-classes

[Cancer Ag 15-3 | Serum or Plasma | Chemistry - non-challenge](#)<sup>c</sup>, [Cancer Ag 15-3|Arbitrary Concentration|Moment in time|Blood, Serum or Plasma](#)<sup>c</sup>, [Cancer antigen 15-3 measurement](#)<sup>c</sup>

## **Cancer Ag 15-3 | Serum or Plasma | Chemistry - non-challenge<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041060>

has super-classes

[Cancer Ag 15-3](#)<sup>c</sup>

has sub-classes

[Cancer Ag 15-3 \[Units/volume\] in Serum or Plasma](#)<sup>c</sup>

## **Cancer Ag 15-3|Arbitrary Concentration|Moment in time|Blood, Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038387>

has super-classes

[Flowsheet - laboratory](#)<sup>c</sup>

has sub-classes

[Cancer Ag 15-3 \[Units/volume\] in Serum or Plasma](#)<sup>c</sup>

## **Cancer antigen 15-3 measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039793>

has super-classes

[Glycoproteins measurement](#)<sup>c</sup>, [Tumor antigen measurement](#)<sup>c</sup>

has sub-classes

[Cancer Ag 15-3 \[Units/volume\] in Serum or Plasma](#)<sup>c</sup>

## **Cancer Grade<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** [https://cancerimage.eu/ontology/EUCAIM#mCODE:Cancer\\_Stage](https://cancerimage.eu/ontology/EUCAIM#mCODE:Cancer_Stage)

has super-classes

[Staging and scales](#)<sup>c</sup>

has sub-classes

[Gleason finding](#)<sup>c</sup>, [Gleason grade finding for prostatic cancer](#)<sup>c</sup>, [Grade 1 tumor](#)<sup>c</sup>, [Grade 2 tumor](#)<sup>c</sup>, [Grade 3 tumor](#)<sup>c</sup>, [Grade 4 tumor](#)<sup>c</sup>, [Tumor Regression Grade](#)<sup>c</sup>

## **Cancer of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000075>

One of the most common malignant tumors afflicting men. The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes. Adenocarcinomas represent the overwhelming majority of prostatic carcinomas. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. [NCIT]

has super-classes

[Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>, [Malignant tumor of male genital organ](#)<sup>c</sup>, [Malignant tumor of pelvis](#)<sup>c</sup>, [Neoplasm of prostate](#)<sup>c</sup>

has sub-classes

[Carcinoma of prostate](#)<sup>c</sup>, [Hormone refractory prostate cancer](#)<sup>c</sup>, [Hormone sensitive prostate cancer](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>, [Squamous cell carcinoma of prostate](#)<sup>c</sup>

## **Cancer Patient<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001051>

has super-classes

[Patient](#)<sup>c</sup>

## **Cancer staging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044563>

has super-classes

[Tumor staging](#)<sup>c</sup>

has sub-classes

[AJCC/UICC finding](#)<sup>c</sup>, [Generic tumor staging descriptor](#)<sup>c</sup>

## **Canon<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000050>

has super-classes

[Manufacturer](#)<sup>c</sup>

## **Capecitabine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035836>

A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

## **Carbamazepine Injection<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033130>

has super-classes

[Drug or medicament](#)<sup>c</sup>



## **Carboplatin<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035863>

A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)

has super-classes

[Antineoplastic agent<sup>c</sup>](#)

## **Carcinoembryonic Ag [Mass/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045880>

A quantitative procedure that measures the concentration (mass/volume) of carcinoembryonic antigen in a serum or plasma specimen. [NCIT]

has super-classes

[Carcinoembryonic Ag|Mass Concentration|Moment in time|Blood, Serum or Plasma<sup>c</sup>](#), [Carcinoembryonic Ag|Moment in time|Serum or Plasma<sup>c</sup>](#), [Carcinoembryonic antigen measurement<sup>c</sup>](#), [Measurement<sup>c</sup>](#)

## **Carcinoembryonic Ag|Mass Concentration|Moment in time|Blood, Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038452>

has super-classes

[Flowsheet - laboratory<sup>c</sup>](#)

has sub-classes

[Carcinoembryonic Ag.\[Mass/volume\] in Serum or Plasma<sup>c</sup>](#)

## **Carcinoembryonic Ag|Moment in time|Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036497>

has super-classes

[Mass-Molar conversion<sup>c</sup>](#)

has sub-classes

[Carcinoembryonic Ag \[Mass/volume\] in Serum or Plasma<sup>c</sup>](#)

## **Carcinoembryonic antigen measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039547>

has super-classes

[Protein measurement](#)<sup>c</sup>, [Tumor marker measurement](#)<sup>c</sup>

has sub-classes

[Carcinoembryonic Ag.\[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>

### **Carcinoma in situ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002243>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Carcinoma in situ of male genital organ](#)<sup>c</sup>

### **Carcinoma in situ of male genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002307>

has super-classes

[Carcinoma in situ](#)<sup>c</sup>, [Neoplasm of male genital organ](#)<sup>c</sup>

has sub-classes

[Carcinoma in situ of prostate](#)<sup>c</sup>

### **Carcinoma in situ of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015917>

has super-classes

[Carcinoma in situ of male genital organ](#)<sup>c</sup>, [Neoplasm of prostate](#)<sup>c</sup>

has sub-classes

[Intraductal carcinoma, noninfiltrating, NOS, of prostate gland](#)<sup>c</sup>

### **Carcinoma of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000169>

A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla. [NCIT]

has super-classes

[Breast cancer](#)<sup>c</sup>, [Malignant epithelial neoplasm](#)<sup>c</sup>

has sub-classes

[HER2 negative](#)<sup>c</sup>, [HER2 positive](#)<sup>c</sup>, [Human epidermal growth factor 2 negative carcinoma of breast](#)<sup>c</sup>

### **Carcinoma of colon<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000174>

A malignant epithelial neoplasm that arises from the colon and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas. [NCIT]

has super-classes

[Colon cancer](#)<sup>c</sup>, [Malignant epithelial neoplasm](#)<sup>c</sup>

### **Carcinoma of genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000178>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Carcinoma of prostate](#)<sup>c</sup>

### **Carcinoma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000179>

One of the most common malignant tumors afflicting men. The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes. Adenocarcinomas represent the overwhelming majority of prostatic carcinomas. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. [NCIT]

has super-classes

[Cancer of prostate](#)<sup>c</sup>, [Carcinoma of genital organ](#)<sup>c</sup>

### **Care regime<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034299>

has super-classes

[Regimes and therapies](#)<sup>c</sup>

has sub-classes

[Radiation therapy care](#)<sup>c</sup>

### **Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045931>

A quantitative immune staining procedure that measures the percentage of cells expressing estrogen receptor per the total number of cells in a breast cancer specimen. [NCIT]

has super-classes

[Measurement](#)<sup>c</sup>, [Pathology](#)<sup>c</sup>

## **Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045913>

has super-classes

[Measurement](#)<sup>c</sup>, [Pathology](#)<sup>c</sup>

## **Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046195>

A quantitative immune staining procedure that measures the percentage of cells expressing progesterone receptor per the total number of cells in a breast cancer specimen. [NCIT]

has super-classes

[Measurement](#)<sup>c</sup>, [Pathology](#)<sup>c</sup>

## **Central zone of left half prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004495>

The portion of the central zone of the prostate that is located to the anatomical left of center. [NCIT]

has super-classes

[Central zone of prostate](#)<sup>c</sup>

## **Central zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004459>

PI-RADS: The central zone is the region of the prostate surrounding the ejaculatory ducts posterior and superior, from the base of the prostate to the verumontanum. Its lateral border fuses with the proximal peripheral zone border at the prostate base. It has the shape of an inverted cone with its base oriented towards the base of the gland. It contains about 20% of the glandular tissue. It contains more stroma than glandular tissue. The term “central gland” refers to the central zone and the transition zone combined. The use of this term is discouraged. If the central zone is not seen as a distinct regional part, then a finding in this region should be localized to the transition zone. [RADLEX]

has super-classes

[Glandular zone of prostate](#)<sup>c</sup>

has sub-classes

[Central zone of left half prostate](#)<sup>c</sup>, [Central zone of right half prostate](#)<sup>c</sup>

## **Central zone of right half prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004497>

The portion of the central zone of the prostate that is located to the anatomical right of center. [NCIT]

has super-classes

[Central zone of prostate](#)<sup>c</sup>

## **Cervical spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000120>

The set of vertebrae immediately caudal to the skull. [NCIT]

has super-classes

[Spine](#)<sup>c</sup>, [Structure of musculoskeletal system of cervical spine](#)<sup>c</sup>, [Structure of vertebral region of cervical part of back](#)<sup>c</sup>

## **Chemoradiotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035091>

has super-classes

[Chemotherapy](#)<sup>c</sup>, [Drug therapy](#)<sup>c</sup>, [Radiation oncology AND/OR radiotherapy](#)<sup>c</sup>

## **Chemotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024528>

has super-classes

[Administration of medication](#)<sup>c</sup>, [Drug therapy](#)<sup>c</sup>

has sub-classes

[Chemoradiotherapy](#)<sup>c</sup>, [Chemotherapy cycle](#)<sup>c</sup>

## **Chemotherapy cycle<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035191>

has super-classes

[Chemotherapy](#)<sup>c</sup>

## **Chemotherapy Regimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034214>

has super-classes

[Drug therapy](#)<sup>c</sup>

## **Chest<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000102>

Subdivision of trunk proper, which is demarcated from the neck by the plane of the superior thoracic aperture and from the abdomen internally by the inferior surface of the diaphragm and externally by the costal margin and associated with the thoracic vertebral column and ribcage and from the back of the thorax by the external surface

of the posterolateral part of the rib cage, the anterior surface of the thoracic vertebral column and the posterior axillary lines; together with the abdomen and the perineum, it constitutes the trunk proper. [FMA]

has super-classes

[Chest and abdomen](#)<sup>c</sup>, [Neck and chest](#)<sup>c</sup>, [Thoracic segment of trunk](#)<sup>c</sup>

has sub-classes

[Mediastinum](#)<sup>c</sup>, [Pectoral region structure](#)<sup>c</sup>, [Structure of half of thorax lateral to midsagittal plane](#)<sup>c</sup>,  
[Structure of mammary region](#)<sup>c</sup>

## **Chest and abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000098>

has super-classes

[Chest, abdomen, and pelvis](#)<sup>c</sup>, [Neck, chest and abdomen](#)<sup>c</sup>

has sub-classes

[Chest](#)<sup>c</sup>

## **Chest imaging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016134>

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>

has sub-classes

[MRI of chest](#)<sup>c</sup>, [Radiographic procedure of chest](#)<sup>c</sup>

## **Chest injury<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037253>

has super-classes

[Disorder of thorax](#)<sup>c</sup>

has sub-classes

[Injury of breast](#)<sup>c</sup>

## **Chest, abdomen, and pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000096>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Abdomen](#)<sup>c</sup>, [Abdomen and Pelvis](#)<sup>c</sup>, [Abdominopelvic segment of trunk](#)<sup>c</sup>, [Chest and abdomen](#)<sup>c</sup>

## **Child-Pugh score<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047413>

A standardized rating scale used to assess the severity of liver cirrhosis and determine the prognosis, the required strength of treatment, and the necessity of liver transplantation. This instrument uses the following clinical and lab criteria: encephalopathy grade, ascites, bilirubin, albumin, and prothrombin index. [NCIT]

has super-classes

[Assessment scales](#)<sup>c</sup>

### **Child-Pugh score class A<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048245>

has super-classes

[Liver finding](#)<sup>c</sup>

### **Child-Pugh score class B<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046426>

has super-classes

[Liver finding](#)<sup>c</sup>

### **Child-Pugh score class C<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046463>

has super-classes

[Liver finding](#)<sup>c</sup>

### **Cholangiocarcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047713>

A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas. [NCIT]

has super-classes

[Primary malignant adenomatous neoplasm](#)<sup>c</sup>

### **Cholangitis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038935>

has super-classes

[Disorder of abdomen](#)<sup>c</sup>

has sub-classes

[Sclerosing cholangitis](#)<sup>c</sup>

### **Cholesterol [Mass/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033575>

has super-classes

[Cholesterol measurement](#)<sup>c</sup>

**Cholesterol in HDL [Mass/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033635>

has super-classes

[High density lipoprotein cholesterol measurement](#)<sup>c</sup>

**Cholesterol in LDL [Mass/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033680>

has super-classes

[Low density lipoprotein cholesterol measurement](#)<sup>c</sup>

**Cholesterol measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033557>

has super-classes

[Steroid measurement](#)<sup>c</sup>

has sub-classes

[Cholesterol \[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>, [High density lipoprotein cholesterol measurement](#)<sup>c</sup>,  
[Low density lipoprotein cholesterol measurement](#)<sup>c</sup>

**Chronic digestive system disorder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039877>

has super-classes

[Disorder of digestive system](#)<sup>c</sup>

has sub-classes

[Chronic liver disease](#)<sup>c</sup>

**Chronic disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040312>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Chronic inflammatory disorder](#)<sup>c</sup>

**Chronic disease monitoring<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009957>



has super-classes

[Monitoring of patient](#)<sup>c</sup>

has sub-classes

[Monitoring of patient with cancer](#)<sup>c</sup>

### **Chronic hepatitis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046355>

An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders. [NCIT]

has super-classes

[Chronic inflammatory disorder](#)<sup>c</sup>, [Chronic liver disease](#)<sup>c</sup>, [Inflammatory disease of liver](#)<sup>c</sup>

### **Chronic inflammatory disorder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040402>

has super-classes

[Chronic disease](#)<sup>c</sup>

has sub-classes

[Chronic hepatitis](#)<sup>c</sup>

### **Chronic liver disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037342>

has super-classes

[Chronic digestive system disorder](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>

has sub-classes

[Chronic hepatitis](#)<sup>c</sup>, [Cirrhosis of liver](#)<sup>c</sup>

### **Cirrhosis of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045775>

has super-classes

[Chronic liver disease](#)<sup>c</sup>, [Hepatic fibrosis](#)<sup>c</sup>, [Liver regeneration](#)<sup>c</sup>

### **Clinical equipment and/or device<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000106>

has super-classes

[device](#)<sup>c</sup>

has sub-classes

[Biomedical device](#)<sup>c</sup>

## **Clinical finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000004>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Administrative statuses](#)<sup>c</sup>, [Disease](#)<sup>c</sup>, [Evaluation finding](#)<sup>c</sup>, [Finding of lesion](#)<sup>c</sup>, [Finding of pelvic region of trunk](#)<sup>c</sup>, [Finding of trunk structure](#)<sup>c</sup>, [Finding of urinary tract proper](#)<sup>c</sup>, [Functional finding](#)<sup>c</sup>, [Gastrointestinal tract finding](#)<sup>c</sup>, [General clinical state finding](#)<sup>c</sup>, [General finding of observation of patient](#)<sup>c</sup>, [Infant feeding method - finding](#)<sup>c</sup>, [Mass of digestive structure](#)<sup>c</sup>, [Menopause finding](#)<sup>c</sup>, [Uses contraception \(finding\)](#)<sup>c</sup>

## **Clinical history/examination observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040048>

has super-classes

[Observable entity](#)<sup>c</sup>

has sub-classes

[Lesion observable](#)<sup>c</sup>, [Pregnancy, childbirth / puerperium observable](#)<sup>c</sup>, [Survival time](#)<sup>c</sup>

## **Clinical Module<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000001>

This module defines the categories/entities that are specified in clinical context (e.g., cancer types, treatments, procedures, etc.).

has super-classes

[thing](#)<sup>c</sup>

has sub-classes

[Clinical Test Result](#)<sup>c</sup>, [Clinical finding](#)<sup>c</sup>, [Clinical specialty](#)<sup>c</sup>, [Diagnosis](#)<sup>c</sup>, [Diagnostic/Screening Processes or Results](#)<sup>c</sup>, [Measurement](#)<sup>c</sup>, [Medication](#)<sup>c</sup>, [Metastasis](#)<sup>c</sup>, [Observable entity](#)<sup>c</sup>, [Procedure](#)<sup>c</sup>, [Situation with explicit context](#)<sup>c</sup>, [Specimen](#)<sup>c</sup>, [Staging and scales](#)<sup>c</sup>

## **Clinical specialty<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036560>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Pathology](#)<sup>c</sup>

## **Clinical Test Result<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000200>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Laboratory Test Result](#)<sup>c</sup>

**Clip<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000113>

has super-classes

[Biomedical device](#)<sup>c</sup>

has sub-classes

[Surgical clip](#)<sup>c</sup>

**cM category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033341>

has super-classes

[M category](#)<sup>c</sup>

has sub-classes

[TNM Clin M](#)<sup>c</sup>

**cM0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001860>

has super-classes

[American Joint Committee on Cancer clinical M category allowable value](#)<sup>c</sup>

**cM1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000246>

has super-classes

[American Joint Committee on Cancer clinical M category allowable value](#)<sup>c</sup>

**cM1a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000258>

has super-classes

[American Joint Committee on Cancer clinical M category allowable value](#)<sup>c</sup>

**cM1b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000271>

has super-classes

[American Joint Committee on Cancer clinical M category allowable value](#)<sup>c</sup>

**cM1c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001876>

has super-classes

[American Joint Committee on Cancer clinical M category allowable value](#)<sup>c</sup>

**cN category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033358>

has super-classes

[N category](#)<sup>c</sup>

has sub-classes

[TNM Clin N](#)<sup>c</sup>

**cN0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000285>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000300>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN1mi<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001397>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001399>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN2a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001402>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN2b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001406>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001411>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN3a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001417>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN3b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001424>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cN3c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001432>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**cNX<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001441>

has super-classes

[American Joint Committee on Cancer clinical N category allowable value](#)<sup>c</sup>

**Co-morbid conditions<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048316>

has super-classes

[General problem AND/OR complaint](#)<sup>c</sup>

## **Colon<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000266>

The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion. [NCIT]

has super-classes

[Abdomen and Pelvis](#)<sup>c</sup>

## **Colon and rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004407>

has super-classes

[Combined site](#)<sup>c</sup>

## **Colon cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000057>

A malignant epithelial neoplasm that arises from the colon and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas. [NCIT]

has super-classes

[Malignant neoplasm of colon and/or rectum](#)<sup>c</sup>, [Neoplasm of colon](#)<sup>c</sup>

has sub-classes

[Carcinoma of colon](#)<sup>c</sup>, [Primary malignant neoplasm of colon](#)<sup>c</sup>

## **Combined site<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004392>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Bronchus and lung](#)<sup>c</sup>, [Colon and rectum](#)<sup>c</sup>, [Uterus and fallopian tubes](#)<sup>c</sup>

## **Common Module<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000001>

This module defines the categories/entities that are not specified in imaging or clinical context (e.g., procedure qualifiers, age, gender, etc.).

has super-classes

[thing](#)<sup>c</sup>

has sub-classes

[Age AND/OR growth period](#)<sup>c</sup>, [Gender](#)<sup>c</sup>, [Person](#)<sup>c</sup>, [Physical object](#)<sup>c</sup>, [Qualifier](#)<sup>c</sup>, [Sex assigned at birth](#)<sup>c</sup>

### **Complete excision<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004692>

has super-classes

[Excision](#)<sup>c</sup>, [Procedure on organ](#)<sup>c</sup>

has sub-classes

[Removal of entire genital organ](#)<sup>c</sup>

### **Computed tomography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000026>

A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. [NCIT]

has super-classes

[Tomography](#)<sup>c</sup>

### **Conformal radiotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015948>

has super-classes

[Destructive procedure](#)<sup>c</sup>, [Radiation oncology AND/OR radiotherapy](#)<sup>c</sup>

has sub-classes

[3D CRT three dimensional conformal radiation therapy](#)<sup>c</sup>

### **Context values<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001061>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Finding context value](#)<sup>c</sup>

### **Continent of urine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024607>

has super-classes

[Bladder control - finding](#)<sup>c</sup>, [Bladder finding](#)<sup>c</sup>

### **Contouring<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000089>

Annotation type (INCISIVE, Annotation Definitions and guidelines)

has super-classes

[Qualifier](#)<sup>c</sup>

### **Correspondence Module<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000001>

This module defines the OMOP domain and FHIR resourceType as defined in local CDMs).

has super-classes

[thing](#)<sup>c</sup>

has sub-classes

[Domain-OMOP](#)<sup>c</sup>, [ResourceType-FHIR](#)<sup>c</sup>

### **Cortisol [Mass/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033932>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Creatinine [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033482>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Creatinine [Mass/volume] in Urine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034107>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Cross-sectional abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016525>

has super-classes

[Abdominopelvic cross-sectional segment](#)<sup>c</sup>

has sub-classes

[Liver and/or biliary structure](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>

### **Cross-sectional pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002036>

This cross-sectional segment is bounded superiorly by a virtual horizontal plane at the level of the plane traversing the superior boundary of the iliac crest; and inferiorly it extends to the perineum and includes part but not necessarily the entire external genitalia. The segment includes the volume of the true and false pelvic cavities (and also part of the lower abdominal volume below the level of the virtual superior boundary). The volume includes the entire transverse thickness of the body over the longitudinal extent between the superior (upper) and inferior (lower) boundaries including the skin and subcutaneous tissue. The segment relates to the cross-sectional or projectional volume as perceived by transmissive or emissive imaging. [SNOMEDCT]

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Pelvis](#)<sup>c</sup>

**cross-sectional procedure attribute<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016625>

has super-classes

[imaging procedure property](#)<sup>c</sup>

has sub-classes

[MR procedure attribute](#)<sup>c</sup>

**cT category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033379>

has super-classes

[T category](#)<sup>c</sup>

has sub-classes

[TNM Clin T](#)<sup>c</sup>

**cT0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000316>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000333>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT1a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001451>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT1b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001462>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT1c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001474>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT1mi<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001487>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000351>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT2a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000370>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT2b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000390>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT2c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000411>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000433>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT3a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000456>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT3b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000480>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000505>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT4a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001501>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT4b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001516>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT4c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001532>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cT4d<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001549>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cTisDCIs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001818>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cTisPaget<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001831>

has super-classes

[American Joint Committee on Cancer clinical T category allowable value](#)<sup>c</sup>

**cubic millimeter<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000149>

has super-classes

[Unit of measure](#)<sup>c</sup>

**Cyclophosphamide<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035871>

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramidate mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. [NCIT]

has super-classes

[Alkylating agent](#)<sup>c</sup>, [Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

**Cyst of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038260>

has super-classes

[Abdominal mass](#)<sup>c</sup>, [Disorder of abdomen](#)<sup>c</sup>

has sub-classes

[Cyst of liver](#)<sup>c</sup>

### **Cyst of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047905>

A cystic lesion located in the liver. [NCIT]

has super-classes

[Cyst of abdomen](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>, [Liver mass](#)<sup>c</sup>

### **Cystadenoma of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045763>

has super-classes

[Adenoma of liver](#)<sup>c</sup>

### **Cystic, mucinous and serous neoplasms<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046888>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Mucinous adenocarcinoma](#)<sup>c</sup>

### **Damage<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016586>

has super-classes

[Lesion](#)<sup>c</sup>

has sub-classes

[focal damage](#)<sup>c</sup>

### **Dead<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024687>

has super-classes

[General clinical state finding](#)<sup>c</sup>

### **Degenerative disorder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038077>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[steatosis of liver](#)<sup>c</sup>

### **Degrees of severity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001335>

has super-classes

[Ranked categories](#)<sup>c</sup>

has sub-classes

[First degree](#)<sup>c</sup>, [Second degree](#)<sup>c</sup>

### **Deposit<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000220>

has super-classes

[Morphologic Finding](#)<sup>c</sup>

has sub-classes

[Calcifications](#)<sup>c</sup>, [Macrocalcifications](#)<sup>c</sup>

### **Derived<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000012>

An indication that a data element has been derived from one or more data elements. [NCIT]

has super-classes

[General adjectival modifier](#)<sup>c</sup>

### **Destructive procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1014088>

has super-classes

[Surgical procedure](#)<sup>c</sup>

has sub-classes

[Conformal radiotherapy](#)<sup>c</sup>, [Intensity modulated radiation therapy](#)<sup>c</sup>

### **device<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000104>

has super-classes

[Physical object](#)<sup>c</sup>

has sub-classes

[Clinical equipment and/or device](#)<sup>c</sup>

### **Diagnosis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000002>

The determination of the nature of a disease or condition, or the distinguishing of one disease or condition from another. Assessment may be made through physical examination, laboratory tests, or the likes. Computerized programs may be used to enhance the decision-making process. [MeSH]

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Adenocarcinoma, NOS, of prostate gland](#)<sup>c</sup>, [Adenomas and adenocarcinomas](#)<sup>c</sup>, [Carcinoma in situ](#)<sup>c</sup>, [Carcinoma of genital organ](#)<sup>c</sup>, [Cystic, mucinous and serous neoplasms](#)<sup>c</sup>, [Ductal and lobular neoplasms](#)<sup>c</sup>, [Embryonal neuroepithelial tumor](#)<sup>c</sup>, [Malignant adenomatous neoplasm](#)<sup>c</sup>, [Malignant adenomatous neoplasm - category](#)<sup>c</sup>, [Malignant epithelial neoplasm](#)<sup>c</sup>, [Malignant glioma](#)<sup>c</sup>, [Malignant neoplasm of abdomen](#)<sup>c</sup>, [Malignant neoplasm of anorectum](#)<sup>c</sup>, [Malignant neoplasm of genital structure](#)<sup>c</sup>, [Malignant neoplasm of genitourinary organ](#)<sup>c</sup>, [Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>, [Malignant neoplasm of lower respiratory tract](#)<sup>c</sup>, [Malignant neoplasm of thorax](#)<sup>c</sup>, [Malignant neoplasms of digestive organs](#)<sup>c</sup>, [Malignant neoplastic disease](#)<sup>c</sup>, [Malignant neuroendocrine neoplasm, neural](#)<sup>c</sup>, [Malignant tumor of intestine](#)<sup>c</sup>, [Malignant tumor of male genital organ](#)<sup>c</sup>, [Malignant tumor of pelvis](#)<sup>c</sup>, [Malignant tumor of upper limb](#)<sup>c</sup>, [Metastasis to digestive organs](#)<sup>c</sup>, [Neoplasm of breast](#)<sup>c</sup>, [Neoplasm of colon](#)<sup>c</sup>, [Neoplasm of large intestine](#)<sup>c</sup>, [Neoplasm of liver](#)<sup>c</sup>, [Neoplasm of lung](#)<sup>c</sup>, [Neoplasm of prostate](#)<sup>c</sup>, [Neoplasm of rectum](#)<sup>c</sup>, [Neuroendocrine tumor](#)<sup>c</sup>, [Primary malignant neoplasm](#)<sup>c</sup>, [Primary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>, [Primary malignant neoplasm of trunk](#)<sup>c</sup>, [Secondary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>, [Squamous cell carcinoma, NOS, of prostate gland](#)<sup>c</sup>

## **Diagnostic ultrasonography procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016595>

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>

## **Diagnostic/Screening Processes or Results<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018455>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[High risk of recurrence, prostate cancer](#)<sup>c</sup>, [Intermediate risk of recurrence, prostate cancer](#)<sup>c</sup>, [Low risk of recurrence, prostate cancer](#)<sup>c</sup>, [Prostate cancer risk of recurrence not determined or neither low, intermediate nor high](#)<sup>c</sup>

## **Diffuse intrinsic pontine glioma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000062>

A glioma that grows diffusely in the pons. It usually affects children and has a poor prognosis. [NCIT]

has super-classes

[Malignant glioma](#)<sup>c</sup>

## **Digestive organ structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001977>

has super-classes

[Body organ structure](#)<sup>c</sup>, [Body part](#)<sup>c</sup>

has sub-classes

[Liver and/or biliary structure](#)<sup>c</sup>, [Pancreas](#)<sup>c</sup>

## **Digital examination<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018533>

has super-classes

[Examination by method](#)<sup>c</sup>

has sub-classes

[Digital examination of rectum](#)<sup>c</sup>

## **Digital examination of rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028950>

has super-classes

[Digital examination](#)<sup>c</sup>, [Palpation of abdomen](#)<sup>c</sup>, [Rectal examination](#)<sup>c</sup>

## **Digital mammography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000032>

has super-classes

[Mammography](#)<sup>c</sup>

## **Digital Radiography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000028>

Acquisition or display of radiographic images using digital techniques. [NCIT]

has super-classes

[Projection radiography](#)<sup>c</sup>

## **Disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002855>

has super-classes



[Clinical finding](#)<sup>c</sup>

has sub-classes

[Abscess](#)<sup>c</sup>, [Autoimmune disease](#)<sup>c</sup>, [Chronic disease](#)<sup>c</sup>, [Degenerative disorder](#)<sup>c</sup>, [Disorder due to infection](#)<sup>c</sup>, [Disorder of body cavity](#)<sup>c</sup>, [Disorder of breast](#)<sup>c</sup>, [Disorder of digestive organ](#)<sup>c</sup>, [Disorder of digestive system](#)<sup>c</sup>, [Disorder of trunk](#)<sup>c</sup>, [Drug-related disorder](#)<sup>c</sup>, [Inflammation of specific body organs](#)<sup>c</sup>, [Liver disorder due to infection](#)<sup>c</sup>, [Neoplasm and/or hamartoma](#)<sup>c</sup>

### **Disease caused by parasite<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036310>

has super-classes

[Disorder due to infection](#)<sup>c</sup>

has sub-classes

[Disease due to Taeniidae](#)<sup>c</sup>, [Infection of liver caused by parasite](#)<sup>c</sup>

### **Disease due to Taeniidae<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036317>

has super-classes

[Disease caused by parasite](#)<sup>c</sup>

has sub-classes

[Echinococcosis](#)<sup>c</sup>

### **Disease Grade Qualifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001768>

has super-classes

[Disease morphology qualifier](#)<sup>c</sup>

has sub-classes

[Tumor Regression Score 0](#)<sup>c</sup>, [Tumor Regression Score 1](#)<sup>c</sup>, [Tumor Regression Score 2](#)<sup>c</sup>, [Tumor Regression Score 3](#)<sup>c</sup>

### **Disease morphology qualifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000029>

has super-classes

[Disease qualifier](#)<sup>c</sup>

has sub-classes

[Benign](#)<sup>c</sup>, [Disease Grade Qualifier](#)<sup>c</sup>, [Invasive](#)<sup>c</sup>, [Malignant](#)<sup>c</sup>

### **Disease of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036385>

has super-classes

[Disorder of abdomen](#)<sup>c</sup>, [Disorder of digestive organ](#)<sup>c</sup>, [Liver finding](#)<sup>c</sup>

has sub-classes

[Abscess of liver](#)<sup>c</sup>, [Autoimmune liver disease](#)<sup>c</sup>, [Chronic liver disease](#)<sup>c</sup>, [Cyst of liver](#)<sup>c</sup>, [Drug-induced disorder of liver](#)<sup>c</sup>, [Focal nodular hyperplasia of liver](#)<sup>c</sup>, [Hepatic fibrosis](#)<sup>c</sup>, [Inflammatory disease of liver](#)<sup>c</sup>, [Lesion of liver](#)<sup>c</sup>, [Liver damage](#)<sup>c</sup>, [Liver regeneration](#)<sup>c</sup>, [steatosis of liver](#)<sup>c</sup>

### **Disease qualifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000026>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Disease morphology qualifier](#)<sup>c</sup>

### **Disorder caused by alcohol<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036460>

has super-classes

[Drug-related disorder](#)<sup>c</sup>

has sub-classes

[Alcoholic liver damage](#)<sup>c</sup>

### **Disorder due to infection<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036308>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Disease caused by parasite](#)<sup>c</sup>

### **Disorder of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002712>

has super-classes

[Finding of abdomen](#)<sup>c</sup>

has sub-classes

[Abdominal abscess](#)<sup>c</sup>, [Cholangitis](#)<sup>c</sup>, [Cyst of abdomen](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>, [Disorder of prostate](#)<sup>c</sup>, [Injury of abdomen](#)<sup>c</sup>, [Intra-abdominal collection](#)<sup>c</sup>

### **Disorder of abdominopelvic segment of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003002>

has super-classes

[Disorder of trunk](#)<sup>c</sup>

has sub-classes

[Disorder of pelvic region of trunk](#)<sup>c</sup>

## **Disorder of body cavity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036973>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Intraabdominal bile collection](#)<sup>c</sup>

## **Disorder of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037532>

has super-classes

[Breast finding](#)<sup>c</sup>, [Disease](#)<sup>c</sup>, [Disorder of thorax](#)<sup>c</sup>

has sub-classes

[Injury of breast](#)<sup>c</sup>

## **Disorder of digestive organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038585>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Disease of liver](#)<sup>c</sup>

## **Disorder of digestive system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036685>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Chronic digestive system disorder](#)<sup>c</sup>, [Gastrointestinal and digestive injury](#)<sup>c</sup>

## **Disorder of male genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003230>

has super-classes

[Disorder of male reproductive system](#)<sup>c</sup>

has sub-classes

[Disorder of prostate](#)<sup>c</sup>, [Neoplasm of male genital organ](#)<sup>c</sup>

## **Disorder of male reproductive system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003153>

has super-classes

[Disorder of pelvic region of trunk](#)<sup>c</sup>

has sub-classes

[Disorder of male genital organ](#)<sup>c</sup>

### **Disorder of pelvic region of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003077>

has super-classes

[Disorder of abdominopelvic segment of trunk](#)<sup>c</sup>

has sub-classes

[Disorder of male reproductive system](#)<sup>c</sup>, [Disorder of pelvis](#)<sup>c</sup>

### **Disorder of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003387>

has super-classes

[Disorder of pelvic region of trunk](#)<sup>c</sup>

has sub-classes

[Disorder of prostate](#)<sup>c</sup>, [Neoplasm of pelvis](#)<sup>c</sup>

### **Disorder of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002783>

has super-classes

[Disorder of abdomen](#)<sup>c</sup>, [Disorder of male genital organ](#)<sup>c</sup>, [Disorder of pelvis](#)<sup>c</sup>, [Prostate finding](#)<sup>c</sup>

has sub-classes

[Hyperplasia of prostate](#)<sup>c</sup>, [Lesion of prostate](#)<sup>c</sup>, [Neoplasm of prostate](#)<sup>c</sup>

### **Disorder of thoracic segment of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037168>

has super-classes

[Finding of upper trunk](#)<sup>c</sup>

has sub-classes

[Disorder of thorax](#)<sup>c</sup>

### **Disorder of thorax<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037210>

has super-classes

[Disorder of thoracic segment of trunk](#)<sup>c</sup>, [Finding of region of thorax](#)<sup>c</sup>

has sub-classes

[Chest injury](#)<sup>c</sup>, [Disorder of breast](#)<sup>c</sup>

### **Disorder of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002928>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Disorder of abdominopelvic segment of trunk](#)<sup>c</sup>

### **Distant Metastasis (NOS)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031222>

has super-classes

[Metastasis](#)<sup>c</sup>

### **Docetaxel<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035856>

A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, *Taxus baccata*. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

### **Docetaxel Injection<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033193>

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Domain-OMOP<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000037>

has super-classes

[Correspondence Module](#)<sup>c</sup>

has sub-classes

[Domain: Drug](#)<sup>c</sup>, [Domain: Meas Value](#)<sup>c</sup>, [Domain: Measurement](#)<sup>c</sup>, [Domain: Observation](#)<sup>c</sup>, [Domain: Observation](#)<sup>c</sup>, [Domain: Procedure](#)<sup>c</sup>, [Domain: Spec Anatomic Site](#)<sup>c</sup>

**Domain: Drug<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000100>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

**Domain: Meas Value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000058>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

**Domain: Measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000050>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

**Domain: Observation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000043>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

**Domain: Observation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000067>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

**Domain: Procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000088>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

**Domain: Spec Anatomic Site<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000077>

has super-classes

[Domain-OMOP<sup>c</sup>](#)

## **Doxorubicin<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035838>

An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium *Streptomyces peucetius* var. *caesius*, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects. [NCIT]

has super-classes

[Antineoplastic agent<sup>c</sup>](#)

## **Doxorubicin liposomal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035845>

has super-classes

[Drug or medicament<sup>c</sup>](#)

## **Drug measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008873>

has super-classes

[Measurement of substance<sup>c</sup>](#)

has sub-classes

[Measurement of level of drug in blood<sup>c</sup>](#)

## **Drug or medicament<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034110>

has super-classes

[Medication<sup>c</sup>](#)

has sub-classes

[ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS<sup>c</sup>](#), [Abemaciclib<sup>c</sup>](#), [Alkylating agent<sup>c</sup>](#), [Antineoplastic Agents<sup>c</sup>](#), [Antineoplastic agent<sup>c</sup>](#), [Carbamazepine Injection<sup>c</sup>](#), [Docetaxel Injection<sup>c</sup>](#), [Doxorubicin liposomal<sup>c</sup>](#), [FOLFIRI<sup>c</sup>](#), [FOLFIRINOX<sup>c</sup>](#), [FOLFOX<sup>c</sup>](#), [Immunologic agent<sup>c</sup>](#), [Immunotherapeutic agent<sup>c</sup>](#), [Palbociclib<sup>c</sup>](#), [Sacituzumab govitecan<sup>c</sup>](#), [TDM1<sup>c</sup>](#), [Tamoxifen<sup>c</sup>](#), [Trastuzumab deruxtecan<sup>c</sup>](#)

## **Drug therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1014762>

has super-classes

[Therapeutic procedure](#)<sup>c</sup>

has sub-classes

[Chemoradiotherapy](#)<sup>c</sup>, [Chemotherapy](#)<sup>c</sup>, [Chemotherapy Regimen](#)<sup>c</sup>, [Hormone therapy](#)<sup>c</sup>

### **Drug-induced disorder of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036803>

has super-classes

[Disease of liver](#)<sup>c</sup>, [Drug-related disorder](#)<sup>c</sup>

has sub-classes

[Alcoholic liver damage](#)<sup>c</sup>

### **Drug-induced lesion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037010>

has super-classes

[Drug-related disorder](#)<sup>c</sup>

has sub-classes

[Alcoholic liver damage](#)<sup>c</sup>

### **Drug-related disorder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036443>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Disorder caused by alcohol](#)<sup>c</sup>, [Drug-induced disorder of liver](#)<sup>c</sup>, [Drug-induced lesion](#)<sup>c</sup>

### **DUCT CARCINOMA/ Invasive carcinoma of no special type<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047035>

has super-classes

[Ductal and lobular neoplasms](#)<sup>c</sup>

### **Ductal and lobular neoplasms<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046985>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[DUCT CARCINOMA/ Invasive carcinoma of no special type](#)<sup>c</sup>

### **Durvalumab<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036186>

A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

## **Dysplasia<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016582>

has super-classes

[Growth alteration](#)<sup>c</sup>, [Lesion](#)<sup>c</sup>

has sub-classes

[Dysplastic nodule](#)<sup>c</sup>

## **Dysplastic nodule<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016592>

has super-classes

[Dysplasia](#)<sup>c</sup>, [Nodule](#)<sup>c</sup>

## **Ear<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000131>

A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance. [NCIT]

has super-classes

[Auricular region structure](#)<sup>c</sup>, [Ear, nose and throat structure](#)<sup>c</sup>, [Structure of peripheral auditory system](#)<sup>c</sup>

## **Ear, nose and throat structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000542>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Ear](#)<sup>c</sup>

## **Echinococcosis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036322>

has super-classes

[Disease due to Taeniidae](#)<sup>c</sup>

has sub-classes

[Echinococcosis of liver](#)<sup>c</sup>

**Echinococcosis of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045766>

has super-classes

[Echinococcosis](#)<sup>c</sup>, [Infection of liver caused by parasite](#)<sup>c</sup>

**ECOG performance status - grade 0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024768>

has super-classes

[ECOG performance status finding](#)<sup>c</sup>

**ECOG performance status - grade 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024850>

has super-classes

[ECOG performance status finding](#)<sup>c</sup>

**ECOG performance status - grade 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024933>

has super-classes

[ECOG performance status finding](#)<sup>c</sup>

**ECOG performance status - grade 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025017>

has super-classes

[ECOG performance status finding](#)<sup>c</sup>

**ECOG performance status - grade 4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025102>

has super-classes

[ECOG performance status finding](#)<sup>c</sup>

## **ECOG performance status - grade 5<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025188>

has super-classes

[ECOG performance status finding](#)<sup>c</sup>

## **ECOG performance status finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015980>

has super-classes

[General clinical state finding](#)<sup>c</sup>

has sub-classes

[ECOG performance status - grade 0](#)<sup>c</sup>, [ECOG performance status - grade 1](#)<sup>c</sup>, [ECOG performance status - grade 2](#)<sup>c</sup>, [ECOG performance status - grade 3](#)<sup>c</sup>, [ECOG performance status - grade 4](#)<sup>c</sup>, [ECOG performance status - grade 5](#)<sup>c</sup>

## **Edition of American Joint Commission on Cancer, Cancer Staging Manual used for TNM staging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045761>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

## **Elscint<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000055>

has super-classes

[Manufacturer](#)<sup>c</sup>

## **Embryonal neuroepithelial tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000113>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Neuroblastoma](#)<sup>c</sup>

## **Endocrine gland structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000276>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Adrenal gland](#)<sup>c</sup>

## **ENDOCRINE THERAPY<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001605>

has super-classes

[ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS](#)<sup>c</sup>

has sub-classes

[HORMONE ANTAGONISTS AND RELATED AGENTS](#)<sup>c</sup>, [HORMONES AND RELATED AGENTS](#)<sup>c</sup>

## **Endoscopic operation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003713>

has super-classes

[Endoscopic procedure](#)<sup>c</sup>, [Surgical procedure](#)<sup>c</sup>

has sub-classes

[Robotic assisted surgery](#)<sup>c</sup>

## **Endoscopic procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003630>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Endoscopic operation](#)<sup>c</sup>, [Laparoscopic procedure](#)<sup>c</sup>

## **Entire body region<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004410>

has super-classes

[Body part](#)<sup>c</sup>

## **Entire limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000566>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Arm](#)<sup>c</sup>

## **Enzyme level - finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018612>

has super-classes

[Protein level - finding](#)<sup>c</sup>

has sub-classes

[Prostate specific antigen normal](#)<sup>c</sup>

### **Enzyme measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012788>

has super-classes

[Protein measurement](#)<sup>c</sup>

has sub-classes

[Measurement of liver enzyme](#)<sup>c</sup>, [Prostate specific antigen measurement](#)<sup>c</sup>

### **Epirubicin<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035841>

A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

### **ER negative<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048920>

The absence of detectable estrogen receptor alpha in a tissue sample. [NCIT]

has super-classes

[Hormone receptor negative neoplasm](#)<sup>c</sup>

### **ER positive<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046663>

An indication that estrogen receptor alpha expression has been detected in a sample. [NCIT]

has super-classes

[Hormone receptor positive tumor](#)<sup>c</sup>

### **ERBB2 gene duplication [Presence] in Breast cancer specimen by FISH<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045805>

A fluorescent in situ hybridization-based procedure that detects ERBB2 gene duplications in a breast cancer specimen. [NCIT]

has super-classes

[Measurement](#)<sup>c</sup>, [Molecular pathology](#)<sup>c</sup>

### **Eribulin<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035880>

An analogue of halichondrin B, a substance derived from a marine sponge (*Lissodendoryx* sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

### **Esaote<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000049>

has super-classes

[Manufacturer](#)<sup>c</sup>

### **Estrogen receptor Ag [Presence] in Breast cancer specimen by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045815>

An immune staining procedure that detects estrogen receptor in a breast cancer specimen. [NCIT]

has super-classes

[Measurement](#)<sup>c</sup>, [Pathology](#)<sup>c</sup>

### **Evaluation finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002372>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Abnormal finding on evaluation procedure](#)<sup>c</sup>, [Biopsy finding](#)<sup>c</sup>, [Finding of immune status](#)<sup>c</sup>, [Genetic finding](#)<sup>c</sup>, [Histopathology finding](#)<sup>c</sup>, [Imaging finding](#)<sup>c</sup>, [Measurement finding](#)<sup>c</sup>, [Microscopic specimen observation](#)<sup>c</sup>

### **Evaluation of gastrointestinal tract<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004143>

has super-classes

[Evaluation procedure](#)<sup>c</sup>

## **Evaluation procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004055>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Evaluation of gastrointestinal tract](#)<sup>c</sup>, [Examination by method](#)<sup>c</sup>, [Laboratory test](#)<sup>c</sup>, [Measurement](#)<sup>c</sup>,  
[Monitoring of patient](#)<sup>c</sup>

## **Examination by method<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004232>

has super-classes

[Evaluation procedure](#)<sup>c</sup>

has sub-classes

[Digital examination](#)<sup>c</sup>, [Palpation](#)<sup>c</sup>

## **Examination of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010667>

has super-classes

[Procedure on abdomen](#)<sup>c</sup>

has sub-classes

[Palpation of abdomen](#)<sup>c</sup>, [Rectal examination](#)<sup>c</sup>

## **Excision<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004598>

has super-classes

[Surgical removal](#)<sup>c</sup>

has sub-classes

[Complete excision](#)<sup>c</sup>, [Trunk excision](#)<sup>c</sup>

## **Excision of abdominal lymph node<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004883>

has super-classes

[Abdomen excision](#)<sup>c</sup>

has sub-classes

[Excision of pelvic lymph node](#)<sup>c</sup>

## **Excision of pelvic lymph node<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004980>

has super-classes

[Excision of abdominal lymph node<sup>c</sup>](#), [Excision of pelvis<sup>c</sup>](#)

has sub-classes

[Block dissection of pelvic lymph nodes<sup>c</sup>](#)

## **Excision of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005078>

has super-classes

[Operative procedure on pelvis<sup>c</sup>](#), [Trunk excision<sup>c</sup>](#)

has sub-classes

[Excision of pelvic lymph node<sup>c</sup>](#), [Prostatectomy<sup>c</sup>](#)

## **Exemestane<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036066>

An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation. [NCIT]

has super-classes

[Antineoplastic agent<sup>c</sup>](#)

## **External beam radiation therapy procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005277>

has super-classes

[Procedure<sup>c</sup>](#)

has sub-classes

[Stereotactic radiotherapy<sup>c</sup>](#)

## **Extramural vein invasion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041767>

has super-classes

[Pathology<sup>c</sup>](#)

has sub-classes

[Extramural vein invasion](#) | [Colorectal cancer specimen](#) | [Pathology<sup>c</sup>](#)



## **Extramural vein invasion [Presence] in Colorectal cancer specimen by Light microscopy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045796>

has super-classes

[Extramural vein invasion](#) | [Colorectal cancer specimen](#) | [Pathology](#)<sup>c</sup>, [Pathology](#)<sup>c</sup>

## **Extramural vein invasion | Colorectal cancer specimen | Pathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041872>

has super-classes

[Extramural vein invasion](#)<sup>c</sup>

has sub-classes

[Extramural vein invasion \[Presence\] in Colorectal cancer specimen by Light microscopy](#)<sup>c</sup>

## **Extraprostatic Extension (EPE)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033248>

has super-classes

[NotClassified](#)<sup>c</sup>

## **Extremity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000104>

A body region referring to an upper or lower extremity. [NCIT]

has super-classes

[Body part structure](#)<sup>c</sup>, [Structure of half of body lateral to midsagittal plane](#)<sup>c</sup>

has sub-classes

[Arm](#)<sup>c</sup>, [Extremity part](#)<sup>c</sup>, [Structure of long bone of lower limb](#)<sup>c</sup>

## **Extremity part<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004467>

has super-classes

[Extremity](#)<sup>c</sup>

has sub-classes

[Lymph node structure of limb](#)<sup>c</sup>

## **Eye region structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004435>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Structure of orbital region](#)<sup>c</sup>

## **Face and/or neck structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001592>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Neck](#)<sup>c</sup>

## **Family history of cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048388>

["A record of a patient's medical background regarding the cancer and cancer-related problems of blood relatives."]

has super-classes

[Family history of neoplasm](#)<sup>c</sup>

## **Family history of clinical finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029073>

has super-classes

[Family history with explicit context](#)<sup>c</sup>, [Finding suspected or known present](#)<sup>c</sup>, [Finding with explicit context](#)<sup>c</sup>

has sub-classes

[Family history of disorder](#)<sup>c</sup>

## **Family history of disorder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037960>

has super-classes

[Family history of clinical finding](#)<sup>c</sup>

has sub-classes

[Family history of neoplasm](#)<sup>c</sup>

## **Family history of neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038018>

has super-classes

[Family history of disorder](#)<sup>c</sup>

has sub-classes

[Family history of cancer](#)<sup>c</sup>

### **Family history unknown<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029197>

has super-classes

[Family history with explicit context](#)<sup>c</sup>, [Finding with explicit context](#)<sup>c</sup>

### **Family history with explicit context<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018692>

has super-classes

[Situation with explicit context](#)<sup>c</sup>

has sub-classes

[Family history of clinical finding](#)<sup>c</sup>, [Family history unknown](#)<sup>c</sup>, [No family history of clinical finding](#)<sup>c</sup>

### **Feet first orientation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016709>

has super-classes

[Patient Orientation](#)<sup>c</sup>

### **FEMALE<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000177>

is equivalent to

[Female \(finding\)](#)<sup>c</sup>

has super-classes

[Gender](#)<sup>c</sup>

### **Female (finding)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001370>

has super-classes

[Finding related to biological sex](#)<sup>c</sup>

### **Female genital tract functions<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043933>

has super-classes

[Sexual function](#)<sup>c</sup>

has sub-classes

[Menopause, function](#)<sup>c</sup>

## **Female genital tract structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004122>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Uterus](#)<sup>c</sup>

## **Female genitalia finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039388>

has super-classes

[Finding of pelvic region of trunk](#)<sup>c</sup>, [Genital finding](#)<sup>c</sup>

has sub-classes

[Premenopause - Menopause absent](#)<sup>c</sup>

## **Fibrolamellar hepatocellular carcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043567>

A distinctive type of liver cell carcinoma that arises in non-cirrhotic livers and is seen predominantly in young patients. The tumor cells are polygonal and deeply eosinophilic, and are embedded in a fibrous stroma. The prognosis is similar to classical hepatocellular carcinoma that arises in non-cirrhotic livers, and better than hepatocellular carcinoma that arises in cirrhotic livers. [NCIT]

has super-classes

[Liver cell carcinoma](#)<sup>c</sup>

## **Finding context value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001066>

has super-classes

[Context values](#)<sup>c</sup>

has sub-classes

[Unknown](#)<sup>c</sup>

## **Finding of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000272>

has super-classes

[Finding of abdominopelvic segment of trunk](#)<sup>c</sup>

has sub-classes

[Abdominal mass](#)<sup>c</sup>, [Abdominal organ finding](#)<sup>c</sup>, [Disorder of abdomen](#)<sup>c</sup>, [Prostate finding](#)<sup>c</sup>

## **Finding of abdominopelvic segment of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000263>

has super-classes

[Finding of trunk structure](#)<sup>c</sup>

has sub-classes

[Finding of abdomen](#)<sup>c</sup>, [Urogenital finding](#)<sup>c</sup>

## **Finding of bowel continence<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018773>

has super-classes

[Finding of defecation](#)<sup>c</sup>

has sub-classes

[Bowels: fully continent](#)<sup>c</sup>, [Incontinence of feces](#)<sup>c</sup>

## **Finding of change compared to previous radiologic examination<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016335>

has super-classes

[Radiologic finding](#)<sup>c</sup>

## **Finding of change compared to previous radiologic examination finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016597>

has super-classes

[Radiologic finding](#)<sup>c</sup>

## **Finding of defecation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006222>

has super-classes

[Functional finding of gastrointestinal tract](#)<sup>c</sup>

has sub-classes

[Finding of bowel continence](#)<sup>c</sup>

## **Finding of Hepatitis B status<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048038>

has super-classes

[Finding of immune status](#)<sup>c</sup>

## **Finding of Hepatitis C status<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049081>

has super-classes

[Measurement finding<sup>c</sup>](#)

## **Finding of immune status<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038863>

has super-classes

[Evaluation finding<sup>c</sup>](#)

has sub-classes

[Finding of Hepatitis B status<sup>c</sup>](#)

## **Finding of large intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018855>

has super-classes

[Bowel finding<sup>c</sup>](#)

has sub-classes

[Bowels: fully continent<sup>c</sup>](#)

## **Finding of lesion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002438>

has super-classes

[Clinical finding<sup>c</sup>](#)

has sub-classes

[Tumor finding<sup>c</sup>](#)

## **Finding of pelvic region of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005583>

has super-classes

[Clinical finding<sup>c</sup>](#)

has sub-classes

[Female genitalia finding<sup>c</sup>](#), [Finding of pelvis<sup>c</sup>](#), [Incontinence<sup>c</sup>](#)

## **Finding of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005687>

has super-classes

[Finding of pelvic region of trunk<sup>c</sup>](#)

has sub-classes

[Pelvic organ finding](#)<sup>c</sup>

## **Finding of region of thorax<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037087>

has super-classes

[Finding of upper trunk](#)<sup>c</sup>

has sub-classes

[Breast finding](#)<sup>c</sup>, [Disorder of thorax](#)<sup>c</sup>

## **Finding of sexual function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1018938>

has super-classes

[Functional finding](#)<sup>c</sup>

has sub-classes

[Abnormal sexual function](#)<sup>c</sup>, [Normal sexual function](#)<sup>c</sup>

## **Finding of substance level<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005792>

has super-classes

[Measurement finding](#)<sup>c</sup>

has sub-classes

[Protein level - finding](#)<sup>c</sup>

## **Finding of trunk structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000255>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Finding of abdominopelvic segment of trunk](#)<sup>c</sup>, [Finding of upper trunk](#)<sup>c</sup>

## **Finding of upper trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037048>

has super-classes

[Finding of trunk structure](#)<sup>c</sup>

has sub-classes

[Disorder of thoracic segment of trunk](#)<sup>c</sup>, [Finding of region of thorax](#)<sup>c</sup>

## **Finding of urinary tract proper<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006005>

has super-classes

[Clinical finding](#)<sup>c</sup>

**Finding related to biological sex<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038792>

has super-classes

[General clinical state finding](#)<sup>c</sup>

has sub-classes

[Female \(finding\)](#)<sup>c</sup>, [Male \(finding\)](#)<sup>c</sup>

**Finding suspected or known present<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016013>

has super-classes

[Finding with explicit context](#)<sup>c</sup>

has sub-classes

[Family history of clinical finding](#)<sup>c</sup>, [History of clinical finding in subject](#)<sup>c</sup>

**Finding value<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000181>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Absence findings](#)<sup>c</sup>, [American Joint Committee on Cancer allowable value](#)<sup>c</sup>, [Presence findings](#)<sup>c</sup>

**Finding with explicit context<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1013593>

has super-classes

[Situation with explicit context](#)<sup>c</sup>

has sub-classes

[Family history of clinical finding](#)<sup>c</sup>, [Family history unknown](#)<sup>c</sup>, [Finding suspected or known present](#)<sup>c</sup>,  
[History of clinical finding in subject](#)<sup>c</sup>, [No family history of clinical finding](#)<sup>c</sup>

**First degree<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001361>

has super-classes

[Degrees of severity](#)<sup>c</sup>



## **Flowsheet - laboratory<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038323>

has super-classes

[Measurement](#)<sup>c</sup>

has sub-classes

[Cancer Ag 15-3|Arbitrary Concentration|Moment in time|Blood, Serum or Plasma](#)<sup>c</sup>, [Carcinoembryonic Ag|Mass Concentration|Moment in time|Blood, Serum or Plasma](#)<sup>c</sup>

## **Fluorouracil<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035901>

An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluorouracil is converted to the active metabolite 5-fluorouridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

## **focal damage<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016594>

has super-classes

[Damage](#)<sup>c</sup>

## **Focal nodular hyperplasia of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047651>

A non-neoplastic, regenerating hepatocellular hyperplasia, secondary to the presence of focal vascular abnormalities in the liver. [NCIT]

has super-classes

[Disease of liver](#)<sup>c</sup>

## **FOLFIRI<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036303>

A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus ziv-aflibercept that is used for the treatment of appendiceal adenocarcinoma and colorectal cancer. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **FOLFIRINOX<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036306>

A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, ampullary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **FOLFOX<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036301>

One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Follow-up<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001952>

has super-classes

[Timepoint](#)<sup>c</sup>

### **Follow-up status<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035758>

has super-classes

[Administrative statuses](#)<sup>c</sup>

### **Foot<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000112>

The structure found below the ankle joint. [NCIT]

has super-classes

[Structure of ankle and/or foot](#)<sup>c</sup>

## **Free prostate specific antigen level<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022987>

has super-classes

[Prostate specific antigen measurement](#)<sup>c</sup>

## **Free:total PSA ratio<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023043>

has super-classes

[Prostate specific antigen measurement](#)<sup>c</sup>

## **Frequencies<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001338>

has super-classes

[Time patterns](#)<sup>c</sup>

has sub-classes

[Regular frequency](#)<sup>c</sup>

## **Frequency interval<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001347>

has super-classes

[Regular frequency](#)<sup>c</sup>

has sub-classes

[Intervals of weeks and months](#)<sup>c</sup>

## **Fujifilm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000060>

has super-classes

[Manufacturer](#)<sup>c</sup>

## **Function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043688>

has super-classes

[Observable entity](#)<sup>c</sup>

has sub-classes

[Sexual function](#)<sup>c</sup>

## **Functional finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002505>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Bladder control - finding](#)<sup>c</sup>, [Finding of sexual function](#)<sup>c</sup>, [Functional finding of gastrointestinal tract](#)<sup>c</sup>,  
[Impaired urinary system function](#)<sup>c</sup>

**Functional finding of gastrointestinal tract<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006113>

has super-classes

[Functional finding](#)<sup>c</sup>

has sub-classes

[Finding of defecation](#)<sup>c</sup>

**G1 - American Joint Committee on Cancer grade G1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001750>

has super-classes

[American Joint Committee on Cancer clinical grade allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological grade allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer yp grade allowable value](#)<sup>c</sup>

**G2 - American Joint Committee on Cancer grade G2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001755>

has super-classes

[American Joint Committee on Cancer clinical grade allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological grade allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer yp grade allowable value](#)<sup>c</sup>

**G3 - American Joint Committee on Cancer grade G3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001761>

has super-classes

[American Joint Committee on Cancer clinical grade allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological grade allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer yp grade allowable value](#)<sup>c</sup>

**Gallbladder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000133>

A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods. [NCIT]

has super-classes

[Biliary tract structure](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>

## **Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033810>

has super-classes

[Laboratory test](#)<sup>c</sup>

## **Gastrointestinal and digestive injury<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036713>

has super-classes

[Disorder of digestive system](#)<sup>c</sup>

has sub-classes

[Liver damage](#)<sup>c</sup>

## **Gastrointestinal tract finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006332>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Bowel finding](#)<sup>c</sup>

## **Gemcitabine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035926>

A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in "masked termination" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

## **Gender<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000175>

has super-classes

[Common Module](#)<sup>c</sup>

has sub-classes

[FEMALE](#)<sup>c</sup>, [MALE](#)<sup>c</sup>

### **Gene mutation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042523>

has super-classes

[Molecular pathology](#)<sup>c</sup>

has sub-classes

[BRCA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal](#)<sup>c</sup>,  
[BRCA1+BRCA2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal](#)<sup>c</sup>

### **General adjectival modifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000033>

has super-classes

[Adjectival modifier](#)<sup>c</sup>

has sub-classes

[Benign](#)<sup>c</sup>, [Binary](#)<sup>c</sup>, [Derived](#)<sup>c</sup>, [Indeterminate](#)<sup>c</sup>, [Malignant](#)<sup>c</sup>, [Positive](#)<sup>c</sup>, [Primary](#)<sup>c</sup>

### **General body state finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045487>

has super-classes

[General finding of observation of patient](#)<sup>c</sup>

has sub-classes

[Surviving free of recurrence of neoplastic disease](#)<sup>c</sup>

### **General clinical state finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002573>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Alive](#)<sup>c</sup>, [Dead](#)<sup>c</sup>, [ECOG performance status finding](#)<sup>c</sup>, [Finding related to biological sex](#)<sup>c</sup>

### **General Electric<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000047>

has super-classes

[Manufacturer](#)<sup>c</sup>

### **General finding of observation of patient<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045218>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[General body state finding](#)<sup>c</sup>, [General problem AND/OR complaint](#)<sup>c</sup>

### **General problem AND/OR complaint<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045352>

has super-classes

[General finding of observation of patient](#)<sup>c</sup>

has sub-classes

[Co-morbid conditions](#)<sup>c</sup>

### **Generic tumor staging descriptor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044435>

has super-classes

[Cancer staging](#)<sup>c</sup>, [Malignant tumor staging](#)<sup>c</sup>

has sub-classes

[TNM tumor staging classifications](#)<sup>c</sup>, [Tumor histopathological grade status values](#)<sup>c</sup>

### **Genetic finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034515>

has super-classes

[Evaluation finding](#)<sup>c</sup>

has sub-classes

[Genetic finding detected](#)<sup>c</sup>, [Genetic finding not detected](#)<sup>c</sup>

### **Genetic finding detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034544>

has super-classes

[Genetic finding](#)<sup>c</sup>

has sub-classes

[Breast cancer genetic marker of susceptibility detected](#)<sup>c</sup>

### **Genetic finding not detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034605>

has super-classes

[Genetic finding](#)<sup>c</sup>

has sub-classes

[Breast cancer genetic marker of susceptibility not detected](#)<sup>c</sup>

### **Genetic test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034460>

has super-classes

[Laboratory test](#)<sup>c</sup>

has sub-classes

[Molecular genetic test](#)<sup>c</sup>

### **Genital finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041357>

has super-classes

[Urogenital finding](#)<sup>c</sup>

has sub-classes

[Female genitalia finding](#)<sup>c</sup>

### **Genitourinary sample<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006443>

has super-classes

[Specimen](#)<sup>c</sup>

has sub-classes

[Specimen from genital system](#)<sup>c</sup>

### **Glandular zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004456>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Central zone of prostate](#)<sup>c</sup>, [Peripheral zone of prostate](#)<sup>c</sup>

### **Gleason finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022077>

has super-classes

[Cancer Grade](#)<sup>c</sup>, [Tumor finding](#)<sup>c</sup>



has sub-classes

[Gleason Primary Pattern Grade 1](#)<sup>c</sup>, [Gleason Primary Pattern Grade 2](#)<sup>c</sup>, [Gleason Primary Pattern Grade 3](#)<sup>c</sup>, [Gleason Primary Pattern Grade 4](#)<sup>c</sup>, [Gleason Primary Pattern Grade 5](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 1](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 2](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 3](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 4](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 5](#)<sup>c</sup>, [Primary Gleason Pattern 1](#)<sup>c</sup>, [Primary Gleason Pattern 2](#)<sup>c</sup>, [Primary Gleason Pattern 3](#)<sup>c</sup>, [Primary Gleason Pattern 4](#)<sup>c</sup>, [Primary Gleason Pattern 5](#)<sup>c</sup>, [Secondary Gleason Pattern 1](#)<sup>c</sup>, [Secondary Gleason Pattern 2](#)<sup>c</sup>, [Secondary Gleason Pattern 3](#)<sup>c</sup>, [Secondary Gleason Pattern 4](#)<sup>c</sup>, [Secondary Gleason Pattern 5](#)<sup>c</sup>

## **Gleason grade finding for prostatic cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016047>

has super-classes

[Cancer Grade](#)<sup>c</sup>, [Tumor finding](#)<sup>c</sup>

has sub-classes

[Gleason grade group 1](#)<sup>c</sup>, [Gleason grade group 2](#)<sup>c</sup>, [Gleason grade group 3](#)<sup>c</sup>, [Gleason grade group 4](#)<sup>c</sup>, [Gleason grade group 5](#)<sup>c</sup>, [Gleason grade score 10 out of 10](#)<sup>c</sup>, [Gleason grade score 2 out of 10](#)<sup>c</sup>, [Gleason grade score 3 out of 10](#)<sup>c</sup>, [Gleason grade score 4 out of 10](#)<sup>c</sup>, [Gleason grade score 5 out of 10](#)<sup>c</sup>, [Gleason grade score 6 out of 10](#)<sup>c</sup>, [Gleason grade score 7 out of 10](#)<sup>c</sup>, [Gleason grade score 8 out of 10](#)<sup>c</sup>, [Gleason grade score 9 out of 10](#)<sup>c</sup>

## **Gleason grade group 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025275>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

## **Gleason grade group 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025363>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

## **Gleason grade group 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025452>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

## **Gleason grade group 4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025542>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade group 5<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025633>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 10 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025725>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 2 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025818>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 3 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1025912>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 4 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026007>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 5 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026103>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 6 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026200>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 7 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026298>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 8 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026397>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason grade score 9 out of 10<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026497>

has super-classes

[Gleason grade finding for prostatic cancer](#)<sup>c</sup>

**Gleason Primary Pattern Grade 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022267>

is equivalent to

[Primary Gleason Pattern 1](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 1 tumor](#)<sup>c</sup>

**Gleason Primary Pattern Grade 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022308>

is equivalent to

[Primary Gleason Pattern 2](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 2 tumor](#)<sup>c</sup>

**Gleason Primary Pattern Grade 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022350>

is equivalent to

[Primary Gleason Pattern 3](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 3 tumor](#)<sup>c</sup>

## **Gleason Primary Pattern Grade 4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022393>

is equivalent to

[Primary Gleason Pattern 4](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 4 tumor](#)<sup>c</sup>

## **Gleason Primary Pattern Grade 5<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022528>

is equivalent to

[Primary Gleason Pattern 5](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>

## **Gleason Secondary Pattern Grade 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022575>

is equivalent to

[Secondary Gleason Pattern 1](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 1 tumor](#)<sup>c</sup>

## **Gleason Secondary Pattern Grade 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022623>

is equivalent to

[Secondary Gleason Pattern 2](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 2 tumor](#)<sup>c</sup>

## **Gleason Secondary Pattern Grade 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022672>

is equivalent to

[Secondary Gleason Pattern 3](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 3 tumor](#)<sup>c</sup>

## **Gleason Secondary Pattern Grade 4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022722>

is equivalent to

[Secondary Gleason Pattern 4](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 4 tumor](#)<sup>c</sup>

### **Gleason Secondary Pattern Grade 5<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022773>

is equivalent to

[Secondary Gleason Pattern 5](#)<sup>c</sup>

has super-classes

[Gleason finding](#)<sup>c</sup>

### **Glucose [Mass/volume] in Venous blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033440>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Glycoproteins measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041978>

has super-classes

[Protein measurement](#)<sup>c</sup>

has sub-classes

[Cancer antigen 15-3 measurement](#)<sup>c</sup>

### **Gonadotropin releasing hormone analogues<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021450>

has super-classes

[HORMONES AND RELATED AGENTS](#)<sup>c</sup>

### **Grade 1 tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022113>

has super-classes

[Cancer Grade](#)<sup>c</sup>

has sub-classes

[Gleason Primary Pattern Grade 1](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 1](#)<sup>c</sup>, [Primary Gleason Pattern 1](#)<sup>c</sup>,

[Secondary Gleason Pattern 1](#)<sup>c</sup>

### **Grade 2 tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022150>

has super-classes

[Cancer Grade](#)<sup>c</sup>

has sub-classes

[Gleason Primary Pattern Grade 2](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 2](#)<sup>c</sup>, [Primary Gleason Pattern 2](#)<sup>c</sup>,  
[Secondary Gleason Pattern 2](#)<sup>c</sup>

### **Grade 3 tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022188>

has super-classes

[Cancer Grade](#)<sup>c</sup>

has sub-classes

[Gleason Primary Pattern Grade 3](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 3](#)<sup>c</sup>, [Primary Gleason Pattern 3](#)<sup>c</sup>,  
[Secondary Gleason Pattern 3](#)<sup>c</sup>

### **Grade 4 tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022227>

has super-classes

[Cancer Grade](#)<sup>c</sup>

has sub-classes

[Gleason Primary Pattern Grade 4](#)<sup>c</sup>, [Gleason Secondary Pattern Grade 4](#)<sup>c</sup>, [Primary Gleason Pattern 4](#)<sup>c</sup>,  
[Secondary Gleason Pattern 4](#)<sup>c</sup>

### **Grades<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001353>

has super-classes

[Ranked categories](#)<sup>c</sup>

has sub-classes

[Histological grades](#)<sup>c</sup>

### **Gravida (observable entity)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048535>

has super-classes

[Measure of pregnancy](#)<sup>c</sup>

### **Growth alteration<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016565>

has super-classes

[Morphologically abnormal structure](#) <sup>c</sup>

has sub-classes

[Dysplasia](#) <sup>c</sup>

**GX: Histologic grade cannot be assessed<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047590>

has super-classes

[Histological grades](#) <sup>c</sup>

**Head<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000107>

The anterior and superior part of a human bearing the mouth, the brain and sensory organs. [NCIT]

has super-classes

[Head and neck](#) <sup>c</sup>

**Head and neck<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000105>

For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas. [NCIT]

has super-classes

[Upper body part structure](#) <sup>c</sup>

has sub-classes

[Head](#) <sup>c</sup>

**Head first orientation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016724>

has super-classes

[Patient Orientation](#) <sup>c</sup>

**Heart<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000129>

A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood). [NCIT]

has super-classes

[Heart and/or pericardium structure](#)<sup>c</sup>, [Heart, mediastinum, and pleura](#)<sup>c</sup>, [Structure of thoracic viscus](#)<sup>c</sup>

## **Heart and/or pericardium structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000701>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Heart](#)<sup>c</sup>

## **Heart, mediastinum, and pleura<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000644>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Heart](#)<sup>c</sup>

## **Hemangioma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046540>

A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.  
[NCIT]

has super-classes

[Neoplasm and/or hamartoma](#)<sup>c</sup>

## **Hematocrit [Volume Fraction] of Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033425>

has super-classes

[Laboratory test](#)<sup>c</sup>

## **Hemoglobin [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033419>

has super-classes

[Laboratory test](#)<sup>c</sup>

## **Hemoglobin A1c/Hemoglobin.total in Blood by HPLC<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034034>

has super-classes



[Laboratory test](#)<sup>c</sup>

### **Hepatic cystadenoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037483>

has super-classes

[Adenoma of liver](#)<sup>c</sup>

### **Hepatic fibrosis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036868>

has super-classes

[Disease of liver](#)<sup>c</sup>, [Lesion of liver](#)<sup>c</sup>

has sub-classes

[Cirrhosis of liver](#)<sup>c</sup>

### **HER2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044953>

has super-classes

[Pathology](#)<sup>c</sup>

has sub-classes

[HER2 | Breast cancer specimen | Pathology](#)<sup>c</sup>

### **HER2 [Presence] in Breast cancer specimen by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045851>

An immunoassay procedure that detects receptor tyrosine-protein kinase erbb-2 in a breast cancer specimen. [NCIT]

has super-classes

[HER2 | Breast cancer specimen | Pathology](#)<sup>c</sup>, [Pathology](#)<sup>c</sup>

### **HER2 negative<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048106>

The absence of detectable HER2/Neu in a tissue sample. [NCIT]

has super-classes

[Carcinoma of breast](#)<sup>c</sup>

### **HER2 positive<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046795>

A laboratory test result indicating the presence of HER2/Neu in a tissue sample. [NCIT]

has super-classes

[Carcinoma of breast](#)<sup>c</sup>

**HER2 | Breast cancer specimen | Pathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045085>

has super-classes

[HER2](#)<sup>c</sup>

has sub-classes

[HER2 \[Presence\] in Breast cancer specimen by Immune stain](#)<sup>c</sup>

**High density lipoprotein cholesterol measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033614>

has super-classes

[Cholesterol measurement](#)<sup>c</sup>

has sub-classes

[Cholesterol in HDL \[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>

**High risk of recurrence, prostate cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023158>

has super-classes

[Diagnostic/Screening Processes or Results](#)<sup>c</sup>

**Hip joint<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000095>

A ball-and-socket joint between the head of the femur and the acetabulum. [NCIT]

has super-classes

[Hip region structure](#)<sup>c</sup>, [Joint structure of lower extremity](#)<sup>c</sup>, [Joint structure of pelvic girdle](#)<sup>c</sup>, [Structure of spheroidal joint](#)<sup>c</sup>

**Hip region structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000731>

The body part defined by the hip joint and surrounding structures, including the region from the iliac crest to the thigh

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Hip joint](#)<sup>c</sup>

### **Histologic feature of neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039082>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

has sub-classes

[Histologic type of malignant neoplasm](#)<sup>c</sup>

### **Histologic test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034154>

has super-classes

[Laboratory test](#)<sup>c</sup>

has sub-classes

[Histopathology test](#)<sup>c</sup>

### **Histologic type of malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039157>

has super-classes

[Histologic feature of neoplasm](#)<sup>c</sup>

has sub-classes

[Histologic type of primary malignant neoplasm](#)<sup>c</sup>

### **Histologic type of primary malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046060>

has super-classes

[Histologic type of malignant neoplasm](#)<sup>c</sup>

### **Histological<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000029>

Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues. [NCIT]

has super-classes

[Imaging modality](#)<sup>c</sup>

### **Histological grades<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001360>

has super-classes

[Grades](#)<sup>c</sup>

has sub-classes

[GX: Histologic grade cannot be assessed](#)<sup>c</sup>

## **Histopathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048686>

The microscopic study of characteristic tissue abnormalities by employing various cytochemical and immunocytochemical stains. [NCIT]

has super-classes

[Pathology](#)<sup>c</sup>

## **Histopathology finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006668>

has super-classes

[Evaluation finding](#)<sup>c</sup>

## **Histopathology Result<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000209>

has super-classes

[Pathology Result](#)<sup>c</sup>

has sub-classes

[Morphologic Finding](#)<sup>c</sup>

## **Histopathology test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035076>

has super-classes

[Anatomic pathology procedure](#)<sup>c</sup>, [Histologic test](#)<sup>c</sup>

## **History of clinical finding in subject<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046288>

has super-classes

[Finding suspected or known present](#)<sup>c</sup>, [Finding with explicit context](#)<sup>c</sup>

## **Hitachi<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000057>

has super-classes

[Manufacturer](#)<sup>c</sup>

## **HORMONE ANTAGONISTS AND RELATED AGENTS<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019022>

has super-classes

[ENDOCRINE THERAPY](#)<sup>c</sup>

has sub-classes

[Other hormone antagonists and related agents](#)<sup>c</sup>

## **Hormone measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006782>

has super-classes

[Measurement](#)<sup>c</sup>

has sub-classes

[Androgen level](#)<sup>c</sup>, [Insulin measurement](#)<sup>c</sup>

## **Hormone receptor negative neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044057>

has super-classes

[Neoplastic disease](#)<sup>c</sup>

has sub-classes

[ER negative](#)<sup>c</sup>, [PR negative](#)<sup>c</sup>, [Triple negative malignant neoplasm of breast](#)<sup>c</sup>

## **Hormone receptor positive tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041560>

has super-classes

[Neoplastic disease](#)<sup>c</sup>

has sub-classes

[ER positive](#)<sup>c</sup>, [PR positive](#)<sup>c</sup>

## **Hormone refractory prostate cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023100>

has super-classes

[Cancer of prostate](#)<sup>c</sup>

## **Hormone replacement therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035175>

has super-classes

[Hormone therapy](#)<sup>c</sup>

## **Hormone sensitive prostate cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023217>

has super-classes

[Cancer of prostate](#)<sup>c</sup>

## **Hormone therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016082>

has super-classes

[Administration of hormone \(procedure\)](#)<sup>c</sup>, [Drug therapy](#)<sup>c</sup>

has sub-classes

[Androgen deprivation therapy](#)<sup>c</sup>, [Hormone replacement therapy](#)<sup>c</sup>

## **HORMONES AND RELATED AGENTS<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019107>

has super-classes

[ENDOCRINE THERAPY](#)<sup>c</sup>

has sub-classes

[Gonadotropin releasing hormone analogues](#)<sup>c</sup>

## **Human epidermal growth factor 2 negative carcinoma of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038198>

has super-classes

[Carcinoma of breast](#)<sup>c</sup>

has sub-classes

[Triple negative malignant neoplasm of breast](#)<sup>c</sup>

## **Hyperplasia of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019193>

has super-classes

[Disorder of prostate](#)<sup>c</sup>

has sub-classes

[Benign prostatic hyperplasia](#)<sup>c</sup>

## **Hypofractionated stereotactic radiotherapy using megavoltage radiation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029448>

has super-classes

[Stereotactic radiation therapy using megavoltage radiation](#) <sup>c</sup>

**I<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031408>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#) <sup>c</sup>

**I.M.S<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000048>

has super-classes

[Manufacturer](#) <sup>c</sup>

**IGRT (image-guided radiation therapy)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033259>

has super-classes

[Imaging \(Procedure\)](#) <sup>c</sup>

**II<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031387>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#) <sup>c</sup>

**IIA<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1032123>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#) <sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#) <sup>c</sup>

**IIB<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031430>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#)<sup>c</sup>

### **IIc<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1032305>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#)<sup>c</sup>

### **III<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031477>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#)<sup>c</sup>

### **IIIA<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031555>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#)<sup>c</sup>

### **IIIB<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1032503>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#)<sup>c</sup>

### **IIIC<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031453>

has super-classes

[American Joint Committee on Cancer clinical stage group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage group allowable value](#)<sup>c</sup>

### **Imaging (Procedure)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005453>

has super-classes



[Imaging Module](#)<sup>c</sup>

has sub-classes

[Chest imaging](#)<sup>c</sup>, [Diagnostic ultrasonography procedure](#)<sup>c</sup>, [IGRT \(image-guided radiation therapy\)](#)<sup>c</sup>,  
[Imaging by body site](#)<sup>c</sup>, [Imaging guidance](#)<sup>c</sup>, [Imaging of pelvis](#)<sup>c</sup>, [Magnetic resonance imaging](#)<sup>c</sup>, [Nuclear medicine](#)<sup>c</sup>, [Radiographic imaging procedure](#)<sup>c</sup>, [Ultrasound](#)<sup>c</sup>

**Imaging by body site<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005458>

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>

has sub-classes

[Imaging of abdomen](#)<sup>c</sup>, [Imaging of genitourinary system](#)<sup>c</sup>

**Imaging finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003882>

has super-classes

[Evaluation finding](#)<sup>c</sup>, [Imaging Module](#)<sup>c</sup>

has sub-classes

[Imaging result abnormal](#)<sup>c</sup>, [Imaging result normal](#)<sup>c</sup>, [Radiologic finding](#)<sup>c</sup>, [Ultrasound scan finding](#)<sup>c</sup>

**Imaging guidance<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005455>

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>

has sub-classes

[Imaging guided biopsy](#)<sup>c</sup>, [Magnetic resonance imaging guidance](#)<sup>c</sup>, [Ultrasonic guidance procedure](#)<sup>c</sup>

**Imaging guided biopsy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001823>

has super-classes

[Biopsy](#)<sup>c</sup>, [Imaging guidance](#)<sup>c</sup>

has sub-classes

[MRI guided biopsy](#)<sup>c</sup>, [US-guided systematic biopsy](#)<sup>c</sup>, [Ultrasound guided biopsy](#)<sup>c</sup>

**Imaging modality<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000009>

Form of imaging that depends on the way the image is produced

has super-classes

[Imaging Module](#)<sup>c</sup>

has sub-classes

[Histological](#)<sup>c</sup>, [Magnetic resonance imaging](#)<sup>c</sup>, [Nuclear medicine](#)<sup>c</sup>, [Projection radiography](#)<sup>c</sup>, [Tomography](#)<sup>c</sup>, [Ultrasound](#)<sup>c</sup>

## **Imaging Module<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000001>

This module defines the categories/entities that are specified in imaging context (e.g., image modalities, manufacturers, body parts, etc.).

has super-classes

[thing](#)<sup>c</sup>

has sub-classes

[Anatomical Plane](#)<sup>c</sup>, [Body part](#)<sup>c</sup>, [Imaging \(Procedure\)](#)<sup>c</sup>, [Imaging finding](#)<sup>c</sup>, [Imaging modality](#)<sup>c</sup>, [Imaging observable](#)<sup>c</sup>, [Laterality](#)<sup>c</sup>, [Manufacturer](#)<sup>c</sup>, [Patient Position](#)<sup>c</sup>, [Screening procedure](#)<sup>c</sup>, [imaging procedure descriptor](#)<sup>c</sup>, [imaging procedure property](#)<sup>c</sup>

## **Imaging observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016238>

has super-classes

[Imaging Module](#)<sup>c</sup>, [Observable entity](#)<sup>c</sup>

has sub-classes

[Ultrasonographic observable](#)<sup>c</sup>

## **Imaging of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005467>

has super-classes

[Imaging by body site](#)<sup>c</sup>

has sub-classes

[MRI of prostate](#)<sup>c</sup>, [Ultrasonography of abdomen](#)<sup>c</sup>

## **Imaging of genitourinary system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005473>

has super-classes

[Imaging by body site](#)<sup>c</sup>

has sub-classes

[MRI of prostate](#)<sup>c</sup>, [US scan of genitourinary system](#)<sup>c</sup>

## **Imaging of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005462>

has super-classes

[Imaging \(Procedure\)](#) <sup>c</sup>

has sub-classes

[MRI of pelvis](#) <sup>c</sup>, [Pelvic echography](#) <sup>c</sup>

### **imaging procedure descriptor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016607>

has super-classes

[Imaging Module](#) <sup>c</sup>

has sub-classes

[Patient Orientation](#) <sup>c</sup>

### **imaging procedure property<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016619>

has super-classes

[Imaging Module](#) <sup>c</sup>

has sub-classes

[cross-sectional procedure attribute](#) <sup>c</sup>

### **Imaging result abnormal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016118>

has super-classes

[Abnormal finding on evaluation procedure](#) <sup>c</sup>, [Imaging finding](#) <sup>c</sup>

has sub-classes

[MRI scan abnormal](#) <sup>c</sup>

### **Imaging result normal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005611>

has super-classes

[Imaging finding](#) <sup>c</sup>

has sub-classes

[MRI scan normal](#) <sup>c</sup>, [Radiology result normal](#) <sup>c</sup>

### **Immunologic agent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035056>

has super-classes

[Drug or medicament](#) <sup>c</sup>

has sub-classes

[Capecitabine](#)<sup>c</sup>, [Cyclophosphamide](#)<sup>c</sup>, [Docetaxel](#)<sup>c</sup>, [Fluorouracil](#)<sup>c</sup>, [Gemcitabine](#)<sup>c</sup>, [Methotrexate](#)<sup>c</sup>, [Nab paclitaxel](#)<sup>c</sup>, [Paclitaxel](#)<sup>c</sup>, [Vinorelbine](#)<sup>c</sup>

### **Immunological therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034245>

has super-classes

[Medical therapy](#)<sup>c</sup>

has sub-classes

[Immunotherapy for cancer](#)<sup>c</sup>

### **Immunotherapeutic agent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034112>

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Immunotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035133>

has super-classes

[Medical therapy](#)<sup>c</sup>

### **Immunotherapy for cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034262>

has super-classes

[Immunological therapy](#)<sup>c</sup>

has sub-classes

[Antineoplastic chemoimmunotherapy](#)<sup>c</sup>

### **Impaired urinary system function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019280>

has super-classes

[Functional finding](#)<sup>c</sup>, [Urinary system finding](#)<sup>c</sup>

has sub-classes

[Urinary incontinence](#)<sup>c</sup>

### **Incontinence<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019368>

has super-classes

[Finding of pelvic region of trunk](#)<sup>c</sup>

has sub-classes

[Incontinence of feces](#)<sup>c</sup>, [Urinary incontinence](#)<sup>c</sup>

**Incontinence of feces<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026598>

has super-classes

[Finding of bowel continence](#)<sup>c</sup>, [Incontinence](#)<sup>c</sup>

**Indeterminate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000044>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

Cannot distinguish between two or more possible values in the current context. [NCIT]

has super-classes

[General adjectival modifier](#)<sup>c</sup>

**Infant feeding method - finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036835>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Breast fed](#)<sup>c</sup>

**Infection of liver caused by parasite<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036313>

has super-classes

[Disease caused by parasite](#)<sup>c</sup>, [Liver disorder due to infection](#)<sup>c</sup>

has sub-classes

[Echinococcosis of liver](#)<sup>c</sup>

**Infiltrating duct carcinoma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016155>

has super-classes

[Malignant epithelial neoplasm](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>

has sub-classes

[Infiltrating duct carcinoma, NOS, of prostate gland](#)<sup>c</sup>

**Infiltrating duct carcinoma, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023862>

has super-classes

[Infiltrating duct carcinoma of prostate](#) <sup>c</sup>

**Inflammation of specific body organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042635>

has super-classes

[Disease](#) <sup>c</sup>

has sub-classes

[Inflammatory disease of liver](#) <sup>c</sup>

**Inflammatory disease of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037582>

has super-classes

[Disease of liver](#) <sup>c</sup>, [Inflammation of specific body organs](#) <sup>c</sup>

has sub-classes

[Autoimmune hepatitis](#) <sup>c</sup>, [Chronic hepatitis](#) <sup>c</sup>

**Injury of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041158>

has super-classes

[Disorder of abdomen](#) <sup>c</sup>

has sub-classes

[Abdominal cavity injury](#) <sup>c</sup>

**Injury of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045991>

has super-classes

[Chest injury](#) <sup>c</sup>, [Disorder of breast](#) <sup>c</sup>

**Insulin [Units/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033459>

has super-classes

[Insulin measurement](#) <sup>c</sup>

**Insulin measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033449>

has super-classes

[Hormone measurement](#)<sup>c</sup>

has sub-classes

[Insulin \[Units/volume\] in Serum or Plasma](#)<sup>c</sup>

**Intensity modulated radiation therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023277>

has super-classes

[Destructive procedure](#)<sup>c</sup>, [Radiation oncology AND/OR radiotherapy](#)<sup>c</sup>

**Intermediate risk of recurrence, prostate cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023338>

has super-classes

[Diagnostic/Screening Processes or Results](#)<sup>c</sup>

**Interpretation of findings<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035055>

has super-classes

[Observable entity](#)<sup>c</sup>

has sub-classes

[Residual cancer burden class](#)<sup>c</sup>

**Intervals of weeks and months<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046750>

has super-classes

[Frequency interval](#)<sup>c</sup>

**Interventional procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034145>

has super-classes

[Procedure](#)<sup>c</sup>

**Intestinal structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003287>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Small intestine](#)<sup>c</sup>, [Structure of large intestine](#)<sup>c</sup>

### **Intra-abdominal collection<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044692>

has super-classes

[Disorder of abdomen](#)<sup>c</sup>

has sub-classes

[Intraabdominal bile collection](#)<sup>c</sup>

### **Intra-abdominal digestive structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001919>

has super-classes

[Body part](#)<sup>c</sup>, [Intra-abdominopelvic structure](#)<sup>c</sup>, [Structure of compartment of abdomen](#)<sup>c</sup>

has sub-classes

[Liver and/or biliary structure](#)<sup>c</sup>, [Pancreas](#)<sup>c</sup>

### **Intra-abdominal proper structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016513>

has super-classes

[Abdomen proper](#)<sup>c</sup>, [Intra-abdominopelvic structure](#)<sup>c</sup>, [Subdivision of intra-abdominopelvic structure](#)<sup>c</sup>

has sub-classes

[Structure of organ within abdomen proper cavity](#)<sup>c</sup>

### **Intra-abdominal urinary structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000861>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Kidney](#)<sup>c</sup>

### **Intra-abdominopelvic structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016375>

has super-classes

[Abdomen](#)<sup>c</sup>, [Body part structure](#)<sup>c</sup>

has sub-classes

[Intra-abdominal digestive structure](#)<sup>c</sup>, [Intra-abdominal proper structure](#)<sup>c</sup>, [Intra-pelvic structure of true pelvis](#)<sup>c</sup>, [Organ within abdominopelvic cavity](#)<sup>c</sup>, [Subdivision of intra-abdominopelvic structure](#)<sup>c</sup>



## **Intra-pelvic structure of true pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016429>

has super-classes

[Intra-abdominopelvic structure](#)<sup>c</sup>, [Pelvis](#)<sup>c</sup>, [Subdivision of intra-abdominopelvic structure](#)<sup>c</sup>

has sub-classes

[Lower bowel structures](#)<sup>c</sup>, [Pelvic alimentary structure](#)<sup>c</sup>

## **Intraabdominal bile collection<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047471>

has super-classes

[Disorder of body cavity](#)<sup>c</sup>, [Intra-abdominal collection](#)<sup>c</sup>

## **Intracranial structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000371>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Brain](#)<sup>c</sup>

## **Intraductal carcinoma, noninfiltrating, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023932>

has super-classes

[Carcinoma in situ of prostate](#)<sup>c</sup>

## **Invasion into the Seminal vesicle<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033271>

has super-classes

[NotClassified](#)<sup>c</sup>

## **Invasive<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000101>

Marked by a tendency to spread, especially into healthy surrounding tissue. [NCIT]

has super-classes

[Disease morphology qualifier](#)<sup>c</sup>

## **IV<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031502>

has super-classes

[American Joint Committee on Cancer clinical stage\\_group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage\\_group allowable value](#)<sup>c</sup>

### **IVA<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031348>

has super-classes

[American Joint Committee on Cancer clinical stage\\_group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage\\_group allowable value](#)<sup>c</sup>

### **IVB<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031367>

has super-classes

[American Joint Committee on Cancer clinical stage\\_group allowable value](#)<sup>c</sup>, [American Joint Committee on Cancer pathological stage\\_group allowable value](#)<sup>c</sup>

### **Joint structure of lower extremity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000827>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Hip joint](#)<sup>c</sup>

### **Joint structure of pelvic girdle<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000762>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Hip joint](#)<sup>c</sup>

### **Kidney<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000132>

Body organ that filters blood for the secretion of urine and that regulates ion concentrations. [MeSH]

has super-classes

[Intra-abdominal urinary structure](#)<sup>c</sup>, [Retroperitoneal compartment structure](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>, [Structure of upper urinary system](#)<sup>c</sup>, [Structure of urinary organ](#)<sup>c</sup>

## **Knee<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000130>

A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends. [NCIT]

has super-classes

[Structure of free lower limb<sup>c</sup>](#), [Structure of joint region of lower limb<sup>c</sup>](#)

## **Known<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000135>

has super-classes

[Qualifier<sup>c</sup>](#)

has sub-classes

[Known absent<sup>c</sup>](#), [Known present<sup>c</sup>](#)

## **Known absent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000140>

has super-classes

[Known<sup>c</sup>](#)

## **Known present<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000146>

has super-classes

[Known<sup>c</sup>](#)

## **Laboratory procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033405>

has super-classes

[Procedure<sup>c</sup>](#)

has sub-classes

[Anatomic pathology procedure<sup>c</sup>](#), [Laboratory procedure categorized by method<sup>c</sup>](#), [Laboratory test<sup>c</sup>](#)

## **Laboratory procedure categorized by method<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034409>

has super-classes

[Laboratory procedure<sup>c</sup>](#)

has sub-classes

[Staining method](#)<sup>c</sup>

## **Laboratory procedure performed<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035065>

has super-classes

[Laboratory Procedures](#)<sup>c</sup>

## **Laboratory Procedures<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034130>

has super-classes

[Procedure with explicit context](#)<sup>c</sup>

has sub-classes

[Laboratory procedure performed](#)<sup>c</sup>

## **Laboratory test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033407>

has super-classes

[Evaluation procedure](#)<sup>c</sup>, [Laboratory procedure](#)<sup>c</sup>

has sub-classes

[Alanine aminotransferase \[Enzymatic activity/volume\] in Blood](#)<sup>c</sup>, [Albumin/Protein.total in 24 hour Urine by Electrophoresis](#)<sup>c</sup>, [Alkaline phosphatase \[Enzymatic activity/volume\] in Blood](#)<sup>c</sup>, [C reactive protein \[Mass/volume\] in Blood by High sensitivity method](#)<sup>c</sup>, [Calcium \[Mass/volume\] in Blood](#)<sup>c</sup>, [Cortisol \[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>, [Creatinine \[Mass/volume\] in Blood](#)<sup>c</sup>, [Creatinine \[Mass/volume\] in Urine](#)<sup>c</sup>, [Gamma glutamyl transferase \[Enzymatic activity/volume\] in Serum or Plasma](#)<sup>c</sup>, [Genetic test](#)<sup>c</sup>, [Glucose \[Mass/volume\] in Venous blood](#)<sup>c</sup>, [Hematocrit \[Volume Fraction\] of Blood](#)<sup>c</sup>, [Hemoglobin A1c/Hemoglobin.total in Blood by HPLC](#)<sup>c</sup>, [Hemoglobin \[Mass/volume\] in Blood](#)<sup>c</sup>, [Histologic test](#)<sup>c</sup>, [Lactate dehydrogenase \[Enzymatic activity/volume\] in Red Blood Cells](#)<sup>c</sup>, [Leukocytes \[# /volume\] in Stem cell product](#)<sup>c</sup>, [Natriuretic peptide B \[Mass/volume\] in Blood](#)<sup>c</sup>, [Platelets \[# /volume\] in Blood](#)<sup>c</sup>, [Potassium \[Mass/volume\] in Blood](#)<sup>c</sup>, [Sodium \[Moles/volume\] in Blood](#)<sup>c</sup>, [Thyrotropin \[Units/volume\] in Blood](#)<sup>c</sup>, [Triglyceride \[Mass/volume\] in Blood](#)<sup>c</sup>, [Urate \[Mass/volume\] in Blood](#)<sup>c</sup>, [Urea \[Mass/volume\] in Blood](#)<sup>c</sup>

## **Laboratory Test Result<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000202>

has super-classes

[Clinical Test Result](#)<sup>c</sup>

has sub-classes

[Pathology Result](#)<sup>c</sup>

## **Lactate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033869>

has super-classes

[Laboratory test](#)<sup>c</sup>

## **Laparoscopic procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019457>

has super-classes

[Endoscopic procedure](#)<sup>c</sup>

has sub-classes

[Robot assisted laparoscopic radical prostatectomy](#)<sup>c</sup>

## **Laparoscopic Procedures on the Prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019547>

has super-classes

[Surgical Procedures on the Prostate](#)<sup>c</sup>

has sub-classes

[Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed](#)<sup>c</sup>

## **Laparoscopic prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016193>

has super-classes

[Prostatectomy](#)<sup>c</sup>

has sub-classes

[Laparoscopic radical prostatectomy](#)<sup>c</sup>

## **Laparoscopic radical prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024148>

has super-classes

[Laparoscopic prostatectomy](#)<sup>c</sup>

## **Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023400>

has super-classes

## **Lapatinib<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036006>

A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

## **Large cell neuroendocrine carcinoma of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024003>

has super-classes

[Neuroendocrine tumor](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>

## **Large intestine part<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002417>

has super-classes

[Body part](#)<sup>c</sup>, [Structure of large intestine](#)<sup>c</sup>

has sub-classes

[Rectum](#)<sup>c</sup>

## **Laterality<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016305>

has super-classes

[Imaging Module](#)<sup>c</sup>

has sub-classes

[Bilateral](#)<sup>c</sup>, [Left position](#)<sup>c</sup>, [Right position](#)<sup>c</sup>, [Unilateral](#)<sup>c</sup>

## **Left anterior apical part of transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004504>

has super-classes

[Left apical transition zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

## **Left anterior apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004509>

The region of the prostate that is located on the anatomical left side of the anterior portion of the apical division of the peripheral zone. [NCIT]

has super-classes

[Left apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Left anterior basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004515>

The region of the prostate that is located on the anatomical left side of the anterior portion of the basal division of the peripheral zone. [NCIT]

has super-classes

[Left basal peripheral zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Left anterior basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004522>

The region of the prostate that is located on the anatomical left side of the anterior portion of the basal division of the transition zone. [NCIT]

has super-classes

[Left basal transition zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Left anterior middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004530>

The region of the prostate that is located on the anatomical left side of the anterior portion of the middle division of the peripheral zone. [NCIT]

has super-classes

[Left lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Left anterior middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004539>

The region of the prostate that is located on the anatomical left side of the anterior portion of the middle division of the transition zone. [NCIT]

has super-classes

[Left middle transition zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Left apical anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004560>

The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the apical division of the anterior lobe. [NCIT]

has super-classes

[Apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

**Left apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005346>

has super-classes

[Apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

has sub-classes

[Left anterior apical peripheral zone of prostate](#)<sup>c</sup>, [Left posterolateral apical peripheral zone of prostate](#)<sup>c</sup>,  
[Left posteromedial apical peripheral zone of prostate](#)<sup>c</sup>

**Left apical transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005401>

has super-classes

[Apical transition zone of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

has sub-classes

[Left anterior apical part of transition zone of prostate](#)<sup>c</sup>, [Left posterior apical part of transition zone of prostate](#)<sup>c</sup>

**Left basal anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029575>

has super-classes

[Basal anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

**Left basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005376>

has super-classes

[Basal peripheral zone of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

has sub-classes

[Left anterior basal peripheral zone of prostate](#)<sup>c</sup>, [Left posterolateral basal peripheral zone of prostate](#)<sup>c</sup>

**Left basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005331>

has super-classes

[Basal transition zone of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

has sub-classes



[Left anterior basal transition zone of prostate](#)<sup>c</sup>, [Left posterior basal transition zone of prostate](#)<sup>c</sup>

### **Left breast structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016577>

has super-classes

[Breast](#)<sup>c</sup>, [Left thorax structure](#)<sup>c</sup>

### **Left lateral middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005446>

has super-classes

[Middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

has sub-classes

[Left anterior middle peripheral zone of prostate](#)<sup>c</sup>, [Left posterolateral middle peripheral zone of prostate](#)<sup>c</sup>,  
[Left posteromedial middle peripheral zone of prostate](#)<sup>c</sup>

### **Left middle anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004572>

The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the middle division of the anterior lobe. [NCIT]

has super-classes

[Middle anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

### **Left middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005338>

has super-classes

[Middle transition zone of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>

has sub-classes

[Left anterior middle transition zone of prostate](#)<sup>c</sup>, [Left posterior middle transition zone of prostate](#)<sup>c</sup>

### **Left position<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016670>

has super-classes

[Laterality](#)<sup>c</sup>

### **Left posterior apical part of transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004599>

has super-classes

[Left apical transition zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posterior basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004614>

The region of the prostate that is located on the anatomical left side of the posterior portion of the basal division of the transition zone. [NCIT]

has super-classes

[Left basal transition zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posterior middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004630>

The region of the prostate that is located on the anatomical left side of the posterior portion of the middle division of the transition zone. [NCIT]

has super-classes

[Left middle transition zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posterolateral apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004647>

The region of the prostate that is located on the anatomical left side of the posterolateral portion of the apical division of the peripheral zone. [NCIT]

has super-classes

[Left apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posterolateral basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004665>

The region of the prostate that is located on the anatomical left side of the posterolateral portion of the basal division of the peripheral zone. [NCIT]

has super-classes

[Left basal peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posterolateral middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004684>

The region of the prostate that is located on the anatomical left side of the posterolateral portion of the middle division of the peripheral zone. [NCIT]

has super-classes

[Left lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posteromedial apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004704>

The region of the prostate that is located on the anatomical left side of the posteromedial portion of the apical division of the peripheral zone. [NCIT]

has super-classes

[Left apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left posteromedial middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004725>

The region of the prostate that is located on the anatomical left side of the posteromedial portion of the middle division of the peripheral zone. [NCIT]

has super-classes

[Left lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Left thorax structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016555>

has super-classes

[Structure of half of thorax lateral to midsagittal plane](#)<sup>c</sup>

has sub-classes

[Left breast structure](#)<sup>c</sup>

### **Length dimension of neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034812>

has super-classes

[Measurement](#)<sup>c</sup>, [Neoplasm observable](#)<sup>c</sup>

has sub-classes

[Primary tumor size](#)<sup>c</sup>

### **Lesion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016402>

has super-classes

[Morphologically abnormal structure](#)<sup>c</sup>

has sub-classes

[Damage](#)<sup>c</sup>, [Dysplasia](#)<sup>c</sup>, [Mass](#)<sup>c</sup>

## **Lesion observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047971>

has super-classes

[Clinical history/examination observable<sup>c</sup>](#)

## **Lesion of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044822>

has super-classes

[Disease of liver<sup>c</sup>](#)

has sub-classes

[Hepatic fibrosis<sup>c</sup>](#), [Liver damage<sup>c</sup>](#), [Liver mass<sup>c</sup>](#)

## **Lesion of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007130>

has super-classes

[Disorder of prostate<sup>c</sup>](#)

has sub-classes

[Prostate mass<sup>c</sup>](#)

## **Lesion size<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019638>

has super-classes

[Measurement<sup>c</sup>](#)

has sub-classes

[Lesion size, additional dimension<sup>c</sup>](#), [Lesion size, greatest dimension<sup>c</sup>](#)

## **Lesion size, additional dimension<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029703>

has super-classes

[Lesion size<sup>c</sup>](#)

## **Lesion size, greatest dimension<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029832>

has super-classes

[Lesion size<sup>c</sup>](#)

## **Letrozole<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036088>

A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

**Leukocytes [# /volume] in Stem cell product<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033414>

has super-classes

[Laboratory test](#)<sup>c</sup>

**Liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000123>

A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate. [NCIT]

has super-classes

[Liver and intrahepatic bile ducts](#)<sup>c</sup>, [Liver and/or biliary structure](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>

**Liver and intrahepatic bile ducts<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001127>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Liver](#)<sup>c</sup>

**Liver and/or biliary structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001169>

has super-classes

[Body part](#)<sup>c</sup>, [Cross-sectional abdomen](#)<sup>c</sup>, [Digestive organ structure](#)<sup>c</sup>, [Intra-abdominal digestive structure](#)<sup>c</sup>

has sub-classes

[Liver](#)<sup>c</sup>

**Liver cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000071>

A carcinoma that arises from the hepatocytes or intrahepatic bile ducts. The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma. [NCIT]

has super-classes

[Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>, [Malignant tumor of digestive organ](#)<sup>c</sup>, [Neoplasm of liver](#)<sup>c</sup>

has sub-classes

[Adenocarcinoma of liver](#)<sup>c</sup>, [Malignant lymphoma of liver](#)<sup>c</sup>, [Primary malignant neoplasm of liver](#)<sup>c</sup>,  
[Sarcoma of liver](#)<sup>c</sup>, [Secondary malignant neoplasm of liver](#)<sup>c</sup>

## **Liver cell carcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043447>

A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. [NCIT]

has super-classes

[Adenocarcinoma of liver](#)<sup>c</sup>, [Primary malignant neoplasm of liver](#)<sup>c</sup>

has sub-classes

[Fibrolamellar hepatocellular carcinoma](#)<sup>c</sup>

## **Liver damage<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036742>

has super-classes

[Abdominal cavity injury](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>, [Gastrointestinal and digestive injury](#)<sup>c</sup>, [Lesion of liver](#)<sup>c</sup>

has sub-classes

[Alcoholic liver damage](#)<sup>c</sup>

## **Liver disorder due to infection<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038518>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Infection of liver caused by parasite](#)<sup>c</sup>

## **Liver finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043328>

has super-classes

[Abdominal organ finding](#)<sup>c</sup>

has sub-classes

[Child-Pugh score class A](#)<sup>c</sup>, [Child-Pugh score class B](#)<sup>c</sup>, [Child-Pugh score class C](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>

## **Liver mass<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037903>

has super-classes

[Abdominal mass](#)<sup>c</sup>, [Lesion of liver](#)<sup>c</sup>, [Mass of digestive structure](#)<sup>c</sup>

has sub-classes

[Abscess of liver](#)<sup>c</sup>, [Cyst of liver](#)<sup>c</sup>

## **Liver regeneration<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036412>

has super-classes

[Disease of liver](#)<sup>c</sup>

has sub-classes

[Cirrhosis of liver](#)<sup>c</sup>

## **Low density lipoprotein cholesterol measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033657>

has super-classes

[Cholesterol measurement](#)<sup>c</sup>

has sub-classes

[Cholesterol in LDL \[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>

## **Low risk of recurrence, prostate cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023463>

has super-classes

[Diagnostic/Screening Processes or Results](#)<sup>c</sup>

## **Lower body part structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000090>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Abdominopelvic segment of trunk](#)<sup>c</sup>, [Pelvis and lower extremities](#)<sup>c</sup>

### **Lower bowel structures<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002552>

has super-classes

[Body part](#)<sup>c</sup>, [Intra-pelvic structure of true pelvis](#)<sup>c</sup>, [Structure of large intestine](#)<sup>c</sup>

has sub-classes

[Rectum](#)<sup>c</sup>

### **Lower gastrointestinal procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010812>

has super-classes

[Procedure on abdomen](#)<sup>c</sup>

### **Lower respiratory tract structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001394>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Lung](#)<sup>c</sup>

### **Lumbar spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000115>

Those vertebrae between the ribs and the pelvis, L1-L5 in man. [NCIT]

has super-classes

[Spine](#)<sup>c</sup>, [Structure of musculoskeletal system of lumbar spine](#)<sup>c</sup>, [Structure of vertebral region of lumbar part of back](#)<sup>c</sup>

has sub-classes

[Lumbosacral spine](#)<sup>c</sup>

### **Lumbosacral region of spine structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003132>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Sacrum](#)<sup>c</sup>



## **Lumbosacral spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004413>

The part of the spine in the lower back that consists of the lumbar region and the sacrum. [NCIT]

has super-classes

[Lumbar spine<sup>c</sup>](#)

## **Lung<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000117>

Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. [MeSH]

has super-classes

[Lower respiratory tract structure<sup>c</sup>](#), [Pulmonary structure including vessels and lymphoid tissue<sup>c</sup>](#), [Structure of organ in respiratory system<sup>c</sup>](#), [Structure of pulmopleural compartment<sup>c</sup>](#), [Structure of thoracic viscus<sup>c</sup>](#)

## **Lung cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000065>

A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. [NCIT]

has super-classes

[Malignant neoplasm of lower respiratory tract<sup>c</sup>](#), [Malignant neoplasm of thorax<sup>c</sup>](#), [Neoplasm of lung<sup>c</sup>](#)

## **Lymph node observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035012>

has super-classes

[Observable entity<sup>c</sup>](#)

has sub-classes

[Number of lymph nodes containing metastatic neoplasm in excised specimen<sup>c</sup>](#), [Number of lymph nodes examined by microscopy in excised specimen<sup>c</sup>](#)

## **Lymph node structure of limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004469>

has super-classes

[Extremity part<sup>c</sup>](#), [Regional lymph node structure<sup>c</sup>](#)

has sub-classes

[Upper limb lymph node structure<sup>c</sup>](#)

## **Lymph Nodes with Metastasis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033229>

has super-classes

[Metastasis<sup>c</sup>](#)

## **Lymphatic (small vessel) tumor invasion finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016232>

has super-classes

[Tumor invasion finding<sup>c</sup>](#)

has sub-classes

[Lymphatic small vessel invasion by tumor absent<sup>c</sup>](#), [Lymphatic small vessel invasion by tumor present<sup>c</sup>](#)

## **Lymphatic small vessel invasion by tumor absent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026803>

has super-classes

[Lymphatic \(small vessel\) tumor invasion finding<sup>c</sup>](#)

## **Lymphatic small vessel invasion by tumor present<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026907>

has super-classes

[Lymphatic \(small vessel\) tumor invasion finding<sup>c</sup>](#)

## **Lymphovascular invasion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036607>

A term referring to the presence of tumor emboli or tumor masses within lymphatic vessels. [NCIT]

has super-classes

[Pathology<sup>c</sup>](#)

has sub-classes

[Lymphovascular invasion extent<sup>c</sup>](#)

## **Lymphovascular invasion extent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036632>

has super-classes

[Lymphovascular invasion<sup>c</sup>](#)

has sub-classes

[Lymphovascular invasion extent](#) | [Cancer specimen](#) | [Pathology<sup>c</sup>](#)

## **Lymphovascular invasion extent in Cancer specimen Qualitative<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045826>

has super-classes

[Lymphovascular invasion extent](#) | [Cancer specimen](#) | [Pathology<sup>c</sup>](#), [Pathology<sup>c</sup>](#)

## **Lymphovascular invasion extent | Cancer specimen | Pathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036658>

has super-classes

[Lymphovascular invasion extent<sup>c</sup>](#)

has sub-classes

[Lymphovascular invasion extent in Cancer specimen Qualitative<sup>c</sup>](#)

## **M category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033323>

One criteria of the TNM staging system. M refers to the presence of metastasis. [NCIT]

has super-classes

[TNM category<sup>c</sup>](#)

has sub-classes

[cM category<sup>c</sup>](#), [pM category<sup>c</sup>](#)

## **Macrocalcifications<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000221>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

BI-RADS US:Macrocalcifications are coarse calcifications that are 0.5mm or greater in size. As in other areas of the body, macrocalcifications will attenuate the acoustic beam and cause acoustic shadowing. [RADLEX]

has super-classes

[Deposit<sup>c</sup>](#)

## **Magnetic resonance imaging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000022>

Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. [NCIT]

has super-classes

[Imaging \(Procedure\)<sup>c</sup>](#), [Imaging modality<sup>c</sup>](#)

has sub-classes

[MRI of chest](#)<sup>c</sup>, [MRI of pelvis](#)<sup>c</sup>, [Magnetic resonance imaging guidance](#)<sup>c</sup>, [Multiparametric magnetic resonance imaging](#)<sup>c</sup>

## **Magnetic resonance imaging guidance<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005480>

has super-classes

[Imaging guidance](#)<sup>c</sup>, [Magnetic resonance imaging](#)<sup>c</sup>

has sub-classes

[MRI guided biopsy](#)<sup>c</sup>

## **Magnetic resonance imaging of breast for screening for malignant neoplasm procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016600>

has super-classes

[MRI of breast for screening](#)<sup>c</sup>, [Screening for malignant neoplasm of breast](#)<sup>c</sup>

## **MALE<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000180>

is equivalent to

[Male \(finding\)](#)<sup>c</sup>

has super-classes

[Gender](#)<sup>c</sup>

## **Male (finding)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001366>

has super-classes

[Finding related to biological sex](#)<sup>c</sup>

## **Male genital organ structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002159>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Prostate](#)<sup>c</sup>

## **Male genital sample<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1013757>

has super-classes

[Specimen from genital system](#)<sup>c</sup>

has sub-classes

[Specimen from prostate](#)<sup>c</sup>

## **Malignant<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000051>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host. [NCIT]

has super-classes

[Disease morphology qualifier](#)<sup>c</sup>, [General adjectival modifier](#)<sup>c</sup>

## **Malignant adenomatous neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007248>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant epithelial neoplasm](#)<sup>c</sup>

has sub-classes

[Adenocarcinoma of liver](#)<sup>c</sup>, [Adenocarcinoma of pelvis](#)<sup>c</sup>, [Adenosquamous cell carcinoma](#)<sup>c</sup>

## **Malignant adenomatous neoplasm - category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036902>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Primary malignant adenomatous neoplasm](#)<sup>c</sup>

## **Malignant epithelial neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000171>

A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Carcinoma of breast](#)<sup>c</sup>, [Carcinoma of colon](#)<sup>c</sup>, [Infiltrating duct carcinoma of prostate](#)<sup>c</sup>, [Malignant adenomatous neoplasm](#)<sup>c</sup>, [Small cell carcinoma](#)<sup>c</sup>

### **Malignant glioma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000061>

A grade 3 or grade 4 glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Diffuse intrinsic pontine glioma](#)<sup>c</sup>

### **Malignant lymphoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039310>

has super-classes

[Malignant tumor of lymphoid hemopoietic and related tissue](#)<sup>c</sup>

has sub-classes

[Malignant lymphoma of liver](#)<sup>c</sup>

### **Malignant lymphoma of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046321>

has super-classes

[Liver cancer](#)<sup>c</sup>, [Malignant lymphoma](#)<sup>c</sup>

### **Malignant neoplasm of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007367>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>, [Primary malignant neoplasm of abdomen](#)<sup>c</sup>

### **Malignant neoplasm of anorectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000105>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Rectal cancer](#)<sup>c</sup>

**Malignant neoplasm of colon and/or rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000054>

has super-classes

[Malignant tumor of large intestine](#)<sup>c</sup>

has sub-classes

[Colon cancer](#)<sup>c</sup>, [Rectal cancer](#)<sup>c</sup>

**Malignant neoplasm of female breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046621>

has super-classes

[Breast cancer](#)<sup>c</sup>, [Neoplasm of female breast](#)<sup>c</sup>

**Malignant neoplasm of genital structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003548>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplasm of genitourinary organ](#)<sup>c</sup>

has sub-classes

[Malignant tumor of male genital organ](#)<sup>c</sup>

**Malignant neoplasm of genitourinary organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007853>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Malignant neoplasm of genital structure](#)<sup>c</sup>

**Malignant neoplasm of intraabdominal organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000098>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplasm of abdomen](#)<sup>c</sup>, [Neoplasm of intra-abdominal organs](#)<sup>c</sup>

has sub-classes

[Cancer of prostate](#)<sup>c</sup>, [Liver cancer](#)<sup>c</sup>, [Primary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>, [Secondary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>

**Malignant neoplasm of lower respiratory tract<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000083>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Lung cancer](#)<sup>c</sup>

### **Malignant neoplasm of rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000185>

A primary or metastatic malignant neoplasm that affects the rectum. Representative examples include carcinoma, lymphoma, and sarcoma. [NCIT]

has super-classes

[Malignant neoplasms of digestive organs](#)<sup>c</sup>

### **Malignant neoplasm of thorax<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000078>

A primary or metastatic malignant neoplasm affecting the tissues of the thorax. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Breast cancer](#)<sup>c</sup>, [Lung cancer](#)<sup>c</sup>

### **Malignant neoplasms of digestive organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000184>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Malignant neoplasm of rectum](#)<sup>c</sup>

### **Malignant neoplastic disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007977>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Neoplastic disease](#)<sup>c</sup>

has sub-classes

[Malignant epithelial neoplasm](#)<sup>c</sup>, [Malignant neoplasm of abdomen](#)<sup>c</sup>, [Malignant neuroendocrine tumor](#)<sup>c</sup>, [Malignant tumor of lymphoid hemopoietic and related tissue](#)<sup>c</sup>, [Malignant tumor of pelvis](#)<sup>c</sup>, [Primary malignant neoplasm](#)<sup>c</sup>, [Sarcoma](#)<sup>c</sup>, [Secondary malignant neoplastic disease](#)<sup>c</sup>, [Squamous cell carcinoma](#)<sup>c</sup>

### **Malignant neuroendocrine neoplasm, neural<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000132>



has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Neuroblastoma](#)<sup>c</sup>

### **Malignant neuroendocrine tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008102>

has super-classes

[Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Neuroendocrine carcinoma](#)<sup>c</sup>

### **Malignant tumor of axilla<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037685>

has super-classes

[Malignant tumor of upper limb](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of axilla](#)<sup>c</sup>

### **Malignant tumor of digestive organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040585>

has super-classes

[Neoplasm of digestive organ](#)<sup>c</sup>

has sub-classes

[Liver cancer](#)<sup>c</sup>, [Metastasis to digestive organs](#)<sup>c</sup>

### **Malignant tumor of intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000080>

A primary or metastatic malignant neoplasm involving the small intestine, large intestine, or both. Representative examples are carcinomas, lymphomas, and sarcomas. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Malignant tumor of large intestine](#)<sup>c</sup>, [Primary malignant neoplasm of intestinal tract](#)<sup>c</sup>

### **Malignant tumor of large intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000053>

A primary or metastatic malignant neoplasm that affects the colon or rectum. Representative examples include carcinoma, lymphoma, and sarcoma. [NCIT]

has super-classes

[Malignant tumor of intestine](#)<sup>c</sup>, [Neoplasm of large intestine](#)<sup>c</sup>

has sub-classes

[Malignant neoplasm of colon and/or rectum](#)<sup>c</sup>, [Primary malignant neoplasm of large intestine](#)<sup>c</sup>

**Malignant tumor of lymphoid hemopoietic and related tissue<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039233>

has super-classes

[Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Malignant lymphoma](#)<sup>c</sup>

**Malignant tumor of male genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000092>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplasm of genital structure](#)<sup>c</sup>, [Neoplasm of male genital organ](#)<sup>c</sup>

has sub-classes

[Cancer of prostate](#)<sup>c</sup>, [Primary malignant neoplasm of male genital organ](#)<sup>c</sup>, [Squamous cell carcinoma of male genital](#)<sup>c</sup>

**Malignant tumor of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000087>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplastic disease](#)<sup>c</sup>, [Neoplasm of pelvis](#)<sup>c</sup>

has sub-classes

[Adenocarcinoma of pelvis](#)<sup>c</sup>, [Cancer of prostate](#)<sup>c</sup>, [Primary malignant neoplasm of pelvis](#)<sup>c</sup>, [Rectal cancer](#)<sup>c</sup>

**Malignant tumor of upper limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037633>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Malignant tumor of axilla](#)<sup>c</sup>

**Malignant tumor staging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044308>

is equivalent to

[Cancer staging](#)<sup>c</sup>

has super-classes

[Tumor staging](#)<sup>c</sup>

has sub-classes

[Generic tumor staging descriptor](#)<sup>c</sup>

**Mammographic architectural distortion of breast finding**<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016604>

has super-classes

[Mammographic breast tissue appearance](#)<sup>c</sup>

**Mammographic breast composition finding (finding)**<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016347>

has super-classes

[Mammography finding](#)<sup>c</sup>

**Mammographic breast tissue appearance**<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034850>

has super-classes

[Mammography finding](#)<sup>c</sup>

has sub-classes

[Architectural distortion of breast](#)<sup>c</sup>, [Mammographic architectural distortion of breast finding](#)<sup>c</sup>

**Mammography**<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000030>

A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease. [NCIT]

has super-classes

[Projection radiography](#)<sup>c</sup>, [Radiographic procedure of chest](#)<sup>c</sup>

has sub-classes

[Digital mammography](#)<sup>c</sup>, [X-Ray mammography](#)<sup>c</sup>

**Mammography assessment finding**<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016284>

has super-classes

[Mammography finding](#)<sup>c</sup>

**Mammography finding**<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034775>

has super-classes

[Radiologic finding](#)<sup>c</sup>

has sub-classes

[Mammographic breast composition finding \(finding\)](#)<sup>c</sup>, [Mammographic breast tissue appearance](#)<sup>c</sup>,

[Mammography assessment finding](#)<sup>c</sup>, [Mammography normal](#)<sup>c</sup>

**Mammography normal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016374>

has super-classes

[Mammography finding](#)<sup>c</sup>, [Radiology result normal](#)<sup>c</sup>

**Mammography reference location<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016324>

has super-classes

[Radiologic finding](#)<sup>c</sup>

**Management of drug regimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034340>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Pharmacological assessment](#)<sup>c</sup>

**Manual<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000003>

Values for segmentation method (ProCancer-I, Prostate gland segmentation UC)

Of or related to the hands; reference to a task or activity being done by hand (as opposed as being performed with the assistance of automation or other supportive means). [NCIT]

has super-classes

[Modifier mainly for procedure](#)<sup>c</sup>

**Manufacturer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000010>

A person, enterprise, or entity that produces finished goods. [NCIT]

has super-classes

[Imaging Module](#)<sup>c</sup>

has sub-classes

[ADAC](#)<sup>c</sup>, [Agfa](#)<sup>c</sup>, [Canon](#)<sup>c</sup>, [Elscint](#)<sup>c</sup>, [Esaote](#)<sup>c</sup>, [Fujifilm](#)<sup>c</sup>, [General Electric](#)<sup>c</sup>, [Hitachi](#)<sup>c</sup>, [I.M.S](#)<sup>c</sup>, [Marconi](#)<sup>c</sup>,  
[Mediso](#)<sup>c</sup>, [MiE](#)<sup>c</sup>, [Philips](#)<sup>c</sup>, [Picker International](#)<sup>c</sup>, [Shimadzu](#)<sup>c</sup>, [Siemens](#)<sup>c</sup>, [Toshiba](#)<sup>c</sup>

**Marconi<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000053>

has super-classes

[Manufacturer](#)<sup>c</sup>

**Mass<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016511>

has super-classes

[Lesion](#)<sup>c</sup>

has sub-classes

[Nodule](#)<sup>c</sup>

**Mass of digestive structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037847>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Liver mass](#)<sup>c</sup>

**Mass-Molar conversion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036478>

has super-classes

[Measurement](#)<sup>c</sup>

has sub-classes

[Carcinoembryonic Ag|Moment in time|Serum or Plasma](#)<sup>c</sup>

**Measure of pregnancy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045760>

has super-classes

[Pregnancy observable](#)<sup>c</sup>

has sub-classes

[Gravida \(observable entity\)](#)<sup>c</sup>, [Number of births at term](#)<sup>c</sup>

**Measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000003>

has super-classes

[Clinical Module](#)<sup>c</sup>, [Evaluation procedure](#)<sup>c</sup>

has sub-classes

[BRCA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal](#)<sup>c</sup>,  
[BRCA1+BRCA2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal](#)<sup>c</sup>,  
[Carcinoembryonic Ag.\[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>, [Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain](#)<sup>c</sup>,  
[ERBB2 gene duplication \[Presence\] in Breast cancer specimen by FISH](#)<sup>c</sup>, [Estrogen receptor Ag \[Presence\] in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Flowsheet - laboratory](#)<sup>c</sup>, [Hormone measurement](#)<sup>c</sup>, [Length dimension of neoplasm](#)<sup>c</sup>, [Lesion size](#)<sup>c</sup>, [Mass-Molar conversion](#)<sup>c</sup>, [Measurement of substance](#)<sup>c</sup>,  
[Melan-A and Ki67 Ag \[Identifier\] in Tissue by Immune stain](#)<sup>c</sup>, [Molecular pathology](#)<sup>c</sup>, [PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method](#)<sup>c</sup>, [Progesterone receptor Ag \[Presence\] in Breast cancer specimen by Immune stain \(LOINC, 85339-0\)](#)<sup>c</sup>, [Regional lymph nodes examined \[#\] Specimen](#)<sup>c</sup>, [Tumor volume](#)<sup>c</sup>

### **Measurement finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003968>

has super-classes

[Evaluation finding](#)<sup>c</sup>

has sub-classes

[Finding of Hepatitis C status](#)<sup>c</sup>, [Finding of substance level](#)<sup>c</sup>, [Measurement finding within reference range](#)<sup>c</sup>

### **Measurement finding within reference range<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019730>

has super-classes

[Measurement finding](#)<sup>c</sup>

has sub-classes

[Prostate specific antigen normal](#)<sup>c</sup>

### **Measurement of level of drug in blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019823>

has super-classes

[Drug measurement](#)<sup>c</sup>, [Measurement of substance in specimen](#)<sup>c</sup>

has sub-classes

[Serum testosterone measurement](#)<sup>c</sup>

### **Measurement of level of substance in blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1019917>

has super-classes

[Measurement of substance in specimen](#)<sup>c</sup>

has sub-classes

[Serum testosterone measurement](#)<sup>c</sup>

### **Measurement of liver enzyme<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033704>

has super-classes

[Enzyme measurement](#)<sup>c</sup>

has sub-classes

[Aspartate aminotransferase measurement](#)<sup>c</sup>

### **Measurement of substance<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000222>

has super-classes

[Measurement](#)<sup>c</sup>

has sub-classes

[Drug measurement](#)<sup>c</sup>, [Measurement of substance in specimen](#)<sup>c</sup>, [Protein measurement](#)<sup>c</sup>, [Steroid measurement](#)<sup>c</sup>, [Tumor marker measurement](#)<sup>c</sup>

### **Measurement of substance in specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009005>

has super-classes

[Measurement of substance](#)<sup>c</sup>

has sub-classes

[Measurement of level of drug in blood](#)<sup>c</sup>, [Measurement of level of substance in blood](#)<sup>c</sup>

### **Mediastinum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000135>

An anatomic site along the midline and under the sternum that contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues. [NCIT]

has super-classes

[Chest](#)<sup>c</sup>, [Structure of lung and/or mediastinum](#)<sup>c</sup>, [Structure of thoracic cavity and/or content](#)<sup>c</sup>

### **Medical therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034229>

has super-classes

[Therapeutic procedure](#) <sup>c</sup>

has sub-classes

[Immunological therapy](#) <sup>c</sup>, [Immunotherapy](#) <sup>c</sup>

**Medication<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034109>

has super-classes

[Clinical Module](#) <sup>c</sup>

has sub-classes

[Drug or medicament](#) <sup>c</sup>, [Pharmaceutical / biologic product \(product\)](#) <sup>c</sup>

**Medication Review<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034385>

has super-classes

[Pharmacological assessment](#) <sup>c</sup>

has sub-classes

[Targeted medication therapy review](#) <sup>c</sup>

**Mediso<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000056>

has super-classes

[Manufacturer](#) <sup>c</sup>

**Melan-A and Ki67 Ag [Identifier] in Tissue by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047191>

has super-classes

[Measurement](#) <sup>c</sup>, [Pathology](#) <sup>c</sup>

**Menopause finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039467>

has super-classes

[Clinical finding](#) <sup>c</sup>

has sub-classes

[Postmenopausue - Menopause present](#) <sup>c</sup>, [Premenopause - Menopause absent](#) <sup>c</sup>

**Menopause, function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045770>



has super-classes

[Female genital tract functions](#)<sup>c</sup>

### **Metastasis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009407>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Distant Metastasis \(NOS\)](#)<sup>c</sup>, [Lymph Nodes with Metastasis](#)<sup>c</sup>, [Metastasis to bone](#)<sup>c</sup>, [Metastasis to digestive organ](#)<sup>c</sup>, [Metastasis to endocrine gland](#)<sup>c</sup>, [Metastasis to nervous system](#)<sup>c</sup>, [Metastasis to retroperitoneum](#)<sup>c</sup>, [Metastasis to the Viscera](#)<sup>c</sup>

### **Metastasis to adrenal gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022825>

has super-classes

[Metastasis to endocrine gland](#)<sup>c</sup>, [Metastasis to retroperitoneum](#)<sup>c</sup>

### **Metastasis to bone<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1026700>

has super-classes

[Metastasis](#)<sup>c</sup>

### **Metastasis to brain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022878>

has super-classes

[Metastasis to central nervous system](#)<sup>c</sup>

### **Metastasis to central nervous system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020012>

has super-classes

[Metastasis to nervous system](#)<sup>c</sup>

has sub-classes

[Metastasis to brain](#)<sup>c</sup>

### **Metastasis to digestive organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016272>

has super-classes

[Metastasis](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of liver](#)<sup>c</sup>

**Metastasis to digestive organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000191>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant tumor of digestive organ](#)<sup>c</sup>, [Secondary malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of liver](#)<sup>c</sup>

**Metastasis to endocrine gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016313>

has super-classes

[Metastasis](#)<sup>c</sup>

has sub-classes

[Metastasis to adrenal gland](#)<sup>c</sup>

**Metastasis to intrathoracic organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020108>

has super-classes

[Metastasis to the Viscera](#)<sup>c</sup>

has sub-classes

[Metastasis to lung](#)<sup>c</sup>

**Metastasis to kidney<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027663>

has super-classes

[Metastasis to retroperitoneum](#)<sup>c</sup>

**Metastasis to lung<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1022932>

has super-classes

[Metastasis to intrathoracic organs](#)<sup>c</sup>

**Metastasis to nervous system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009543>

has super-classes

[Metastasis](#)<sup>c</sup>

has sub-classes

[Metastasis to central nervous system](#)<sup>c</sup>

## **Metastasis to retroperitoneum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016355>

has super-classes

[Metastasis](#)<sup>c</sup>

has sub-classes

[Metastasis to adrenal gland](#)<sup>c</sup>, [Metastasis to kidney](#)<sup>c</sup>

## **Metastasis to the Viscera<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029322>

has super-classes

[Metastasis](#)<sup>c</sup>

has sub-classes

[Metastasis to intrathoracic organs](#)<sup>c</sup>

## **Methotrexate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035890>

An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

## **mg/kg<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001897>

has super-classes

[Unit of measure](#)<sup>c</sup>

## **mg/m<sup>2</sup><sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001904>

has super-classes

[Unit of measure](#)<sup>c</sup>

## **Microscopic specimen observation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048763>

has super-classes

[Evaluation finding<sup>c</sup>](#)

## **Middle anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005415>

has super-classes

[Middle region of prostate<sup>c</sup>](#)

has sub-classes

[Left middle anterior fibromuscular stroma of prostate<sup>c</sup>](#), [Right middle anterior fibromuscular stroma of prostate<sup>c</sup>](#)

## **Middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005310>

has super-classes

[Middle region of prostate<sup>c</sup>](#)

has sub-classes

[Left lateral middle peripheral zone of prostate<sup>c</sup>](#), [Right lateral middle peripheral zone of prostate<sup>c</sup>](#)

## **Middle region of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005275>

has super-classes

[Region of prostate<sup>c</sup>](#)

has sub-classes

[Middle anterior fibromuscular stroma of prostate<sup>c</sup>](#), [Middle peripheral zone of prostate<sup>c</sup>](#), [Middle transition zone of prostate<sup>c</sup>](#)

## **Middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005295>

has super-classes

[Middle region of prostate<sup>c</sup>](#)

has sub-classes

[Left middle transition zone of prostate<sup>c</sup>](#), [Right middle transition zone of prostate<sup>c</sup>](#)

## **MiE<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000058>

has super-classes

[Manufacturer](#)<sup>c</sup>

**millimeter<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000152>

has super-classes

[Unit of measure](#)<sup>c</sup>

**Missing Value Reason<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001912>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Not identified](#)<sup>c</sup>

**Mixed neuroendocrine non-neuroendocrine neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047086>

A rare neoplasm that consists of neuroendocrine and non-neuroendocrine cellular components. At least 30% of either component should be present for the diagnosis to be made. [NCIT]

has super-classes

[Adenomas and adenocarcinomas](#)<sup>c</sup>

**Modified Ryan Scheme for Tumor Regression<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049085>

has super-classes

[Tumor Regression Grade](#)<sup>c</sup>

**Modifier mainly for procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000103>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Automatic](#)<sup>c</sup>, [Manual](#)<sup>c</sup>, [Semiautomatic](#)<sup>c</sup>

**Molecular genetic test<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034487>

has super-classes

[Genetic test](#)<sup>c</sup>

has sub-classes

[BRCA1 mutation carrier detection test](#)<sup>c</sup>, [BRCA2 mutation carrier detection test](#)<sup>c</sup>

### **Molecular pathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042412>

has super-classes

[Measurement](#)<sup>c</sup>

has sub-classes

[ERBB2 gene duplication \[Presence\] in Breast cancer specimen by FISH](#)<sup>c</sup>, [Gene mutation](#)<sup>c</sup>

### **Monitoring of patient<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009818>

has super-classes

[Evaluation procedure](#)<sup>c</sup>

has sub-classes

[Chronic disease monitoring](#)<sup>c</sup>

### **Monitoring of patient with cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020205>

has super-classes

[Chronic disease monitoring](#)<sup>c</sup>

has sub-classes

[Active surveillance of prostate cancer](#)<sup>c</sup>

### **Morphologic Finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000214>

has super-classes

[Histopathology Result](#)<sup>c</sup>

has sub-classes

[Deposit](#)<sup>c</sup>

### **Morphologically abnormal structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016395>

has super-classes

[Morphologically altered structure](#)<sup>c</sup>

has sub-classes

[Growth alteration](#)<sup>c</sup>, [Lesion](#)<sup>c</sup>

## **Morphologically altered structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016389>

has super-classes

[Body structure](#)<sup>c</sup>

has sub-classes

[Morphologically abnormal structure](#)<sup>c</sup>

## **MR Echo Type<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016640>

has super-classes

[MR procedure attribute](#)<sup>c</sup>

## **MR procedure attribute<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016632>

has super-classes

[cross-sectional procedure attribute](#)<sup>c</sup>

has sub-classes

[MR Echo Type](#)<sup>c</sup>, [Tissue Contrast](#)<sup>c</sup>

## **MRI guided biopsy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005488>

has super-classes

[Imaging guided biopsy](#)<sup>c</sup>, [Magnetic resonance imaging guidance](#)<sup>c</sup>

has sub-classes

[MRI guided biopsy of prostate](#)<sup>c</sup>

## **MRI guided biopsy of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005608>

has super-classes

[MRI guided biopsy](#)<sup>c</sup>, [MRI of prostate](#)<sup>c</sup>

has sub-classes

[MRI-US fusion guided prostate biopsy](#)<sup>c</sup>

## **MRI of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016224>

has super-classes

[MRI of chest](#)<sup>c</sup>

has sub-classes

[MRI of breast for screening](#)<sup>c</sup>

**MRI of breast for screening<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016199>

has super-classes

[MRI of breast](#)<sup>c</sup>, [Screening procedure](#)<sup>c</sup>

has sub-classes

[MRI of breast for screening for malignant neoplasm](#)<sup>c</sup>, [Magnetic resonance imaging of breast for screening for malignant neoplasm procedure](#)<sup>c</sup>

**MRI of breast for screening for malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016279>

has super-classes

[MRI of breast for screening](#)<sup>c</sup>, [Screening for malignant neoplasm of breast](#)<sup>c</sup>

**MRI of chest<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016211>

has super-classes

[Chest imaging](#)<sup>c</sup>, [Magnetic resonance imaging](#)<sup>c</sup>

has sub-classes

[MRI of breast](#)<sup>c</sup>

**MRI of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005530>

has super-classes

[Imaging of pelvis](#)<sup>c</sup>, [Magnetic resonance imaging](#)<sup>c</sup>

has sub-classes

[MRI of prostate](#)<sup>c</sup>

**MRI of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005507>

has super-classes

[Imaging of abdomen](#)<sup>c</sup>, [Imaging of genitourinary system](#)<sup>c</sup>, [MRI of pelvis](#)<sup>c</sup>

has sub-classes

[MRI guided biopsy of prostate](#)<sup>c</sup>, [Multiparametric MRI of prostate](#)<sup>c</sup>

**MRI scan abnormal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016121>

has super-classes

[Imaging result abnormal](#)<sup>c</sup>

**MRI scan normal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016124>

has super-classes

[Imaging result normal](#)<sup>c</sup>

**MRI-US fusion guided prostate biopsy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016128>

has super-classes

[Biopsy of abdomen using ultrasound guidance](#)<sup>c</sup>, [MRI guided biopsy of prostate](#)<sup>c</sup>, [US scan and biopsy of prostate](#)<sup>c</sup>

**Mucinous adenocarcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046936>

An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland. [NCIT]

has super-classes

[Cystic, mucinous and serous neoplasms](#)<sup>c</sup>

**Multiparametric magnetic resonance imaging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005606>

has super-classes

[Magnetic resonance imaging](#)<sup>c</sup>

has sub-classes

[Multiparametric MRI of prostate](#)<sup>c</sup>

**Multiparametric MRI of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016133>

has super-classes

[MRI of prostate](#)<sup>c</sup>, [Multiparametric magnetic resonance imaging](#)<sup>c</sup>

**Musculoskeletal structure of sacral spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003056>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Sacrum](#)<sup>c</sup>

### **Musculoskeletal structure of spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003366>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Spine](#)<sup>c</sup>

### **N category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033328>

has super-classes

[TNM category](#)<sup>c</sup>

has sub-classes

[cN category](#)<sup>c</sup>, [pN category](#)<sup>c</sup>

### **Nab paclitaxel<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035061>

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

### **nanogram per deciliter<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000167>

has super-classes

[Unit of measure](#)<sup>c</sup>

### **nanogram per milliliter<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000156>

has super-classes

[Unit of measure](#)<sup>c</sup>

### **nanomole per liter<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000174>

has super-classes

[Unit of measure](#)<sup>c</sup>

**Natriuretic peptide B [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033999>

has super-classes

[Laboratory test](#)<sup>c</sup>

**Neck<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000119>

The region that connects the head to the rest of the body. [NCIT]

has super-classes

[Face and/or neck structure](#)<sup>c</sup>, [Neck and chest](#)<sup>c</sup>, [Scalp and/or neck structure](#)<sup>c</sup>

**Neck and chest<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000100>

has super-classes

[Neck, chest and abdomen](#)<sup>c</sup>

has sub-classes

[Chest](#)<sup>c</sup>, [Neck](#)<sup>c</sup>

**Neck, chest and abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000097>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Chest and abdomen](#)<sup>c</sup>, [Neck and chest](#)<sup>c</sup>

**Negative<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001332>

has super-classes

[Absence findings](#)<sup>c</sup>

**Neoadjuvant antineoplastic therapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049098>

has super-classes

[Therapeutic procedure](#)<sup>c</sup>

## **Neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036328>

has super-classes

[Neoplasm and/or hamartoma](#)<sup>c</sup>

has sub-classes

[Neoplasm, benign](#)<sup>c</sup>

## **Neoplasm and/or hamartoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010097>

has super-classes

[Disease](#)<sup>c</sup>

has sub-classes

[Hemangioma](#)<sup>c</sup>, [Neoplasm](#)<sup>c</sup>, [Neoplastic disease](#)<sup>c</sup>

## **Neoplasm observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034929>

has super-classes

[Observable entity](#)<sup>c</sup>

has sub-classes

[Edition of American Joint Commission on Cancer, Cancer Staging Manual used for TNM staging](#)<sup>c</sup>, [Histologic feature of neoplasm](#)<sup>c</sup>, [Length dimension of neoplasm](#)<sup>c</sup>, [Number of lymph nodes containing metastatic neoplasm in excised specimen](#)<sup>c</sup>, [Presence of direct invasion by neoplasm](#)<sup>c</sup>, [Presence of metastatic discontinuous spread of primary malignant neoplasm](#)<sup>c</sup>, [Status of regression of tumor](#)<sup>c</sup>, [Tumor configuration \(finding\)](#)<sup>c</sup>, [Tumor configuration observable entity](#)<sup>c</sup>, [Tumor focality](#)<sup>c</sup>

## **Neoplasm of axilla<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043093>

has super-classes

[Neoplasm of shoulder](#)<sup>c</sup>

has sub-classes

[Neoplasm of axillary lymph nodes](#)<sup>c</sup>

## **Neoplasm of axillary lymph nodes<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043210>

has super-classes

[Neoplasm of axilla](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of axillary lymph nodes](#)<sup>c</sup>

## **Neoplasm of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000059>

A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Breast cancer](#)<sup>c</sup>, [Neoplasm of female breast](#)<sup>c</sup>

## **Neoplasm of colon<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000056>

A benign or malignant neoplasm that affects the colon. Representative examples of benign neoplasms include lipoma and leiomyoma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma. Colonic adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Colon cancer](#)<sup>c</sup>

## **Neoplasm of digestive organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040493>

has super-classes

[Neoplastic disease](#)<sup>c</sup>

has sub-classes

[Malignant tumor of digestive organ](#)<sup>c</sup>

## **Neoplasm of extremity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042748>

has super-classes

[Neoplastic disease](#)<sup>c</sup>

has sub-classes

[Neoplasm of upper limb](#)<sup>c</sup>

## **Neoplasm of female breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036352>

has super-classes

[Neoplasm of breast](#)<sup>c</sup>

has sub-classes

[Malignant neoplasm of female breast](#)<sup>c</sup>

### **Neoplasm of intra-abdominal organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000332>

has super-classes

[Abdominal organ finding](#)<sup>c</sup>

has sub-classes

[Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>

### **Neoplasm of large intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000052>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Malignant tumor of large intestine](#)<sup>c</sup>

### **Neoplasm of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000070>

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Benign neoplasm of liver](#)<sup>c</sup>, [Liver cancer](#)<sup>c</sup>

### **Neoplasm of lung<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000064>

A benign or malignant, primary or metastatic neoplasm involving the lungs. Representative examples of benign neoplasms include adenoma, papilloma, chondroma, and endobronchial lipoma. Representative examples of malignant neoplasms include carcinoma, carcinoid tumor, sarcoma, and lymphoma. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Lung cancer](#)<sup>c</sup>

### **Neoplasm of male genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003308>

has super-classes

[Disorder of male genital organ](#)<sup>c</sup>, [Neoplasm of trunk](#)<sup>c</sup>

has sub-classes

[Carcinoma in situ of male genital organ](#)<sup>c</sup>, [Malignant tumor of male genital organ](#)<sup>c</sup>, [Neoplasm of prostate](#)<sup>c</sup>

### **Neoplasm of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1003467>

has super-classes

[Disorder of pelvis](#)<sup>c</sup>, [Neoplasm of trunk](#)<sup>c</sup>

has sub-classes

[Malignant tumor of pelvis](#)<sup>c</sup>, [Neoplasm of prostate](#)<sup>c</sup>

### **Neoplasm of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000074>

A benign, borderline, or malignant neoplasm that affects the prostate gland. Representative examples include benign prostate phyllodes tumor, prostatic intraepithelial neoplasia, prostate carcinoma, and prostate sarcoma. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>, [Disorder of prostate](#)<sup>c</sup>, [Neoplasm of male genital organ](#)<sup>c</sup>, [Neoplasm of pelvis](#)<sup>c</sup>, [Prostate mass](#)<sup>c</sup>

has sub-classes

[Cancer of prostate](#)<sup>c</sup>, [Carcinoma in situ of prostate](#)<sup>c</sup>

### **Neoplasm of rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000076>

A benign or malignant neoplasm that affects the rectum. Representative examples of benign neoplasms include lipoma and leiomyoma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma. Rectal adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>

has sub-classes

[Rectal cancer](#)<sup>c</sup>

### **Neoplasm of shoulder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042977>

has super-classes

[Neoplasm of upper limb](#)<sup>c</sup>

has sub-classes

[Neoplasm of axilla](#)<sup>c</sup>

## **Neoplasm of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010380>

has super-classes

[Neoplastic disease<sup>c</sup>](#)

has sub-classes

[Neoplasm of male genital organ<sup>c</sup>](#), [Neoplasm of pelvis<sup>c</sup>](#), [Primary malignant neoplasm of trunk<sup>c</sup>](#)

## **Neoplasm of upper limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1042862>

has super-classes

[Neoplasm of extremity<sup>c</sup>](#)

has sub-classes

[Neoplasm of shoulder<sup>c</sup>](#)

## **Neoplasm, benign<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046166>

A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. [NCIT]

has super-classes

[Neoplasm<sup>c</sup>](#)

## **Neoplasm, malignant of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030093>

has super-classes

[Primary malignant neoplasm of prostate<sup>c</sup>](#)

## **Neoplastic disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010238>

has super-classes

[Neoplasm and/or hamartoma<sup>c</sup>](#)

has sub-classes

[Benign neoplastic disease<sup>c</sup>](#), [Hormone receptor negative neoplasm<sup>c</sup>](#), [Hormone receptor positive tumor<sup>c</sup>](#), [Malignant neoplastic disease<sup>c</sup>](#), [Neoplasm of digestive organ<sup>c</sup>](#), [Neoplasm of extremity<sup>c</sup>](#), [Neoplasm of trunk<sup>c</sup>](#), [Neuroendocrine tumor<sup>c</sup>](#), [Primary malignant neoplasm of female breast<sup>c</sup>](#)

## **Neuroblastoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000066>



A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myooclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) [MeSH]

has super-classes

[Embryonal neuroepithelial tumor](#)<sup>c</sup>, [Malignant neuroendocrine neoplasm, neural](#)<sup>c</sup>, [Neuroendocrine tumor](#)<sup>c</sup>, [Primary malignant neoplasm](#)<sup>c</sup>

**Neuroendocrine carcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020303>

has super-classes

[Malignant neuroendocrine tumor](#)<sup>c</sup>

has sub-classes

[Neuroendocrine tumor, NOS, of prostate gland](#)<sup>c</sup>

**Neuroendocrine Carcinoma, NOS<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046841>

A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation. [NCIT]

has super-classes

[Adenomas and adenocarcinomas](#)<sup>c</sup>

**Neuroendocrine tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000122>

A well-differentiated epithelial neuroendocrine neoplasm of low, intermediate, or high grade. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>, [Neoplastic disease](#)<sup>c</sup>

has sub-classes

[Adenocarcinoma with neuroendocrine differentiation of prostate gland](#)<sup>c</sup>, [Large cell neuroendocrine carcinoma of prostate gland](#)<sup>c</sup>, [Neuroblastoma](#)<sup>c</sup>

**Neuroendocrine tumor, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023793>

has super-classes

[Neuroendocrine carcinoma](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>

**No anti-cancer treatment - watchful waiting<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027012>

has super-classes

[Reason for no specific anti-cancer treatment](#)<sup>c</sup>

**No family history of clinical finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1029962>

has super-classes

[Family history with explicit context](#)<sup>c</sup>, [Finding with explicit context](#)<sup>c</sup>

**No vascular invasion by tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027118>

has super-classes

[Tumor invasion finding](#)<sup>c</sup>

**Nodule<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016591>

has super-classes

[Mass](#)<sup>c</sup>

has sub-classes

[Dysplastic nodule](#)<sup>c</sup>

**Non-alcoholic fatty liver disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049088>

has super-classes

[steatosis of liver](#)<sup>c</sup>

**Non-coronary systemic artery structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000321>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Aorta](#)<sup>c</sup>

**None<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001375>

has super-classes

[Absence findings](#)<sup>c</sup>

**Normal sexual function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027225>

has super-classes

[Finding of sexual function](#)<sup>c</sup>

**Not detected<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001388>

has super-classes

[Absence findings](#)<sup>c</sup>

**Not identified<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001921>

has super-classes

[Missing Value Reason](#)<sup>c</sup>

**NotClassified<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031178>

This category includes the concepts that are not yet classified. They will be managed in v0.2 beta.

has super-classes

[thing](#)<sup>c</sup>

has sub-classes

[1+](#)<sup>c</sup>, [2+](#)<sup>c</sup>, [3+](#)<sup>c</sup>, [Extraprostatic Extension \(EPE\)](#)<sup>c</sup>, [Invasion into the Seminal vesicle](#)<sup>c</sup>, [PAM50](#)<sup>c</sup>, [Primary pattern unknown](#), [secondary pattern unknown](#)<sup>c</sup>

**Nuclear medicine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000034>

Nuclear Medicine is the branch of medicine that uses radioactive materials either to image a patient's body or to destroy diseased cells. [NCIT]

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>, [Imaging modality](#)<sup>c</sup>

has sub-classes

[Nuclear medicine imaging procedure](#)<sup>c</sup>

**Nuclear medicine imaging procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016272>

has super-classes

[Nuclear medicine](#)<sup>c</sup>

has sub-classes

[Positron emission tomography](#)<sup>c</sup>

**Number of births at term<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046036>

has super-classes

[Measure of pregnancy](#)<sup>c</sup>, [Obstetric history](#)<sup>c</sup>

**Number of lymph nodes containing metastatic neoplasm in excised specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035616>

has super-classes

[Lymph node observable](#)<sup>c</sup>, [Neoplasm observable](#)<sup>c</sup>

**Number of lymph nodes examined by microscopy in excised specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035721>

has super-classes

[Lymph node observable](#)<sup>c</sup>

**Observable entity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034889>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Clinical history/examination observable](#)<sup>c</sup>, [Function](#)<sup>c</sup>, [Imaging observable](#)<sup>c</sup>, [Interpretation of findings](#)<sup>c</sup>,  
[Lymph node observable](#)<sup>c</sup>, [Neoplasm observable](#)<sup>c</sup>, [Pregnancy observable](#)<sup>c</sup>

**Obstetric history<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040223>

has super-classes

[Pregnancy, childbirth / puerperium observable](#)<sup>c</sup>

has sub-classes

[Number of births at term](#)<sup>c</sup>

## **Open prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012630>

has super-classes

[Prostatectomy](#)<sup>c</sup>

has sub-classes

[Perineal prostatectomy](#)<sup>c</sup>

## **Operation on abdominal region<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000237>

has super-classes

[Procedure on abdomen](#)<sup>c</sup>

has sub-classes

[Abdomen excision](#)<sup>c</sup>

## **Operation on male genital system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1011855>

has super-classes

[Procedure on male genital system](#)<sup>c</sup>

## **Operation on prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012473>

has super-classes

[Procedure on prostate](#)<sup>c</sup>

has sub-classes

[Prostatectomy](#)<sup>c</sup>

## **Operations by approach<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1014255>

has super-classes

[Surgical procedure](#)<sup>c</sup>

has sub-classes

[Perineal prostatectomy](#)<sup>c</sup>, [Retropubic prostatectomy](#)<sup>c</sup>

## **Operative procedure on pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012317>

has super-classes

[Procedure on pelvis](#)<sup>c</sup>

has sub-classes

[Excision of pelvis](#)<sup>c</sup>

### **Optic canal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000124>

has super-classes

[Skull foramen](#)<sup>c</sup>, [Structure of body conduit](#)<sup>c</sup>, [Structure of lesser wing of sphenoid bone](#)<sup>c</sup>

### **Orbit structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004452>

has super-classes

[Structure of orbital region](#)<sup>c</sup>

### **Organ within abdominopelvic cavity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016576>

has super-classes

[Intra-abdominopelvic structure](#)<sup>c</sup>, [Structure of viscus](#)<sup>c</sup>

has sub-classes

[Structure of organ within abdomen proper cavity](#)<sup>c</sup>

### **Other hormone antagonists and related agents<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021453>

has super-classes

[HORMONE ANTAGONISTS AND RELATED AGENTS](#)<sup>c</sup>

### **Paclitaxel<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035850>

A compound extracted from the Pacific yew tree *Taxus brevifolia* with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

### **PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049100>

has super-classes

[Measurement](#)<sup>c</sup>

### **Palbociclib<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036241>

An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Palpation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004322>

has super-classes

[Examination by method](#)<sup>c</sup>

has sub-classes

[Palpation of abdomen](#)<sup>c</sup>

### **Palpation of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020402>

has super-classes

[Examination of abdomen](#)<sup>c</sup>, [Palpation](#)<sup>c</sup>

has sub-classes

[Digital examination of rectum](#)<sup>c</sup>

### **PAM50<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001931>

has super-classes

[NotClassified](#)<sup>c</sup>

### **Pancreas<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000137>

An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells

make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known. [NCIT]

has super-classes

[Digestive organ structure](#)<sup>c</sup>, [Intra-abdominal digestive structure](#)<sup>c</sup>, [Retroperitoneal compartment structure](#)<sup>c</sup>,  
[Structure of endocrine system](#)<sup>c</sup>, [Structure of organ within abdomen proper cavity](#)<sup>c</sup>

## **Pathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036583>

has super-classes

[Clinical specialty](#)<sup>c</sup>

has sub-classes

[Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Estrogen receptor Ag \[Presence\] in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Extramural vein invasion](#)<sup>c</sup>, [Extramural vein invasion \[Presence\] in Colorectal cancer specimen by Light microscopy](#)<sup>c</sup>, [HER2](#)<sup>c</sup>, [HER2 \[Presence\] in Breast cancer specimen by Immune stain](#)<sup>c</sup>, [Histopathology](#)<sup>c</sup>, [Lymphovascular invasion](#)<sup>c</sup>, [Lymphovascular invasion extent in Cancer specimen Qualitative](#)<sup>c</sup>, [Melan-A and Ki67 Ag \[Identifier\] in Tissue by Immune stain](#)<sup>c</sup>, [Perineural invasion \[Presence\] in Cancer specimen](#)<sup>c</sup>, [Progesterone receptor Ag \[Presence\] in Breast cancer specimen by Immune stain](#)<sup>c</sup>

## **Pathology Result<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000205>

has super-classes

[Laboratory Test Result](#)<sup>c</sup>

has sub-classes

[Histopathology Result](#)<sup>c</sup>

## **Patient<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001047>

has super-classes

[Person in the healthcare environment](#)<sup>c</sup>

has sub-classes

[Cancer Patient](#)<sup>c</sup>

## **Patient Orientation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016610>

has super-classes

[imaging procedure descriptor](#)<sup>c</sup>



has sub-classes

[Feet first orientation](#)<sup>c</sup>, [Head first orientation](#)<sup>c</sup>

### **Patient Position<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016605>

has super-classes

[Imaging Module](#)<sup>c</sup>

### **Pectoral region structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000419>

has super-classes

[Body part](#)<sup>c</sup>, [Chest](#)<sup>c</sup>

has sub-classes

[Breast](#)<sup>c</sup>

### **Pelvic alimentary structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016531>

has super-classes

[Intra-pelvic structure of true pelvis](#)<sup>c</sup>

has sub-classes

[Anorectal structure](#)<sup>c</sup>

### **Pelvic echography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005543>

has super-classes

[Imaging of pelvis](#)<sup>c</sup>

has sub-classes

[US scan and biopsy of pelvis](#)<sup>c</sup>, [US scan of prostate](#)<sup>c</sup>

### **Pelvic lymphadenectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027333>

has super-classes

[Block dissection of pelvic lymph nodes](#)<sup>c</sup>

### **Pelvic organ finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000347>

has super-classes

[Abdominal organ finding](#)<sup>c</sup>, [Finding of pelvis](#)<sup>c</sup>

has sub-classes

[Bladder finding](#)<sup>c</sup>

## **Pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000092>

Subdivision of abdomen, which is demarcated from the abdomen proper by the plane of the superior pelvic aperture, and from the perineum by the inferior surface of the pelvic diaphragm; together with the abdomen proper, it constitutes the abdomen. [FMA]

has super-classes

[Abdomen](#)<sup>c</sup>, [Cross-sectional pelvis](#)<sup>c</sup>, [Pelvis and lower extremities](#)<sup>c</sup>, [Structure of pelvic segment of trunk](#)<sup>c</sup>

has sub-classes

[Intra-pelvic structure of true pelvis](#)<sup>c</sup>, [Prostate](#)<sup>c</sup>

## **Pelvis and lower extremities<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000091>

has super-classes

[Lower body part structure](#)<sup>c</sup>

has sub-classes

[Pelvis](#)<sup>c</sup>

## **Pembrolizumab<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036160>

A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

## **percent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000161>

has super-classes

[Unit of measure](#)<sup>c</sup>

## **Performance measure status<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035835>

has super-classes

[Administrative statuses](#)<sup>c</sup>

**Perineal prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020502>

has super-classes

[Open prostatectomy](#)<sup>c</sup>, [Operations by approach](#)<sup>c</sup>

has sub-classes

[Radical Perineal prostatectomy](#)<sup>c</sup>

**Perineural Invasion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033284>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Perineural invasion](#) | [Cancer specimen](#) | [Pathology](#)<sup>c</sup>

**Perineural invasion [Presence] in Cancer specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046111>

has super-classes

[Pathology](#)<sup>c</sup>, [Perineural invasion](#) | [Cancer specimen](#) | [Pathology](#)<sup>c</sup>

**Perineural invasion | Cancer specimen | Pathology<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037435>

has super-classes

[Perineural Invasion](#)<sup>c</sup>

has sub-classes

[Perineural invasion \[Presence\] in Cancer specimen](#)<sup>c</sup>

**Peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004463>

PI-RADS: The peripheral zone covers the outer posterior, lateral, and apex regions of the prostate. It makes up most of the apex of the prostate. [RADLEX]

has super-classes

[Glandular zone of prostate](#)<sup>c</sup>

## **Person<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001042>

has super-classes

[Common Module](#)<sup>c</sup>

has sub-classes

[Person in the healthcare environment](#)<sup>c</sup>

## **Person in the healthcare environment<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001044>

has super-classes

[Person](#)<sup>c</sup>

has sub-classes

[Patient](#)<sup>c</sup>

## **Pertuzumab<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035971>

A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

## **Pharmaceutical / biologic product (product)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035146>

has super-classes

[Medication](#)<sup>c</sup>

## **Pharmacological assessment<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034362>

has super-classes

[Management of drug regimen](#)<sup>c</sup>

has sub-classes

[Medication Review](#)<sup>c</sup>

## **Pharmacotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034200>

has super-classes

[Administration of medication](#)<sup>c</sup>, [Therapeutic procedure](#)<sup>c</sup>

**Philips<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000046>

has super-classes

[Manufacturer](#)<sup>c</sup>

**Physical object<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000004>

has super-classes

[Common Module](#)<sup>c</sup>

has sub-classes

[device](#)<sup>c</sup>

**Picker International<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000059>

has super-classes

[Manufacturer](#)<sup>c</sup>

**Platelets [#/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033432>

has super-classes

[Laboratory test](#)<sup>c</sup>

**pM category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033349>

has super-classes

[M category](#)<sup>c</sup>

has sub-classes

[TNM Path M](#)<sup>c</sup>

**pM0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001845>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

### **pM1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000531>

is equivalent to

[American Joint Committee on Cancer pM1](#) <sup>c</sup>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

### **pM1a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000558>

is equivalent to

[American Joint Committee on Cancer pM1a \(qualifier value\)](#) <sup>c</sup>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

### **pM1b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000586>

is equivalent to

[American Joint Committee on Cancer pM1b \(qualifier value\)](#) <sup>c</sup>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

### **pM1c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000615>

is equivalent to

[American Joint Committee on Cancer pM1c \(qualifier value\)](#) <sup>c</sup>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

### **pM1d<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001250>

has super-classes

[American Joint Committee on Cancer pathological M category allowable value](#) <sup>c</sup>

### **pN category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033368>

has super-classes

[N category](#)<sup>c</sup>

has sub-classes

[TNM Path N](#)<sup>c</sup>

**pN0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000645>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pN1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000676>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pN2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001550>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pN3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001552>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pN3a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001555>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pN3b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001559>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pN3c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001564>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**pNX<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001570>

has super-classes

[American Joint Committee on Cancer pathological N category allowable value](#)<sup>c</sup>

**Positive<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001310>

has super-classes

[General adjectival modifier](#)<sup>c</sup>, [Presence findings](#)<sup>c</sup>

**Positron emission tomography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000037>

A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered. [NCIT]

has super-classes

[Nuclear medicine imaging procedure](#)<sup>c</sup>

**Postmenopausal - Menopause present<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048610>

has super-classes

[Menopause finding](#)<sup>c</sup>

**Potassium [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033509>

has super-classes

[Laboratory test](#)<sup>c</sup>

**PR negative<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049000>

An indication that progesterone receptor (PRG; PR) expression has not been detected in a sample. [NCIT]

has super-classes

[Hormone receptor negative neoplasm](#)<sup>c</sup>

**PR positive<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048841>

An indication that progesterone receptor (PRG; PR) expression has been detected in a sample. [NCIT]

has super-classes

[Hormone receptor positive tumor](#)<sup>c</sup>

**Pregnancy observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045623>

has super-classes

[Observable entity](#)<sup>c</sup>

has sub-classes

[Measure of pregnancy](#)<sup>c</sup>

**Pregnancy, childbirth / puerperium observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1040135>

has super-classes

[Clinical history/examination observable](#)<sup>c</sup>

has sub-classes

[Obstetric history](#)<sup>c</sup>

**Premenopause - Menopause absent<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046580>

has super-classes

[Female genitalia finding](#)<sup>c</sup>, [Menopause finding](#)<sup>c</sup>

**Presence findings<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001072>

has super-classes

[Finding value](#)<sup>c</sup>

has sub-classes

[Positive](#)<sup>c</sup>, [Present](#)<sup>c</sup>, [Yes](#)<sup>c</sup>

**Presence of direct invasion by malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035520>

has super-classes

[Presence of direct invasion by neoplasm<sup>c</sup>](#)

has sub-classes

[Presence of direct invasion by primary malignant neoplasm<sup>c</sup>](#)

**Presence of direct invasion by neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035490>

has super-classes

[Neoplasm observable<sup>c</sup>](#)

has sub-classes

[Presence of direct invasion by malignant neoplasm<sup>c</sup>](#)

**Presence of direct invasion by primary malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035551>

has super-classes

[Presence of direct invasion by malignant neoplasm<sup>c</sup>](#)

has sub-classes

[Presence of direct invasion by primary malignant neoplasm to lymphatic vessel and/or small blood vessel<sup>c</sup>](#)

**Presence of direct invasion by primary malignant neoplasm to lymphatic vessel and/or small blood vessel<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035583>

has super-classes

[Presence of direct invasion by primary malignant neoplasm<sup>c</sup>](#)

**Presence of metastatic discontinuous spread of malignant neoplasm of colon to pericolic tissue<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049097>

has super-classes

[Presence of metastatic discontinuous spread of primary malignant neoplasm<sup>c</sup>](#)

**Presence of metastatic discontinuous spread of primary malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049092>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

has sub-classes

[Presence of metastatic discontinuous spread of malignant neoplasm of colon to pericolic tissue](#)<sup>c</sup>

### **Present<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001942>

has super-classes

[Presence findings](#)<sup>c</sup>

### **Primary<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000017>

Occurring first in time or sequence; original; of greatest rank or importance or value. [NCIT]

has super-classes

[General adjectival modifier](#)<sup>c</sup>

### **Primary adenocarcinoma of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016398>

has super-classes

[Adenocarcinoma of pelvis](#)<sup>c</sup>, [Primary malignant neoplasm of pelvis](#)<sup>c</sup>

has sub-classes

[Adenocarcinoma with neuroendocrine differentiation of prostate gland](#)<sup>c</sup>, [Adenosquamous carcinoma of prostate gland](#)<sup>c</sup>, [Basal cell adenocarcinoma of prostate gland](#)<sup>c</sup>

### **Primary Gleason Pattern 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031198>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 1 tumor](#)<sup>c</sup>

### **Primary Gleason Pattern 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031187>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 2 tumor](#)<sup>c</sup>

### **Primary Gleason Pattern 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031232>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 3 tumor](#)<sup>c</sup>

### **Primary Gleason Pattern 4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031243>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 4 tumor](#)<sup>c</sup>

### **Primary Gleason Pattern 5<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031192>

has super-classes

[Gleason finding](#)<sup>c</sup>

### **Primary malignant adenomatous neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036937>

has super-classes

[Malignant adenomatous neoplasm - category](#)<sup>c</sup>

has sub-classes

[Cholangiocarcinoma](#)<sup>c</sup>

### **Primary malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000143>

A malignant tumor at the original site of growth. [NCIT]

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Adenosquamous cell carcinoma](#)<sup>c</sup>, [Neuroblastoma](#)<sup>c</sup>, [Primary malignant neoplasm of trunk](#)<sup>c</sup>, [Small cell carcinoma](#)<sup>c</sup>

### **Primary malignant neoplasm of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007730>

has super-classes

[Malignant neoplasm of abdomen](#)<sup>c</sup>, [Primary malignant neoplasm of trunk](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>

### **Primary malignant neoplasm of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000068>

has super-classes

[Breast cancer](#)<sup>c</sup>, [Primary malignant neoplasm of trunk](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of breast with axillary lymph node invasion](#)<sup>c</sup>

**Primary malignant neoplasm of breast with axillary lymph node invasion<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046501>

has super-classes

[Primary malignant neoplasm of breast](#)<sup>c</sup>, [Secondary malignant neoplasm of axillary lymph nodes](#)<sup>c</sup>

**Primary malignant neoplasm of colon<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045970>

has super-classes

[Colon cancer](#)<sup>c</sup>, [Primary malignant neoplasm of large intestine](#)<sup>c</sup>

**Primary malignant neoplasm of female breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047300>

has super-classes

[Neoplastic disease](#)<sup>c</sup>

**Primary malignant neoplasm of intestinal tract<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036362>

has super-classes

[Malignant tumor of intestine](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of large intestine](#)<sup>c</sup>

**Primary malignant neoplasm of intra-abdominal organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000168>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>, [Primary malignant neoplasm of abdomen](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of liver](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>

**Primary malignant neoplasm of large intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036373>

has super-classes

[Malignant tumor of large intestine](#)<sup>c</sup>, [Primary malignant neoplasm of intestinal tract](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of colon](#)<sup>c</sup>, [Primary malignant neoplasm of rectum](#)<sup>c</sup>

### **Primary malignant neoplasm of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000072>

An epithelial or non-epithelial malignant neoplasm that arises from the liver. Representative examples include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and sarcoma. [NCIT]

has super-classes

[Liver cancer](#)<sup>c</sup>, [Primary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>

has sub-classes

[Liver cell carcinoma](#)<sup>c</sup>

### **Primary malignant neoplasm of male genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008355>

has super-classes

[Malignant tumor of male genital organ](#)<sup>c</sup>, [Primary malignant neoplasm of trunk](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of prostate](#)<sup>c</sup>

### **Primary malignant neoplasm of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008612>

has super-classes

[Malignant tumor of pelvis](#)<sup>c</sup>, [Primary malignant neoplasm of trunk](#)<sup>c</sup>

has sub-classes

[Primary adenocarcinoma of pelvis](#)<sup>c</sup>, [Primary malignant neoplasm of prostate](#)<sup>c</sup>, [Primary malignant neoplasm of rectum](#)<sup>c</sup>

### **Primary malignant neoplasm of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008742>

has super-classes

[Cancer of prostate](#)<sup>c</sup>, [Primary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>, [Primary malignant neoplasm of male genital organ](#)<sup>c</sup>, [Primary malignant neoplasm of pelvis](#)<sup>c</sup>

has sub-classes

[Acinar cell carcinoma of prostate gland](#)<sup>c</sup>, [Adenocarcinoma with neuroendocrine differentiation of prostate gland](#)<sup>c</sup>, [Adenosquamous carcinoma of prostate gland](#)<sup>c</sup>, [Basal cell adenocarcinoma of prostate gland](#)<sup>c</sup>, [Infiltrating duct carcinoma of prostate](#)<sup>c</sup>, [Large cell neuroendocrine carcinoma of prostate gland](#)<sup>c</sup>,

[Neoplasm, malignant of prostate gland](#)<sup>c</sup>, [Neuroendocrine tumor, NOS, of prostate gland](#)<sup>c</sup>, [Small cell carcinoma of prostate](#)<sup>c</sup>, [Transitional cell carcinoma, NOS, of prostate gland](#)<sup>c</sup>

### **Primary malignant neoplasm of rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045950>

has super-classes

[Primary malignant neoplasm of large intestine](#)<sup>c</sup>, [Primary malignant neoplasm of pelvis](#)<sup>c</sup>, [Rectal cancer](#)<sup>c</sup>

### **Primary malignant neoplasm of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000155>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Neoplasm of trunk](#)<sup>c</sup>, [Primary malignant neoplasm](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of abdomen](#)<sup>c</sup>, [Primary malignant neoplasm of breast](#)<sup>c</sup>, [Primary malignant neoplasm of male genital organ](#)<sup>c</sup>, [Primary malignant neoplasm of pelvis](#)<sup>c</sup>

### **Primary pattern unknown, secondary pattern unknown<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033313>

has super-classes

[NotClassified](#)<sup>c</sup>

### **Primary sclerosing cholangitis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046225>

A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure. [NCIT]

has super-classes

[Sclerosing cholangitis](#)<sup>c</sup>

### **Primary tumor size<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035355>

has super-classes

[Length dimension of neoplasm](#)<sup>c</sup>

### **problematic<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000119>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

has super-classes

[Qualifier for certainty of diagnosis](#)<sup>c</sup>

### **Procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000005>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Administration of medication](#)<sup>c</sup>, [Endoscopic procedure](#)<sup>c</sup>, [Evaluation procedure](#)<sup>c</sup>, [External beam radiation therapy procedure](#)<sup>c</sup>, [Interventional procedure](#)<sup>c</sup>, [Laboratory procedure](#)<sup>c</sup>, [Management of drug regimen](#)<sup>c</sup>, [Procedure on organ](#)<sup>c</sup>, [Radiation Therapy \(Procedure\)](#)<sup>c</sup>, [Regimes and therapies](#)<sup>c</sup>, [Removal](#)<sup>c</sup>, [Surgical procedure](#)<sup>c</sup>, [Therapeutic procedure](#)<sup>c</sup>, [removal technique](#)<sup>c</sup>

### **Procedure carried out on subject<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034124>

has super-classes

[Procedure with explicit context](#)<sup>c</sup>

### **Procedure on abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000233>

has super-classes

[Procedure on organ](#)<sup>c</sup>, [Procedure on trunk](#)<sup>c</sup>

has sub-classes

[Examination of abdomen](#)<sup>c</sup>, [Lower gastrointestinal procedure](#)<sup>c</sup>, [Operation on abdominal region](#)<sup>c</sup>, [Procedure on prostate](#)<sup>c</sup>

### **Procedure on genitourinary system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1011105>

has super-classes

[Procedure on trunk](#)<sup>c</sup>

has sub-classes

[Procedure on male genital system](#)<sup>c</sup>, [Removal of entire genital organ](#)<sup>c</sup>

### **Procedure on large intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1011402>

has super-classes

[Procedure on organ](#)<sup>c</sup>



has sub-classes

[Procedure on rectum](#)<sup>c</sup>

### **Procedure on lymph node<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035083>

has super-classes

[Procedure on lymphoid organ](#)<sup>c</sup>

### **Procedure on lymphoid organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034175>

has super-classes

[Procedure on organ](#)<sup>c</sup>

has sub-classes

[Procedure on lymph node](#)<sup>c</sup>

### **Procedure on male genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1011703>

has super-classes

[Procedure on male genital system](#)<sup>c</sup>, [Procedure on organ](#)<sup>c</sup>

has sub-classes

[Procedure on prostate](#)<sup>c</sup>

### **Procedure on male genital system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1011253>

has super-classes

[Procedure on genitourinary system](#)<sup>c</sup>, [Procedure on pelvic region of trunk](#)<sup>c</sup>

has sub-classes

[Biopsy of male genital system](#)<sup>c</sup>, [Operation on male genital system](#)<sup>c</sup>, [Procedure on male genital organ](#)<sup>c</sup>

### **Procedure on organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000228>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Complete excision](#)<sup>c</sup>, [Procedure on abdomen](#)<sup>c</sup>, [Procedure on large intestine](#)<sup>c</sup>, [Procedure on lymphoid organ](#)<sup>c</sup>, [Procedure on male genital organ](#)<sup>c</sup>, [Procedure on trunk](#)<sup>c</sup>, [Procedures on breast](#)<sup>c</sup>

### **Procedure on pelvic region of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012008>

has super-classes

[Procedure on trunk](#)<sup>c</sup>

has sub-classes

[Procedure on male genital system](#)<sup>c</sup>, [Procedure on pelvis](#)<sup>c</sup>

### **Procedure on pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012162>

has super-classes

[Procedure on pelvic region of trunk](#)<sup>c</sup>

has sub-classes

[Operative procedure on pelvis](#)<sup>c</sup>, [Procedure on prostate](#)<sup>c</sup>, [Procedure on rectum](#)<sup>c</sup>

### **Procedure on prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010958>

has super-classes

[Procedure on abdomen](#)<sup>c</sup>, [Procedure on male genital organ](#)<sup>c</sup>, [Procedure on pelvis](#)<sup>c</sup>

has sub-classes

[Biopsy of prostate](#)<sup>c</sup>, [Operation on prostate](#)<sup>c</sup>

### **Procedure on rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1011552>

has super-classes

[Procedure on large intestine](#)<sup>c</sup>, [Procedure on pelvis](#)<sup>c</sup>

has sub-classes

[Rectal examination](#)<sup>c</sup>

### **Procedure on thorax<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034704>

has super-classes

[Procedure on trunk](#)<sup>c</sup>

has sub-classes

[Procedures on breast](#)<sup>c</sup>

### **Procedure on trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000230>

has super-classes

[Procedure on organ](#)<sup>c</sup>

has sub-classes

[Biopsy of trunk](#)<sup>c</sup>, [Procedure on abdomen](#)<sup>c</sup>, [Procedure on genitourinary system](#)<sup>c</sup>, [Procedure on pelvic region of trunk](#)<sup>c</sup>, [Procedure on thorax](#)<sup>c</sup>

### **Procedure with explicit context<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034119>

has super-classes

[Situation with explicit context](#)<sup>c</sup>

has sub-classes

[Laboratory Procedures](#)<sup>c</sup>, [Procedure carried out on subject](#)<sup>c</sup>, [Treatment changed](#)<sup>c</sup>

### **Procedures on breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034670>

has super-classes

[Procedure on organ](#)<sup>c</sup>, [Procedure on thorax](#)<sup>c</sup>

### **Progesterone receptor Ag [Presence] in Breast cancer specimen by Immune stain<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046085>

has super-classes

[Pathology](#)<sup>c</sup>

### **Progesterone receptor Ag [Presence] in Breast cancer specimen by Immune stain (LOINC, 85339-0),<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047245>

has super-classes

[Measurement](#)<sup>c</sup>

### **Projection radiography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004453>

Examination of any part of the body for diagnostic purposes by means of roentgen rays, recording the image on a sensitized surface (such as photographic film). [MeSH]

has super-classes

[Imaging modality](#)<sup>c</sup>

has sub-classes

[Digital Radiography](#)<sup>c</sup>, [Mammography](#)<sup>c</sup>

### **Prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000088>

A gland in males that surrounds the neck of the bladder and the urethra. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the pubic symphysis, above the deep layer of the triangular ligament, and rests upon the rectum. [MeSH]

has super-classes

[Male genital organ structure](#)<sup>c</sup>, [Pelvis](#)<sup>c</sup>, [Prostate and vas deferens structures](#)<sup>c</sup>, [Prostatic and/or seminal vesicle structures](#)<sup>c</sup>, [Structure of organ within cavity of true pelvis](#)<sup>c</sup>

has sub-classes

[Prostate part](#)<sup>c</sup>

**Prostate and vas deferens structures<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002351>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Prostate](#)<sup>c</sup>

**Prostate cancer risk of recurrence not determined or neither low, intermediate nor high<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1023527>

has super-classes

[Diagnostic/Screening Processes or Results](#)<sup>c</sup>

**Prostate finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007013>

has super-classes

[Finding of abdomen](#)<sup>c</sup>

has sub-classes

[Disorder of prostate](#)<sup>c</sup>

**Prostate mass<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000293>

has super-classes

[Abdominal mass](#)<sup>c</sup>, [Lesion of prostate](#)<sup>c</sup>

has sub-classes

[Neoplasm of prostate](#)<sup>c</sup>

**Prostate part<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004395>

has super-classes

[Prostate](#)<sup>c</sup>

has sub-classes

[Prostatic gland structure](#)<sup>c</sup>, [Region of prostate](#)<sup>c</sup>

## **Prostate specific Ag [Mass/volume] in Serum or Plasma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033410>

A quantitative procedure that measures the concentration (mass/volume) of prostate-specific antigen in a serum or plasma specimen. [NCIT]

has super-classes

[Prostate specific antigen measurement](#)<sup>c</sup>

## **Prostate specific antigen measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000227>

The determination of the prostate specific antigen present in a sample. [NCIT]

has super-classes

[Enzyme measurement](#)<sup>c</sup>, [Tumor marker measurement](#)<sup>c</sup>

has sub-classes

[Free prostate specific antigen level](#)<sup>c</sup>, [Free:total PSA ratio](#)<sup>c</sup>, [Prostate specific Ag \[Mass/volume\] in Serum or Plasma](#)<sup>c</sup>, [Total prostate specific antigen level](#)<sup>c</sup>

## **Prostate specific antigen normal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030225>

has super-classes

[Enzyme level - finding](#)<sup>c</sup>, [Measurement finding within reference range](#)<sup>c</sup>

## **Prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000248>

has super-classes

[Abdomen excision](#)<sup>c</sup>, [Excision of pelvis](#)<sup>c</sup>, [Operation on prostate](#)<sup>c</sup>

has sub-classes

[Laparoscopic prostatectomy](#)<sup>c</sup>, [Open prostatectomy](#)<sup>c</sup>, [Radical prostatectomy](#)<sup>c</sup>, [Retropubic prostatectomy](#)<sup>c</sup>

## **Prostatic and/or seminal vesicle structures<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002286>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Prostate](#)<sup>c</sup>, [Seminal Vesicles](#)<sup>c</sup>

**Prostatic gland structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004398>

has super-classes

[Prostate part](#)<sup>c</sup>

**Protein level - finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005898>

has super-classes

[Finding of substance level](#)<sup>c</sup>

has sub-classes

[Enzyme level - finding](#)<sup>c</sup>

**Protein measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009138>

has super-classes

[Measurement of substance](#)<sup>c</sup>

has sub-classes

[Carcinoembryonic antigen measurement](#)<sup>c</sup>, [Enzyme measurement](#)<sup>c</sup>, [Glycoproteins measurement](#)<sup>c</sup>

**pT category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033391>

has super-classes

[T category](#)<sup>c</sup>

has sub-classes

[TNM Path T](#)<sup>c</sup>

**pT0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000708>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000741>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000775>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT2a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000810>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT2b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000846>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT2c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000883>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000921>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT3a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000960>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT3b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001000>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001041>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT4a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001577>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pT4b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001585>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pTis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001594>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**pTX<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001604>

has super-classes

[American Joint Committee on Cancer pathological T category allowable value](#)<sup>c</sup>

**Pulmonary structure including vessels and lymphoid tissue<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001301>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Lung](#)<sup>c</sup>

**Qualifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000002>

A term that helps define and render a concept unique. [NCIT]

has super-classes

[Common Module](#)<sup>c</sup>

has sub-classes

[Action](#)<sup>c</sup>, [Adjectival modifier](#)<sup>c</sup>, [Bounding box](#)<sup>c</sup>, [Context values](#)<sup>c</sup>, [Contouring](#)<sup>c</sup>, [Disease qualifier](#)<sup>c</sup>, [Finding value](#)<sup>c</sup>, [Known](#)<sup>c</sup>, [Missing Value Reason](#)<sup>c</sup>, [Modifier mainly for procedure](#)<sup>c</sup>, [Perineural Invasion](#)<sup>c</sup>, [Qualifier for certainty of diagnosis](#)<sup>c</sup>, [Ranked categories](#)<sup>c</sup>, [Temporal Qualifier](#)<sup>c</sup>, [Unit of measure](#)<sup>c</sup>

### **Qualifier for certainty of diagnosis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000038>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Suspicious](#)<sup>c</sup>, [problematic](#)<sup>c</sup>

### **Qualitative distribution of primary malignant neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035433>

has super-classes

[Tumor focality](#)<sup>c</sup>

### **Radiation oncology AND/OR radiotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1014933>

has super-classes

[Therapeutic procedure](#)<sup>c</sup>

has sub-classes

[Chemoradiotherapy](#)<sup>c</sup>, [Conformal radiotherapy](#)<sup>c</sup>, [Intensity modulated radiation therapy](#)<sup>c</sup>

### **Radiation Therapy (Procedure)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1012947>

has super-classes

[Procedure](#)<sup>c</sup>, [Therapeutic procedure](#)<sup>c</sup>

has sub-classes

[Radiation Therapy @ Male Reproductive System \(Procedure\)](#)<sup>c</sup>

### **Radiation Therapy @ Male Reproductive System (Procedure)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1013107>

has super-classes

[Radiation Therapy\\_\(Procedure\)](#)<sup>c</sup>

has sub-classes

[Radiation Therapy, Male Reproductive System, Beam Radiation](#)<sup>c</sup>, [Radiation Therapy, Male Reproductive System, Brachytherapy](#)<sup>c</sup>

**Radiation Therapy @ Male Reproductive System @ Beam Radiation @ Prostate Display label: Beam Radiation of Prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

IRI: <https://cancerimage.eu/ontology/EUCAIM#CLIN1033199>

has super-classes

[Radiation Therapy, Male Reproductive System, Beam Radiation](#)<sup>c</sup>

**Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

IRI: <https://cancerimage.eu/ontology/EUCAIM#CLIN1020603>

has super-classes

[Radiation Therapy, Male Reproductive System, Brachytherapy](#)<sup>c</sup>

has sub-classes

[Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate @ High Dose Rate \(HDR\) \(Display label: Brachytherapy of Prostate - High Dose Rate\)](#)<sup>c</sup>, [Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate @ Low Dose Rate \(LDR\) \(Display label: Brachytherapy of Prostate - Low Dose Rate\)](#)<sup>c</sup>

**Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate @ High Dose Rate (HDR) (Display label: Brachytherapy of Prostate - High Dose Rate)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

IRI: <https://cancerimage.eu/ontology/EUCAIM#CLIN1033203>

has super-classes

[Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate](#)<sup>c</sup>

**Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate @ Low Dose Rate (LDR) (Display label: Brachytherapy of Prostate - Low Dose Rate)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

IRI: <https://cancerimage.eu/ontology/EUCAIM#CLIN1033208>

has super-classes

[Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate](#)<sup>c</sup>

**Radiation therapy care<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

IRI: <https://cancerimage.eu/ontology/EUCAIM#CLIN1035110>

has super-classes

[Care regime](#)<sup>c</sup>

## **Radiation Therapy, Male Reproductive System, Beam Radiation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020705>

has super-classes

[Radiation Therapy @ Male Reproductive System \(Procedure\)](#)<sup>c</sup>

has sub-classes

[Radiation Therapy @ Male Reproductive System @ Beam Radiation @ Prostate Display label: Beam Radiation of Prostate](#)<sup>c</sup>

## **Radiation Therapy, Male Reproductive System, Brachytherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1013268>

has super-classes

[Radiation Therapy @ Male Reproductive System \(Procedure\)](#)<sup>c</sup>

has sub-classes

[Radiation Therapy @ Male Reproductive System @ Brachytherapy @ Prostate](#)<sup>c</sup>

## **Radical Perineal prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030358>

has super-classes

[Perineal prostatectomy](#)<sup>c</sup>, [Removal of entire genital organ](#)<sup>c</sup>

## **Radical prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016442>

has super-classes

[Prostatectomy](#)<sup>c</sup>

has sub-classes

[Robot assisted laparoscopic radical prostatectomy](#)<sup>c</sup>

## **Radical Retropubic prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030492>

has super-classes

[Removal of entire genital organ](#)<sup>c</sup>, [Retropubic prostatectomy](#)<sup>c</sup>

## **Radiographic imaging procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016143>

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>

has sub-classes

[X-Ray Computed Tomography](#)<sup>c</sup>

## **Radiographic lesion margin characteristics<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016314>

has super-classes

[Radiologic finding](#)<sup>c</sup>

## **Radiographic lesion shape finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016297>

has super-classes

[Radiologic finding](#)<sup>c</sup>

## **Radiographic procedure of chest<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016136>

has super-classes

[Chest imaging](#)<sup>c</sup>

has sub-classes

[Mammography](#)<sup>c</sup>

## **Radiologic finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034739>

has super-classes

[Imaging finding](#)<sup>c</sup>

has sub-classes

[Finding of change compared to previous radiologic examination](#)<sup>c</sup>, [Finding of change compared to previous radiologic examination finding](#)<sup>c</sup>, [Mammography finding](#)<sup>c</sup>, [Mammography reference location](#)<sup>c</sup>, [Radiographic lesion margin characteristics](#)<sup>c</sup>, [Radiographic lesion shape finding](#)<sup>c</sup>, [Radiology result normal](#)<sup>c</sup>

## **Radiology result normal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016269>

has super-classes

[Imaging result normal](#)<sup>c</sup>, [Radiologic finding](#)<sup>c</sup>

has sub-classes

[Mammography normal](#)<sup>c</sup>

## Ranked categories<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001333>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Degrees of severity](#)<sup>c</sup>, [Grades](#)<sup>c</sup>

## Reason for no specific anti-cancer treatment<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020808>

has super-classes

[Reasons for treatment](#)<sup>c</sup>

has sub-classes

[No anti-cancer treatment - watchful waiting](#)<sup>c</sup>

## Reasons for treatment<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000380>

has super-classes

[Administrative statuses](#)<sup>c</sup>

has sub-classes

[Reason for no specific anti-cancer treatment](#)<sup>c</sup>

## Rectal cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000077>

A malignant epithelial neoplasm that arises from the rectum. The vast majority are adenocarcinomas. [NCIT]

has super-classes

[Malignant neoplasm of anorectum](#)<sup>c</sup>, [Malignant neoplasm of colon and/or rectum](#)<sup>c</sup>, [Malignant tumor of pelvis](#)<sup>c</sup>, [Neoplasm of rectum](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of rectum](#)<sup>c</sup>

## Rectal examination<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1020912>

has super-classes

[Examination of abdomen](#)<sup>c</sup>, [Procedure on rectum](#)<sup>c</sup>

has sub-classes

[Digital examination of rectum](#)<sup>c</sup>

## Rectum<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000116>

The distal segment of the large intestine, between the sigmoid colon and the anal canal. [MeSH]

has super-classes

[Anorectal structure](#)<sup>c</sup>, [Large intestine part](#)<sup>c</sup>, [Lower bowel structures](#)<sup>c</sup>

### **Recurrent tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027442>

has super-classes

[Tumor finding](#)<sup>c</sup>

### **Regimes and therapies<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034280>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Care regime](#)<sup>c</sup>

### **Region of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004454>

has super-classes

[Prostate part](#)<sup>c</sup>

has sub-classes

[Base of prostate](#)<sup>c</sup>, [Glandular zone of prostate](#)<sup>c</sup>, [Middle region of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>, [Structure of apex of prostate](#)<sup>c</sup>, [Structure of left half of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>, [Structure of right half of prostate](#)<sup>c</sup>, [Transition zone of prostate](#)<sup>c</sup>

### **Regional lymph node structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005452>

has super-classes

[Structure of lymph node](#)<sup>c</sup>

has sub-classes

[Lymph node structure of limb](#)<sup>c</sup>

### **Regional lymph nodes examined [#] Specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1045896>

has super-classes

[Measurement](#)<sup>c</sup>

## **Regular frequency<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001342>

has super-classes

[Frequencies](#)<sup>c</sup>

has sub-classes

[Frequency interval](#)<sup>c</sup>

## **Removal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001658>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Biopsy](#)<sup>c</sup>

## **Removal - action<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001057>

has super-classes

[Action](#)<sup>c</sup>

has sub-classes

[Sampling - action \(qualifier value\)](#)<sup>c</sup>

## **Removal of entire genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005177>

has super-classes

[Complete excision](#)<sup>c</sup>, [Procedure on genitourinary system](#)<sup>c</sup>, [Trunk excision](#)<sup>c</sup>

has sub-classes

[Radical Perineal prostatectomy](#)<sup>c</sup>, [Radical Retropubic prostatectomy](#)<sup>c</sup>

## **removal technique<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034137>

has super-classes

[Procedure](#)<sup>c</sup>

## **Residual cancer burden class<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035685>

has super-classes

[Interpretation of findings](#)<sup>c</sup>

## **ResourceType-FHIR<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000002>

has super-classes

[Correspondence Module](#)<sup>c</sup>

has sub-classes

[ResourceType: Condition](#)<sup>c</sup>, [ResourceType: Diagnostic Report](#)<sup>c</sup>, [ResourceType: Medication Administration](#)<sup>c</sup>, [ResourceType: Observation](#)<sup>c</sup>

## **ResourceType: Condition<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000028>

has super-classes

[ResourceType-FHIR](#)<sup>c</sup>

## **ResourceType: Diagnostic Report<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000032>

has super-classes

[ResourceType-FHIR](#)<sup>c</sup>

## **ResourceType: Medication Administration<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000023>

has super-classes

[ResourceType-FHIR](#)<sup>c</sup>

## **ResourceType: Observation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COR1000025>

has super-classes

[ResourceType-FHIR](#)<sup>c</sup>

## **Retroperitoneal compartment structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000272>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Adrenal gland](#)<sup>c</sup>, [Kidney](#)<sup>c</sup>, [Pancreas](#)<sup>c</sup>

## **Retropubic prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**



**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016487>

has super-classes

[Operations by approach](#)<sup>c</sup>, [Prostatectomy](#)<sup>c</sup>

has sub-classes

[Radical Retropubic prostatectomy](#)<sup>c</sup>

## **Ribociclib<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036300>

An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

## **Right anterior apical part of transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004747>

has super-classes

[Right apical transition zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

## **Right anterior apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004770>

The region of the prostate that is located on the anatomical right side of the anterior portion of the apical division of the peripheral zone. [NCIT]

has super-classes

[Right apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

## **Right anterior basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004794>

The region of the prostate that is located on the anatomical right side of the anterior portion of the basal division of the peripheral zone. [NCIT]

has super-classes

[Right basal peripheral zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

## **Right anterior basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004819>

The region of the prostate that is located on the anatomical right side of the anterior portion of the basal division of the transition zone. [NCIT]

has super-classes

[Right basal transition zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Right anterior middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004845>

The region of the prostate that is located on the anatomical right side of the anterior portion of the middle division of the peripheral zone. [NCIT]

has super-classes

[Right lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Right anterior middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004872>

The region of the prostate that is located on the anatomical right side of the anterior portion of the middle division of the transition zone. [NCIT]

has super-classes

[Right middle transition zone of prostate](#)<sup>c</sup>, [Structure of anterior section of prostate](#)<sup>c</sup>

### **Right apical anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004929>

The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the apical division of the anterior lobe. [NCIT]

has super-classes

[Apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Structure of right half of prostate](#)<sup>c</sup>

### **Right apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005316>

has super-classes

[Apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of right half of prostate](#)<sup>c</sup>

has sub-classes

[Right anterior apical peripheral zone of prostate](#)<sup>c</sup>, [Right posterolateral apical peripheral zone of prostate](#)<sup>c</sup>,  
[Right posteromedial apical peripheral zone of prostate](#)<sup>c</sup>

### **Right apical transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005430>

has super-classes

[Apical transition zone of prostate](#) <sup>c</sup>, [Structure of right half of prostate](#) <sup>c</sup>

has sub-classes

[Right anterior apical part of transition zone of prostate](#) <sup>c</sup>, [Right posterior apical part of transition zone of prostate](#) <sup>c</sup>

### **Right basal anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004959>

The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the basal division of the anterior lobe. [NCIT]

has super-classes

[Basal anterior fibromuscular stroma of prostate](#) <sup>c</sup>, [Structure of right half of prostate](#) <sup>c</sup>

### **Right basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005365>

has super-classes

[Basal peripheral zone of prostate](#) <sup>c</sup>, [Structure of right half of prostate](#) <sup>c</sup>

has sub-classes

[Right anterior basal peripheral zone of prostate](#) <sup>c</sup>, [Right posterolateral basal peripheral zone of prostate](#) <sup>c</sup>

### **Right basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005313>

has super-classes

[Basal transition zone of prostate](#) <sup>c</sup>, [Structure of right half of prostate](#) <sup>c</sup>

has sub-classes

[Right anterior basal transition zone of prostate](#) <sup>c</sup>, [Right posterior basal transition zone of prostate](#) <sup>c</sup>

### **Right breast structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016579>

has super-classes

[Breast](#) <sup>c</sup>, [Right thorax structure](#) <sup>c</sup>

### **Right lateral middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005388>

has super-classes

[Middle peripheral zone of prostate](#) <sup>c</sup>, [Structure of right half of prostate](#) <sup>c</sup>

has sub-classes

[Right anterior middle peripheral zone of prostate](#) <sup>c</sup>, [Right posterolateral middle peripheral zone of prostate](#) <sup>c</sup>, [Right posteromedial middle peripheral zone of prostate](#) <sup>c</sup>

## **Right middle anterior fibromuscular stroma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004990>

The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the middle division of the anterior lobe. [NCIT]

has super-classes

[Middle anterior fibromuscular stroma of prostate<sup>c</sup>](#), [Structure of right half of prostate<sup>c</sup>](#)

## **Right middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005355>

has super-classes

[Middle transition zone of prostate<sup>c</sup>](#), [Structure of right half of prostate<sup>c</sup>](#)

has sub-classes

[Right anterior middle transition zone of prostate<sup>c</sup>](#), [Right posterior middle transition zone of prostate<sup>c</sup>](#)

## **Right position<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016682>

has super-classes

[Laterality<sup>c</sup>](#)

## **Right posterior apical part of transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005022>

has super-classes

[Right apical transition zone of prostate<sup>c</sup>](#), [Structure of posterior section of prostate<sup>c</sup>](#)

## **Right posterior basal transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005055>

The region of the prostate that is located on the anatomical right side of the posterior portion of the basal division of the transition zone. [NCIT]

has super-classes

[Right basal transition zone of prostate<sup>c</sup>](#), [Structure of posterior section of prostate<sup>c</sup>](#)

## **Right posterior middle transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005089>

The region of the prostate that is located on the anatomical right side of the posterior portion of the middle division of the transition zone. [NCIT]

has super-classes

[Right middle transition zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Right posterolateral apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005124>

The region of the prostate that is located on the anatomical right side of the posterolateral portion of the apical division of the peripheral zone. [NCIT]

has super-classes

[Right apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Right posterolateral basal peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005160>

The region of the prostate that is located on the anatomical right side of the posterolateral portion of the basal division of the peripheral zone. [NCIT]

has super-classes

[Right basal peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Right posterolateral middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005197>

The region of the prostate that is located on the anatomical right side of the posterolateral portion of the middle division of the peripheral zone. [NCIT]

has super-classes

[Right lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Right posteromedial apical peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005235>

The region of the prostate that is located on the anatomical right side of the posteromedial portion of the apical division of the peripheral zone. [NCIT]

has super-classes

[Right apical peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Right posteromedial middle peripheral zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005274>

The region of the prostate that is located on the anatomical right side of the posteromedial portion of the middle division of the peripheral zone. [NCIT]

has super-classes

[Right lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Structure of posterior section of prostate](#)<sup>c</sup>

### **Right thorax structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016546>

has super-classes

[Structure of half of thorax lateral to midsagittal plane](#)<sup>c</sup>

has sub-classes

[Right breast structure](#)<sup>c</sup>

### **Robot assisted laparoscopic radical prostatectomy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030763>

has super-classes

[Laparoscopic procedure](#)<sup>c</sup>, [Radical prostatectomy](#)<sup>c</sup>, [Robotic assisted surgery](#)<sup>c</sup>

### **Robotic assisted surgery<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021017>

has super-classes

[Endoscopic operation](#)<sup>c</sup>

has sub-classes

[Robot assisted laparoscopic radical prostatectomy](#)<sup>c</sup>

### **Sacituzumab govitecan<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035940>

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Sacrum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000127>

The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx. [NCIT]

has super-classes

[Lumbosacral region of spine structure](#)<sup>c</sup>, [Musculoskeletal structure of sacral spine](#)<sup>c</sup>, [Spine](#)<sup>c</sup>, [Structure of posterior arch of pelvic ring](#)<sup>c</sup>

### **Sampling - action (qualifier value)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001269>

has super-classes

[Removal - action](#)<sup>c</sup>

### **Sarcoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041458>

has super-classes

[Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Angiosarcoma](#)<sup>c</sup>, [Sarcoma of liver](#)<sup>c</sup>

### **Sarcoma of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036772>

has super-classes

[Liver cancer](#)<sup>c</sup>, [Sarcoma](#)<sup>c</sup>

has sub-classes

[Angiosarcoma of liver](#)<sup>c</sup>

### **Scalp and/or neck structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001644>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Neck](#)<sup>c</sup>

### **Sclerosing cholangitis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039008>

has super-classes

[Cholangitis](#)<sup>c</sup>

has sub-classes

[Primary sclerosing cholangitis](#)<sup>c</sup>

### **Screening for cancer<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016178>

has super-classes

[Screening for neoplasm](#)<sup>c</sup>

has sub-classes

[Screening for malignant neoplasm of breast](#)<sup>c</sup>

### **Screening for disorder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016161>

has super-classes

[Screening procedure](#)<sup>c</sup>

has sub-classes

[Screening for neoplasm](#)<sup>c</sup>

## **Screening for malignant neoplasm of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016188>

has super-classes

[Screening for cancer](#)<sup>c</sup>

has sub-classes

[MRI of breast for screening for malignant neoplasm](#)<sup>c</sup>, [Magnetic resonance imaging of breast for screening for malignant neoplasm procedure](#)<sup>c</sup>

## **Screening for neoplasm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016169>

has super-classes

[Screening for disorder](#)<sup>c</sup>

has sub-classes

[Screening for cancer](#)<sup>c</sup>

## **Screening procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016154>

has super-classes

[Imaging Module](#)<sup>c</sup>

has sub-classes

[MRI of breast for screening](#)<sup>c</sup>, [Screening for disorder](#)<sup>c</sup>

## **Second degree<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001381>

has super-classes

[Degrees of severity](#)<sup>c</sup>

## **Secondary Gleason Pattern 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031205>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 1 tumor](#)<sup>c</sup>



## **Secondary Gleason Pattern 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031213>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 2 tumor](#)<sup>c</sup>

## **Secondary Gleason Pattern 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031180>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 3 tumor](#)<sup>c</sup>

## **Secondary Gleason Pattern 4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031255>

has super-classes

[Gleason finding](#)<sup>c</sup>, [Grade 4 tumor](#)<sup>c</sup>

## **Secondary Gleason Pattern 5<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031183>

has super-classes

[Gleason finding](#)<sup>c</sup>

## **Secondary malignant neoplasm of axilla<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037738>

has super-classes

[Malignant tumor of axilla](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of axillary lymph nodes](#)<sup>c</sup>

## **Secondary malignant neoplasm of axillary lymph nodes<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1037792>

has super-classes

[Neoplasm of axillary lymph nodes](#)<sup>c</sup>, [Secondary malignant neoplasm of axilla](#)<sup>c</sup>

has sub-classes

[Primary malignant neoplasm of breast with axillary lymph node invasion](#)<sup>c</sup>

## **Secondary malignant neoplasm of intra-abdominal organs<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000199>

has super-classes

[Diagnosis](#)<sup>c</sup>, [Malignant neoplasm of intraabdominal organ](#)<sup>c</sup>, [Secondary malignant neoplasm of trunk](#)<sup>c</sup>,  
[Secondary malignant neoplasm of viscera](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of liver](#)<sup>c</sup>

## **Secondary malignant neoplasm of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000192>

has super-classes

[Liver cancer](#)<sup>c</sup>, [Metastasis to digestive organ](#)<sup>c</sup>, [Metastasis to digestive organs](#)<sup>c</sup>, [Secondary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>

## **Secondary malignant neoplasm of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039628>

has super-classes

[Secondary malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>

## **Secondary malignant neoplasm of viscera<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1041663>

has super-classes

[Secondary malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Secondary malignant neoplasm of intra-abdominal organs](#)<sup>c</sup>

## **Secondary malignant neoplastic disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038722>

has super-classes

[Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Metastasis to digestive organs](#)<sup>c</sup>, [Secondary malignant neoplasm of trunk](#)<sup>c</sup>, [Secondary malignant neoplasm of viscera](#)<sup>c</sup>

## **Semiautomatic<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000005>

Values for segmentation method (ProCancer-I, Prostate gland segmentation UC)

Of or related to a process performed using a combination of manual and automatic means. [NCIT]

has super-classes

[Modifier mainly for procedure](#) <sup>c</sup>

## **Seminal Vesicles<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004466>

A saclike, glandular diverticulum on each ductus deferens in male vertebrates. It is united with the excretory duct and serves for temporary storage of semen. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) [MeSH] PI-RADS: One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus (vas) deferens to form the ejaculatory duct at the base of the prostate. [RADLEX]

has super-classes

[Prostatic and/or seminal vesicle structures](#) <sup>c</sup>

## **Serum testosterone measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027552>

has super-classes

[Measurement of level of drug in blood](#) <sup>c</sup>, [Measurement of level of substance in blood](#) <sup>c</sup>, [Testosterone measurement](#) <sup>c</sup>

## **Sex assigned at birth<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001396>

has super-classes

[Common Module](#) <sup>c</sup>

## **Sexual function<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1043810>

has super-classes

[Function](#) <sup>c</sup>

has sub-classes

[Female genital tract functions](#) <sup>c</sup>

## **Shimadzu<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000054>

has super-classes

[Manufacturer](#) <sup>c</sup>

## **Shoulder<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000134>

The body part defined by the shoulder joint and its surrounding structures

has super-classes

[Structure of joint region](#)<sup>c</sup>, [Structure of shoulder and/or upper arm](#)<sup>c</sup>, [Structure of shoulder girdle region](#)<sup>c</sup>

### **Siemens<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000044>

has super-classes

[Manufacturer](#)<sup>c</sup>

### **Situation with explicit context<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1013430>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Family history with explicit context](#)<sup>c</sup>, [Finding with explicit context](#)<sup>c</sup>, [Procedure with explicit context](#)<sup>c</sup>

### **Skull<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000126>

The bones that form the head, made up of the bones of the braincase and face. [NCIT]

has super-classes

[Bone and/or joint structure of cranium](#)<sup>c</sup>, [Bone structure of head](#)<sup>c</sup>

### **Skull foramen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001806>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Optic canal](#)<sup>c</sup>

### **Small cell carcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1007608>

has super-classes

[Malignant epithelial neoplasm](#)<sup>c</sup>, [Primary malignant neoplasm](#)<sup>c</sup>

has sub-classes

[Small cell carcinoma of prostate](#)<sup>c</sup>

## **Small cell carcinoma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016533>

has super-classes

[Primary malignant neoplasm of prostate<sup>c</sup>](#), [Small cell carcinoma<sup>c</sup>](#)

has sub-classes

[Small cell carcinoma, NOS, of prostate gland<sup>c</sup>](#)

## **Small cell carcinoma, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1024075>

has super-classes

[Small cell carcinoma of prostate<sup>c</sup>](#)

## **Small intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000138>

Organ with organ cavity which is continuous proximally with the stomach and distally with the large intestine.  
[FMA]

has super-classes

[Intestinal structure<sup>c</sup>](#)

## **Sodium [Moles/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033524>

has super-classes

[Laboratory test<sup>c</sup>](#)

## **Specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002057>

has super-classes

[Clinical Module<sup>c</sup>](#)

has sub-classes

[Body substance sample<sup>c</sup>](#), [Genitourinary sample<sup>c</sup>](#)

## **Specimen from genital system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1006555>

has super-classes

[Genitourinary sample<sup>c</sup>](#)

has sub-classes

[Male genital sample](#)<sup>c</sup>, [Tissue specimen from genital system](#)<sup>c</sup>

### **Specimen from prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021123>

has super-classes

[Male genital sample](#)<sup>c</sup>

has sub-classes

[Tissue specimen from prostate](#)<sup>c</sup>

### **Spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000114>

A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord. [NCIT]

has super-classes

[Axial skeleton structure](#)<sup>c</sup>, [Musculoskeletal structure of spine](#)<sup>c</sup>, [Structure of vertebral column and/or spinal cord](#)<sup>c</sup>

has sub-classes

[Cervical spine](#)<sup>c</sup>, [Lumbar spine](#)<sup>c</sup>, [Sacrum](#)<sup>c</sup>, [Thoracic spine](#)<sup>c</sup>

### **Squamous cell carcinoma<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008228>

has super-classes

[Malignant neoplastic disease](#)<sup>c</sup>

has sub-classes

[Adenosquamous cell carcinoma](#)<sup>c</sup>, [Squamous cell carcinoma of male genital](#)<sup>c</sup>

### **Squamous cell carcinoma of male genital<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1008483>

has super-classes

[Malignant tumor of male genital organ](#)<sup>c</sup>, [Squamous cell carcinoma](#)<sup>c</sup>

has sub-classes

[Squamous cell carcinoma of prostate](#)<sup>c</sup>

### **Squamous cell carcinoma of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016580>

has super-classes

[Cancer of prostate](#)<sup>c</sup>, [Squamous cell carcinoma of male genital](#)<sup>c</sup>

has sub-classes

[Adenosquamous carcinoma of prostate gland](#)<sup>c</sup>

**Squamous cell carcinoma, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033298>

has super-classes

[Diagnosis](#)<sup>c</sup>

**Staging and scales<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036343>

has super-classes

[Clinical Module](#)<sup>c</sup>

has sub-classes

[Assessment scales](#)<sup>c</sup>, [Cancer Grade](#)<sup>c</sup>, [Tumor staging](#)<sup>c</sup>

**Staining method<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035160>

has super-classes

[Laboratory procedure categorized by method](#)<sup>c</sup>

**Start time<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000122>

has super-classes

[Time patterns](#)<sup>c</sup>

**Status of regression of tumor<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035650>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

**steatosis of liver<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1047356>

has super-classes

[Degenerative disorder](#)<sup>c</sup>, [Disease of liver](#)<sup>c</sup>

has sub-classes

[Non-alcoholic fatty liver disease](#)<sup>c</sup>

## **Stereotactic radiation therapy using megavoltage radiation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021230>

has super-classes

[Stereotactic radiotherapy<sup>c</sup>](#)

has sub-classes

[Hypofractionated stereotactic radiotherapy using megavoltage radiation<sup>c</sup>](#)

## **Stereotactic radiotherapy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005378>

has super-classes

[External beam radiation therapy procedure<sup>c</sup>](#)

has sub-classes

[Stereotactic radiation therapy using megavoltage radiation<sup>c</sup>](#)

## **Steroid measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1009272>

has super-classes

[Measurement of substance<sup>c</sup>](#)

has sub-classes

[Cholesterol measurement<sup>c</sup>](#), [Testosterone measurement<sup>c</sup>](#)

## **Stop time<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000125>

has super-classes

[Time patterns<sup>c</sup>](#)

## **Structure of abdomen proper<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016520>

has super-classes

[Abdomen<sup>c</sup>](#)

has sub-classes

[Structure of organ within abdomen proper cavity<sup>c</sup>](#)

## **Structure of abdominopelvic organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016452>

has super-classes

[Body organ structure<sup>c</sup>](#)



has sub-classes

[Structure of abdominopelvic viscus](#)<sup>c</sup>

## **Structure of abdominopelvic viscus<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016538>

has super-classes

[Structure of abdominopelvic organ](#)<sup>c</sup>, [Structure of subdivision of abdominopelvic compartment](#)<sup>c</sup>, [Structure of viscus](#)<sup>c</sup>

has sub-classes

[Structure of organ within abdomen proper cavity](#)<sup>c</sup>

## **Structure of ankle and/or foot<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000591>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Foot](#)<sup>c</sup>

## **Structure of anterior section of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004500>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Left anterior apical part of transition zone of prostate](#)<sup>c</sup>, [Left anterior apical peripheral zone of prostate](#)<sup>c</sup>, [Left anterior basal peripheral zone of prostate](#)<sup>c</sup>, [Left anterior basal transition zone of prostate](#)<sup>c</sup>, [Left anterior middle peripheral zone of prostate](#)<sup>c</sup>, [Left anterior middle transition zone of prostate](#)<sup>c</sup>, [Right anterior apical part of transition zone of prostate](#)<sup>c</sup>, [Right anterior apical peripheral zone of prostate](#)<sup>c</sup>, [Right anterior basal peripheral zone of prostate](#)<sup>c</sup>, [Right anterior basal transition zone of prostate](#)<sup>c</sup>, [Right anterior middle peripheral zone of prostate](#)<sup>c</sup>, [Right anterior middle transition zone of prostate](#)<sup>c</sup>

## **Structure of apex of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005284>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Apical peripheral zone of prostate](#)<sup>c</sup>, [Apical transition zone of prostate](#)<sup>c</sup>

## **Structure of body conduit<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001751>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Optic canal](#)<sup>c</sup>

**Structure of breast and/or endocrine system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000437>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Breast](#)<sup>c</sup>

**Structure of compartment of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016440>

has super-classes

[Abdomen](#)<sup>c</sup>

has sub-classes

[Intra-abdominal digestive structure](#)<sup>c</sup>, [Structure of subdivision of abdominopelvic compartment](#)<sup>c</sup>

**Structure of endocrine system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001862>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Pancreas](#)<sup>c</sup>

**Structure of female genital system in pelvic cavity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004034>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Uterus](#)<sup>c</sup>

**Structure of female internal genital organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004301>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Uterus](#)<sup>c</sup>

### **Structure of femur<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004422>

has super-classes

[Structure of long bone of lower limb](#)<sup>c</sup>

has sub-classes

[Bone structure of femur](#)<sup>c</sup>

### **Structure of free lower limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001007>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Knee](#)<sup>c</sup>

### **Structure of free upper limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003861>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Arm](#)<sup>c</sup>

### **Structure of genitourinary system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003947>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Urinary tract](#)<sup>c</sup>

### **Structure of great blood vessel (organ)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000294>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Aorta](#)<sup>c</sup>

### **Structure of half of body lateral to midsagittal plane<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001086>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Extremity](#)<sup>c</sup>, [Structure of half of trunk lateral to midsagittal plane](#)<sup>c</sup>, [Structure of left half of body](#)<sup>c</sup>

### **Structure of half of thorax lateral to midsagittal plane<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000386>

has super-classes

[Body part](#)<sup>c</sup>, [Chest](#)<sup>c</sup>, [Structure of half of trunk lateral to midsagittal plane](#)<sup>c</sup>

has sub-classes

[Breast](#)<sup>c</sup>, [Left thorax structure](#)<sup>c</sup>, [Right thorax structure](#)<sup>c</sup>

### **Structure of half of trunk lateral to midsagittal plane<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016465>

has super-classes

[Structure of half of body lateral to midsagittal plane](#)<sup>c</sup>, [Trunk structure](#)<sup>c</sup>

has sub-classes

[Structure of half of thorax lateral to midsagittal plane](#)<sup>c</sup>

### **Structure of joint region<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002762>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Shoulder](#)<sup>c</sup>

### **Structure of joint region of lower limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000969>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Knee](#)<sup>c</sup>

### **Structure of large artery<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000311>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Aorta](#)<sup>c</sup>

## **Structure of large intestine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016516>

has super-classes

[Intestinal structure](#)<sup>c</sup>

has sub-classes

[Large intestine part](#)<sup>c</sup>, [Lower bowel structures](#)<sup>c</sup>

## **Structure of lateral half of abdomen lateral to midsagittal plane<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000281>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Adrenal gland](#)<sup>c</sup>

## **Structure of left half of body<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016510>

has super-classes

[Structure of half of body lateral to midsagittal plane](#)<sup>c</sup>

## **Structure of left half of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004549>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Left apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Left apical peripheral zone of prostate](#)<sup>c</sup>, [Left apical transition zone of prostate](#)<sup>c</sup>, [Left basal anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Left basal peripheral zone of prostate](#)<sup>c</sup>, [Left basal transition zone of prostate](#)<sup>c</sup>, [Left lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Left middle anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Left middle transition zone of prostate](#)<sup>c</sup>

## **Structure of lesser wing of sphenoid bone<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001697>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Optic canal](#)<sup>c</sup>

## **Structure of long bone of lower limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004417>

has super-classes

[Extremity](#)<sup>c</sup>

has sub-classes

[Structure of femur](#)<sup>c</sup>

## **Structure of lung and/or mediastinum<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001491>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Mediastinum](#)<sup>c</sup>

## **Structure of lymph node<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005449>

A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection. [NCIT]

has super-classes

[Structure of lymphatic system](#)<sup>c</sup>

has sub-classes

[Regional lymph node structure](#)<sup>c</sup>

## **Structure of lymphatic system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005447>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Structure of lymph node](#)<sup>c</sup>

## **Structure of lymphatic system of axilla<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004481>

has super-classes

[Structure of lymphatic system of upper limb](#)<sup>c</sup>

has sub-classes

[Axillary lymph node](#)<sup>c</sup>

## **Structure of lymphatic system of upper limb<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004476>

has super-classes

[Upper extremity part](#)<sup>c</sup>

has sub-classes

[Structure of lymphatic system of axilla](#)<sup>c</sup>

## **Structure of mammary region<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000456>

has super-classes

[Body part](#)<sup>c</sup>, [Chest](#)<sup>c</sup>

has sub-classes

[Breast](#)<sup>c</sup>

## **Structure of musculoskeletal system of cervical spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002834>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Cervical spine](#)<sup>c</sup>

## **Structure of musculoskeletal system of lumbar spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001256>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Lumbar spine](#)<sup>c</sup>

## **Structure of musculoskeletal system of thoracic spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003692>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Thoracic spine](#)<sup>c</sup>

## **Structure of orbital region<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004443>

has super-classes

[Eye region structure](#)<sup>c</sup>

has sub-classes

[Orbit structure](#)<sup>c</sup>

## **Structure of organ in respiratory system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001442>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Lung](#)<sup>c</sup>

## **Structure of organ within abdomen proper cavity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000287>

has super-classes

[Body part](#)<sup>c</sup>, [Cross-sectional abdomen](#)<sup>c</sup>, [Intra-abdominal proper structure](#)<sup>c</sup>, [Organ within abdominopelvic cavity](#)<sup>c</sup>, [Structure of abdomen proper](#)<sup>c</sup>, [Structure of abdominopelvic viscus](#)<sup>c</sup>

has sub-classes

[Adrenal gland](#)<sup>c</sup>, [Gallbladder](#)<sup>c</sup>, [Kidney](#)<sup>c</sup>, [Liver](#)<sup>c</sup>, [Pancreas](#)<sup>c</sup>

## **Structure of organ within cavity of true pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002222>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Prostate](#)<sup>c</sup>, [Uterus](#)<sup>c</sup>

## **Structure of pelvic segment of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002097>

This segment relates to the volume of the trunk that is bounded superiorly by and includes: superiorly the boundary of the false pelvis, which is an artificial plane from the symphysis pubis to the superior iliac crests (in front it is incomplete, presenting a wide interval between the anterior borders of the ilia); and inferiorly the perineum and external genitalia. The volume includes the entire transverse thickness of the body over the longitudinal extent between these upper (superior) and lower (inferior) boundaries including the overlying muscles, skin and subcutaneous tissue. The segment includes the volume of the true and false pelvic cavities including the bony pelvis and pelvic wall and the entire perineum and external genitalia. Note, the entire bony pelvis is included within the pelvic segment (but is excluded from the abdomen proper segment of trunk); however the pelvic segment of trunk and the abdomen proper segment of trunk both include the volume of the false pelvis. [SNOMEDCT]

has super-classes

[Abdominopelvic segment of trunk](#)<sup>c</sup>, [Body part](#)<sup>c</sup>



has sub-classes

[Anorectal structure](#)<sup>c</sup>, [Pelvis](#)<sup>c</sup>

## Structure of pelvic viscus<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004211>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Uterus](#)<sup>c</sup>

## Structure of peripheral auditory system<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000497>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Ear](#)<sup>c</sup>

## Structure of posterior arch of pelvic ring<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003209>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Sacrum](#)<sup>c</sup>

## Structure of posterior section of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004585>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Left posterior apical part of transition zone of prostate](#)<sup>c</sup>, [Left posterior basal transition zone of prostate](#)<sup>c</sup>, [Left posterior middle transition zone of prostate](#)<sup>c</sup>, [Left posterolateral apical peripheral zone of prostate](#)<sup>c</sup>, [Left posterolateral basal peripheral zone of prostate](#)<sup>c</sup>, [Left posterolateral middle peripheral zone of prostate](#)<sup>c</sup>, [Left posteromedial apical peripheral zone of prostate](#)<sup>c</sup>, [Left posteromedial middle peripheral zone of prostate](#)<sup>c</sup>, [Right posterior apical part of transition zone of prostate](#)<sup>c</sup>, [Right posterior basal transition zone of prostate](#)<sup>c</sup>, [Right posterior middle transition zone of prostate](#)<sup>c</sup>, [Right posterolateral apical peripheral zone of prostate](#)<sup>c</sup>, [Right posterolateral basal peripheral zone of prostate](#)<sup>c</sup>, [Right posterolateral middle peripheral zone of prostate](#)<sup>c</sup>, [Right posteromedial apical peripheral zone of prostate](#)<sup>c</sup>, [Right posteromedial middle peripheral zone of prostate](#)<sup>c</sup>

## Structure of pulmopleural compartment<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001347>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Lung](#)<sup>c</sup>

### **Structure of right half of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004900>

has super-classes

[Region of prostate](#)<sup>c</sup>

has sub-classes

[Right apical anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Right apical peripheral zone of prostate](#)<sup>c</sup>, [Right apical transition zone of prostate](#)<sup>c</sup>, [Right basal anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Right basal peripheral zone of prostate](#)<sup>c</sup>, [Right basal transition zone of prostate](#)<sup>c</sup>, [Right lateral middle peripheral zone of prostate](#)<sup>c</sup>, [Right middle anterior fibromuscular stroma of prostate](#)<sup>c</sup>, [Right middle transition zone of prostate](#)<sup>c</sup>

### **Structure of shoulder and/or upper arm<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002621>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Arm](#)<sup>c</sup>, [Shoulder](#)<sup>c</sup>

### **Structure of shoulder girdle region<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002691>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Shoulder](#)<sup>c</sup>

### **Structure of spheroidal joint<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000794>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Hip joint](#)<sup>c</sup>

### **Structure of subdivision of abdominopelvic compartment<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016494>

has super-classes

[Structure of compartment of abdomen](#) <sup>c</sup>

has sub-classes

[Structure of abdominopelvic viscus](#) <sup>c</sup>

### **Structure of subregion of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016380>

has super-classes

[Trunk structure](#) <sup>c</sup>

has sub-classes

[Abdominopelvic cross-sectional segment](#) <sup>c</sup>, [Abdominopelvic segment of trunk](#) <sup>c</sup>

### **Structure of thoracic cavity and/or content<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001541>

has super-classes

[Body part](#) <sup>c</sup>

has sub-classes

[Mediastinum](#) <sup>c</sup>

### **Structure of thoracic viscus<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000672>

has super-classes

[Body part](#) <sup>c</sup>

has sub-classes

[Heart](#) <sup>c</sup>, [Lung](#) <sup>c</sup>

### **Structure of upper urinary system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000896>

has super-classes

[Body part](#) <sup>c</sup>

has sub-classes

[Kidney](#) <sup>c</sup>

### **Structure of urinary organ<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000932>

has super-classes

[Body part](#) <sup>c</sup>

has sub-classes

[Kidney](#)<sup>c</sup>

## **Structure of vertebral column and/or spinal cord<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003527>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Spine](#)<sup>c</sup>

## **Structure of vertebral region of cervical part of back<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002907>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Cervical spine](#)<sup>c</sup>

## **Structure of vertebral region of lumbar part of back<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1001212>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Lumbar spine](#)<sup>c</sup>

## **Structure of vertebral region of thoracic part of back<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003609>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Thoracic spine](#)<sup>c</sup>

## **Structure of viscus<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016410>

has super-classes

[Body organ structure](#)<sup>c</sup>

has sub-classes

[Organ within abdominopelvic cavity](#)<sup>c</sup>, [Structure of abdominopelvic viscus](#)<sup>c</sup>

## **Subdivision of intra-abdominopelvic structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016419>

has super-classes

[Intra-abdominopelvic structure](#)<sup>c</sup>

has sub-classes

[Intra-abdominal proper structure](#)<sup>c</sup>, [Intra-pelvic structure of true pelvis](#)<sup>c</sup>

### **Surgical clip<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000078>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)

A type of surgical staple designed to close wounds and control bleeding from blood vessels. [NCIT]

has super-classes

[Clip](#)<sup>c</sup>

### **Surgical procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004413>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Destructive procedure](#)<sup>c</sup>, [Endoscopic operation](#)<sup>c</sup>, [Operations by approach](#)<sup>c</sup>, [Surgical Procedures on the Male Genital System](#)<sup>c</sup>, [Surgical removal](#)<sup>c</sup>

### **Surgical Procedures on the Male Genital System<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1014423>

has super-classes

[Surgical procedure](#)<sup>c</sup>

has sub-classes

[Surgical Procedures on the Prostate](#)<sup>c</sup>

### **Surgical Procedures on the Prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1014592>

has super-classes

[Surgical Procedures on the Male Genital System](#)<sup>c</sup>

has sub-classes

[Laparoscopic Procedures on the Prostate](#)<sup>c</sup>

### **Surgical removal<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004505>

has super-classes

[Surgical procedure](#)<sup>c</sup>

has sub-classes

[Excision](#)<sup>c</sup>

**Survival time<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049082>

has super-classes

[Clinical history/examination observable](#)<sup>c</sup>

**Surviving free of recurrence of neoplastic disease<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1048175>

has super-classes

[General body state finding](#)<sup>c</sup>

**Suspicious<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000068>

Image annotation label (INCISIVE, Annotation Definitions and guidelines)  
Of a questionable or potentially dangerous nature. [NCIT]

has super-classes

[Qualifier for certainty of diagnosis](#)<sup>c</sup>

**Systemic artery of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000302>

has super-classes

[Body part](#)<sup>c</sup>

has sub-classes

[Aorta](#)<sup>c</sup>

**T category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033334>

One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion). [NCIT]

has super-classes

[TNM category](#)<sup>c</sup>

has sub-classes

[cT category](#)<sup>c</sup>, [pT category](#)<sup>c</sup>

## **Tamoxifen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036135>

An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

## **Targeted medication therapy review<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035121>

has super-classes

[Medication Review](#)<sup>c</sup>

## **TDM1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035988>

An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers. [NCIT]

has super-classes

[Drug or medicament](#)<sup>c</sup>

## **Temporal Qualifier<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001943>

has super-classes

[Qualifier](#)<sup>c</sup>

has sub-classes

[Time patterns](#)<sup>c</sup>, [Timepoint](#)<sup>c</sup>

## **Testosterone measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021338>

has super-classes

[Androgen level](#)<sup>c</sup>, [Steroid measurement](#)<sup>c</sup>

has sub-classes

[Serum testosterone measurement](#)<sup>c</sup>

### **Therapeutic procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1010523>

has super-classes

[Procedure](#)<sup>c</sup>

has sub-classes

[Drug therapy](#)<sup>c</sup>, [Medical therapy](#)<sup>c</sup>, [Neoadjuvant antineoplastic therapy](#)<sup>c</sup>, [Pharmacotherapy](#)<sup>c</sup>, [Radiation Therapy \(Procedure\)](#)<sup>c</sup>, [Radiation oncology AND/OR radiotherapy](#)<sup>c</sup>

### **Thoracic segment of trunk<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1003776>

Subdivision of trunk which has as its parts the thorax and the back of thorax. Examples: There is only one thoracic segment of trunk. [RADLEX]

has super-classes

[Body part](#)<sup>c</sup>, [Upper body part structure](#)<sup>c</sup>

has sub-classes

[Chest](#)<sup>c</sup>

### **Thoracic spine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000128>

The vertebrae of the thoracic spine, numbered one through twelve in man. [NCIT]

has super-classes

[Spine](#)<sup>c</sup>, [Structure of musculoskeletal system of thoracic spine](#)<sup>c</sup>, [Structure of vertebral region of thoracic part of back](#)<sup>c</sup>

### **Thyrotropin [Units/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033900>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Time patterns<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000120>

has super-classes

[Temporal Qualifier](#)<sup>c</sup>



has sub-classes

[Frequencies](#)<sup>c</sup>, [Start time](#)<sup>c</sup>, [Stop time](#)<sup>c</sup>

### **Timepoint<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001945>

has super-classes

[Temporal Qualifier](#)<sup>c</sup>

has sub-classes

[Baseline](#)<sup>c</sup>, [Follow-up](#)<sup>c</sup>

### **Tissue Contrast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016649>

has super-classes

[MR procedure attribute](#)<sup>c</sup>

### **Tissue specimen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1002180>

has super-classes

[Body substance sample](#)<sup>c</sup>

has sub-classes

[Tissue specimen from genital system](#)<sup>c</sup>

### **Tissue specimen from genital system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1021447>

has super-classes

[Specimen from genital system](#)<sup>c</sup>, [Tissue specimen](#)<sup>c</sup>

has sub-classes

[Tissue specimen from prostate](#)<sup>c</sup>

### **Tissue specimen from prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027775>

has super-classes

[Specimen from prostate](#)<sup>c</sup>, [Tissue specimen from genital system](#)<sup>c</sup>

### **TNM category<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033316>

has super-classes

[TNM tumor staging classifications](#) <sup>c</sup>

has sub-classes

[M category](#) <sup>c</sup>, [N category](#) <sup>c</sup>, [T category](#) <sup>c</sup>, [TNM classification of malignant tumor after operation](#) <sup>c</sup>

**TNM classification of malignant tumor after operation<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1038653>

has super-classes

[TNM category](#) <sup>c</sup>

**TNM Clin M<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031282>

has super-classes

[cM category](#) <sup>c</sup>

**TNM Clin N<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031528>

has super-classes

[cN category](#) <sup>c</sup>

**TNM Clin Stage Group<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031313>

has super-classes

[TNM stage grouping](#) <sup>c</sup>

**TNM Clin T<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031297>

has super-classes

[cT category](#) <sup>c</sup>

**TNM Path M<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033404>

has super-classes

[pM category](#) <sup>c</sup>

**TNM Path N<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033068>

has super-classes

[pN category](#)<sup>c</sup>

**TNM Path Stage Group<sup>c</sup>** back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031268>

has super-classes

[TNM stage grouping](#)<sup>c</sup>

**TNM Path T<sup>c</sup>** back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033007>

has super-classes

[pT category](#)<sup>c</sup>

**TNM stage grouping<sup>c</sup>** back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033319>

has super-classes

[TNM tumor staging classifications](#)<sup>c</sup>

has sub-classes

[TNM Clin Stage Group](#)<sup>c</sup>, [TNM Path Stage Group](#)<sup>c</sup>

**TNM tumor staging classifications<sup>c</sup>** back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033314>

has super-classes

[Generic tumor staging descriptor](#)<sup>c</sup>

has sub-classes

[TNM category](#)<sup>c</sup>, [TNM stage grouping](#)<sup>c</sup>

**Tomography<sup>c</sup>** back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000025>

Imaging by sections or sectioning. [NCIT]

has super-classes

[Imaging modality](#)<sup>c</sup>

has sub-classes

[Computed tomography](#)<sup>c</sup>

**Toshiba<sup>c</sup>** back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000045>

has super-classes

[Manufacturer](#)<sup>c</sup>

### **Total prostate specific antigen level<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030627>

has super-classes

[Prostate specific antigen measurement](#)<sup>c</sup>

### **Transition zone of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004464>

PI-RADS: Tissue around the urethra that is separated from the peripheral zone by the “surgical capsule” delineated as a low signal line on T2 weighted MRI. It is the site of most BPH. [RADLEX]

has super-classes

[Region of prostate](#)<sup>c</sup>

### **Transitional cell carcinoma, NOS, of prostate gland<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031177>

has super-classes

[Primary malignant neoplasm of prostate](#)<sup>c</sup>

### **Trastuzumab<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035955>

A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

### **Trastuzumab deruxtecan<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036025>

has super-classes

[Drug or medicament](#)<sup>c</sup>

### **Treatment changed<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035796>

has super-classes

[Procedure with explicit context](#)<sup>c</sup>

### **Triglyceride [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033594>

has super-classes

[Laboratory test](#)<sup>c</sup>

### **Triple negative malignant neoplasm of breast<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046256>

has super-classes

[Hormone receptor negative neoplasm](#)<sup>c</sup>, [Human epidermal growth factor 2 negative carcinoma of breast](#)<sup>c</sup>

### **Trunk excision<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1004787>

has super-classes

[Excision](#)<sup>c</sup>

has sub-classes

[Abdomen excision](#)<sup>c</sup>, [Excision of pelvis](#)<sup>c</sup>, [Removal of entire genital organ](#)<sup>c</sup>

### **Trunk structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016377>

has super-classes

[Body part structure](#)<sup>c</sup>

has sub-classes

[Structure of half of trunk lateral to midsagittal plane](#)<sup>c</sup>, [Structure of subregion of trunk](#)<sup>c</sup>

### **Tucatinib<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1036045>

An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>

### **Tumor antigen measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1039710>

has super-classes

[Tumor marker measurement](#)<sup>c</sup>

has sub-classes

[Cancer antigen 15-3 measurement](#)<sup>c</sup>

**Tumor calcification<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035380>

has super-classes

[Tumor finding](#)<sup>c</sup>

**Tumor configuration (finding)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035406>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

**Tumor configuration observable entity<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049103>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

**Tumor finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1005480>

has super-classes

[Finding of lesion](#)<sup>c</sup>

has sub-classes

[Gleason finding](#)<sup>c</sup>, [Gleason grade finding for prostatic cancer](#)<sup>c</sup>, [Recurrent tumor](#)<sup>c</sup>, [Tumor Progression](#)<sup>c</sup>,  
[Tumor calcification](#)<sup>c</sup>, [Tumor invasion finding](#)<sup>c</sup>

**Tumor focality<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034970>

has super-classes

[Neoplasm observable](#)<sup>c</sup>

has sub-classes

[Qualitative distribution of primary malignant neoplasm](#)<sup>c</sup>

**Tumor histopathological grade status values<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1046013>

has super-classes

[Generic tumor staging descriptor](#) <sup>c</sup>

**Tumor invasion finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015105>

has super-classes

[Tumor finding](#) <sup>c</sup>

has sub-classes

[Lymphatic \(small vessel\) tumor invasion finding](#) <sup>c</sup>, [No vascular invasion by tumor](#) <sup>c</sup>, [Tumor invasion of perineural tissue absent \(prostate\)](#) <sup>c</sup>, [Tumor invasion of perineural tissue present \(prostate\)](#) <sup>c</sup>, [Vascular invasion by tumor present](#) <sup>c</sup>

**Tumor invasion of perineural tissue absent (prostate)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1027888>

has super-classes

[Tumor invasion finding](#) <sup>c</sup>

**Tumor invasion of perineural tissue present (prostate)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028002>

has super-classes

[Tumor invasion finding](#) <sup>c</sup>

**Tumor marker measurement<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1000224>

has super-classes

[Measurement of substance](#) <sup>c</sup>

has sub-classes

[Cancer Ag 15-3](#) <sup>c</sup>, [Carcinoembryonic antigen measurement](#) <sup>c</sup>, [Prostate specific antigen measurement](#) <sup>c</sup>, [Tumor antigen measurement](#) <sup>c</sup>

**Tumor Progression<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028117>

has super-classes

[Tumor finding](#) <sup>c</sup>

**Tumor Regression Grade<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1049083>

has super-classes

[Cancer Grade](#)<sup>c</sup>

has sub-classes

[Modified Ryan Scheme for Tumor Regression](#)<sup>c</sup>

### **Tumor Regression Score 0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001776>

has super-classes

[Disease Grade Qualifier](#)<sup>c</sup>

### **Tumor Regression Score 1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001785>

has super-classes

[Disease Grade Qualifier](#)<sup>c</sup>

### **Tumor Regression Score 2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001795>

has super-classes

[Disease Grade Qualifier](#)<sup>c</sup>

### **Tumor Regression Score 3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001806>

has super-classes

[Disease Grade Qualifier](#)<sup>c</sup>

### **Tumor staging<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1044182>

has super-classes

[Staging and scales](#)<sup>c</sup>

has sub-classes

[Cancer staging](#)<sup>c</sup>, [Malignant tumor staging](#)<sup>c</sup>

### **Tumor volume<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1030900>

has super-classes



[Measurement](#)<sup>c</sup>

### **Ultrasonic guidance procedure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005572>

has super-classes

[Imaging guidance](#)<sup>c</sup>, [Ultrasound](#)<sup>c</sup>

has sub-classes

[US-guided systematic biopsy](#)<sup>c</sup>, [Ultrasound guided biopsy](#)<sup>c</sup>

### **Ultrasonographic observable<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016253>

has super-classes

[Imaging observable](#)<sup>c</sup>

has sub-classes

[Acoustic feature of mass](#)<sup>c</sup>

### **Ultrasonography of abdomen<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005518>

has super-classes

[Imaging of abdomen](#)<sup>c</sup>

has sub-classes

[Biopsy of abdomen using ultrasound guidance](#)<sup>c</sup>, [US scan of prostate](#)<sup>c</sup>

### **Ultrasound<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000040>

High frequency sound, generally with a frequency greater than 20,000 Hz. [NCIT]

has super-classes

[Imaging \(Procedure\)](#)<sup>c</sup>, [Imaging modality](#)<sup>c</sup>

has sub-classes

[Ultrasonic guidance procedure](#)<sup>c</sup>

### **Ultrasound guided biopsy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005497>

has super-classes

[Imaging guided biopsy](#)<sup>c</sup>, [Ultrasonic guidance procedure](#)<sup>c</sup>

has sub-classes

[Biopsy of abdomen using ultrasound guidance](#)<sup>c</sup>

## **Ultrasound scan finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016290>

has super-classes

[Imaging finding<sup>c</sup>](#)

## **Unilateral<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016695>

has super-classes

[Laterality<sup>c</sup>](#)

## **Unit of measure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1000147>

has super-classes

[Qualifier<sup>c</sup>](#)

has sub-classes

[cubic millimeter<sup>c</sup>](#), [mg/kg<sup>c</sup>](#), [mg/m2<sup>c</sup>](#), [millimeter<sup>c</sup>](#), [nanogram per deciliter<sup>c</sup>](#), [nanogram per milliliter<sup>c</sup>](#), [nanomole per liter<sup>c</sup>](#), [percent<sup>c</sup>](#)

## **Unknown<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001289>

has super-classes

[Finding context value<sup>c</sup>](#)

## **Upper body part structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1002981>

has super-classes

[Body part<sup>c</sup>](#)

has sub-classes

[Head and neck<sup>c</sup>](#), [Thoracic segment of trunk<sup>c</sup>](#)

## **Upper extremity part<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004472>

has super-classes

[Arm<sup>c</sup>](#)

has sub-classes

[Structure of lymphatic system of upper limb<sup>c</sup>](#)

## Upper limb lymph node structure<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004487>

has super-classes

[Lymph node structure of limb](#)<sup>c</sup>

has sub-classes

[Axillary lymph node](#)<sup>c</sup>

## Urate [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033495>

has super-classes

[Laboratory test](#)<sup>c</sup>

## Urea [Mass/volume] in Blood<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1033470>

has super-classes

[Laboratory test](#)<sup>c</sup>

## Urinary incontinence<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028233>

has super-classes

[Bladder control - finding](#)<sup>c</sup>, [Bladder finding](#)<sup>c</sup>, [Impaired urinary system function](#)<sup>c</sup>, [Incontinence](#)<sup>c</sup>

## Urinary system finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015452>

has super-classes

[Urogenital finding](#)<sup>c</sup>

has sub-classes

[Impaired urinary system function](#)<sup>c</sup>

## Urinary tract<sup>c</sup> back to [ToC](#) or [Class ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000136>

The parts of the urinary system that discharge urine. These include the renal pelvis, ureter, bladder, and urethra. [NCIT]

has super-classes

[Structure of genitourinary system](#)<sup>c</sup>

## **Urogenital finding<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1015278>

has super-classes

[Finding of abdominopelvic segment of trunk<sup>c</sup>](#)

has sub-classes

[Genital finding<sup>c</sup>](#), [Urinary system finding<sup>c</sup>](#)

## **US male genital system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005605>

has super-classes

[US scan of genitourinary system<sup>c</sup>](#)

has sub-classes

[US scan of prostate<sup>c</sup>](#)

## **US scan and biopsy of pelvis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1001997>

has super-classes

[Biopsy of trunk<sup>c</sup>](#), [Pelvic echography<sup>c</sup>](#)

has sub-classes

[US scan and biopsy of prostate<sup>c</sup>](#)

## **US scan and biopsy of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1016628>

has super-classes

[Biopsy of prostate<sup>c</sup>](#), [US scan and biopsy of pelvis<sup>c</sup>](#), [US scan of prostate<sup>c</sup>](#)

has sub-classes

[MRI-US fusion guided prostate biopsy<sup>c</sup>](#)

## **US scan of genitourinary system<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005588>

has super-classes

[Imaging of genitourinary system<sup>c</sup>](#)

has sub-classes

[US male genital system<sup>c</sup>](#)

## **US scan of prostate<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1005557>

has super-classes

[Pelvic echography](#)<sup>c</sup>, [US male genital system](#)<sup>c</sup>, [Ultrasonography of abdomen](#)<sup>c</sup>

has sub-classes

[US scan and biopsy of prostate](#)<sup>c</sup>

### **US-guided systematic biopsy<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1031038>

has super-classes

[Imaging guided biopsy](#)<sup>c</sup>, [Ultrasonic guidance procedure](#)<sup>c</sup>

### **Uses contraception (finding)<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1034434>

has super-classes

[Clinical finding](#)<sup>c</sup>

has sub-classes

[Uses hormonal contraception](#)<sup>c</sup>

### **Uses hormonal contraception<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035208>

has super-classes

[Uses contraception \(finding\)](#)<sup>c</sup>

### **Uterus<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000113>

A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy. [NCIT]

has super-classes

[Female genital tract structure](#)<sup>c</sup>, [Structure of female genital system in pelvic cavity](#)<sup>c</sup>, [Structure of female internal genital organ](#)<sup>c</sup>, [Structure of organ within cavity of true pelvis](#)<sup>c</sup>, [Structure of pelvic viscus](#)<sup>c</sup>

### **Uterus and fallopian tubes<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1004408>

has super-classes

[Combined site](#)<sup>c</sup>

### **Vascular invasion by tumor present<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1028350>

has super-classes

[Tumor invasion finding](#)<sup>c</sup>

## **Vinorelbine<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#CLIN1035913>

A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca<sup>++</sup>-transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. [NCIT]

has super-classes

[Antineoplastic agent](#)<sup>c</sup>, [Immunologic agent](#)<sup>c</sup>

## **X-Ray Computed Tomography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1016270>

has super-classes

[Radiographic imaging procedure](#)<sup>c</sup>

## **X-Ray mammography<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#IMG1000033>

has super-classes

[Mammography](#)<sup>c</sup>

## **Yes<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001363>

has super-classes

[Presence findings](#)<sup>c</sup>

## **ypN0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001080>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

## **ypN1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001082>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN1a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001089>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN1b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001094>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN1c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001100>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN1mi<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001085>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001107>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN2a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001115>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN2b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001124>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001134>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN3a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001145>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN3b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001157>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypN3c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001170>

has super-classes

[American Joint Committee on Cancer ypN category allowable value](#)<sup>c</sup>

**ypT0<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001607>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT1<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001610>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT1a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001614>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>



**ypT1b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001619>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT1c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001625>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT1mi<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001632>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT2<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001640>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT3<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001649>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT4<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001659>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

**ypT4a<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001670>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

### **ypT4b<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001682>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

### **ypT4c<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001695>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

### **ypT4d<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001709>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

### **ypTis<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001724>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

### **ypTx<sup>c</sup> back to [ToC](#) or [Class ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#COM1001740>

has super-classes

[American Joint Committee on Cancer ypT category allowable value](#)<sup>c</sup>

## **Object Properties**

- [Answer of](#)
- [Finding site of](#)
- [Has Answer](#)
- [Has associated morphology](#)
- [Has correspondence](#)
- [Has finding site](#)
- [Has Measurement Unit](#)
- [Has undergone](#)
- [Treats](#)
- [Unit for measuring](#)

### **Answer of<sup>oP</sup> back to [ToC](#) or [Object Property ToC](#)**

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#AnswerOf>

is inverse of

[Has Answer](#)<sup>op</sup>

**Finding site of**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#FindingSiteOf>

is inverse of

[Has finding site](#)<sup>op</sup>

**Has Answer**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#HasAnswer>

is inverse of

[Answer of](#)<sup>op</sup>

**Has associated morphology**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** [https://cancerimage.eu/ontology/EUCAIM#Has\\_associated\\_morphology](https://cancerimage.eu/ontology/EUCAIM#Has_associated_morphology)

**Has correspondence**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#HasCorrespondence>

**Has finding site**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#HasFindingSite>

is inverse of

[Finding site of](#)<sup>op</sup>

**Has Measurement Unit**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#HasMeasurementUnit>

**Has undergone**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#HasUndergone>

**Treats**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#Treats>

**Unit for measuring**<sup>op</sup> back to [ToC](#) or [Object Property ToC](#)

**IRI:** <https://cancerimage.eu/ontology/EUCAIM#UnitFor>

## Legend back to [ToC](#)

<sup>c</sup>: Classes

<sup>oP</sup>: Object Properties

## Acknowledgments back to [ToC](#)

The authors would like to thank [Silvio Peroni](#) for developing [LODE](#), a Live OWL Documentation Environment, which is used for representing the Cross Referencing Section of this document and [Daniel Garijo](#) for developing [Widoco](#), the program used to create the template used in this documentation.